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Chapter One 
General introduction 

General Introduction 
1.1 Clinical aspects of asthma 
Asthma is the most common chronic disease of childhood. Although mortality rates in 
the Netherlands and other Western European countries are low, astlmm causes a great 
deal of morbidity and school absence,! Incidence rates in our country are about 10% 
and recent epidemiologic studies show an increase especially in the young age group.2 3 
Despite the availability of several classes of effective and safe anti-asthma drugs. so far 
childhood asthma can not be cured.' However, there is no doubt that medical treatment 
may result in appreciable clinical improvement. 5 With medical intervention, it is hardly 
possible to address the natural history of asthma from childhood to adulthood. The 
longest prospective ongoing study in Melbourne, following a cohort of 249 subjects 
from 7 to 35 years now revealed that 29% of those with wheeze at age 7 still had 
symptoms at the age of 35 years. 6 Follow-up studies in our country by Gerritsen7 and 
Roorda' showed 43%, respectively 76% of their populations still having respiratory 
symptoms in adulthood. Airway caliber and the degree of airway responsiveness during 
childhood may be predictors of the outcome of childhood asthma. 7 ' 
The last decade several consensus reports have focused on the treatment of childhood 
asthma.9 10 11 12 13 Asthma is flOW generally regarded as an inflammatory disease 
and the cornerstone of treatment constitutes of prophylactic use of inhaled corticoste-
roids. Although airway hyperresponsiveness is not identical to airway inflammation, 
ainvay hyperresponsiveness is considered as the functional abnonnality related to the 
inflammatory process of the disease. 14 15 16 17 As measurements of airway inflam-
mation, such as bronchial biopsies and broncho-alveolar lavage studies, are unethical 
to perfonn in children for effect measurements of medical interventions, measurements 
of airway responsiveness and airway caliber (FEV 1) are now besides symptom scores 
and peak flow measurements regarded as valuable outcome parameters. IS Studies in 
children as well as adults have shown that inhaled corticosteroids may improve asthma 
symptoms, airway caliber as well as airway responsiveness, although the majority of 
patients does not become symptom free and still needs the use of short-acting fil -
agonists for symptom relief. 5 19 20 21 Furthennore, stopping inhaled corticosteroids 
after 1 to 3 years results in reoccurrence of symptoms and lung function 
abnonnalities. 22 23 24 Two long-acting Bragonists, salmeterol and fonnoterol, 
recently became available. Their long duration of action may result in effective 
symptom relief, however it is not yet clear whether these drugs also effect the 
inflammatory process. Their place in the treatment of astluna should be further 
elucidated. 
This thesis deals with the effect of salmeterol in a single dose and during long-telm 
treatment in children with asthma. 
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1.2 Pathophysiology of asthma 
The pathophysiologic concept of asthma has changed during the past decades from 
smooth muscle contraction as the essential mechanism25 to chronic inflammation. 
Activated cells, especially mast cells and eosinophils, playa role and T-lymphocytes 
are regarded to regulate the process. ll 1226 Until recently most infonnation was based 
on autopsy material from patients dying in status asthmaticus. Mucus plugging of 
airways, basement membrane thickening, disruption of airway epithelium (shedding), 
smooth muscle hypertrophy and infiltration of the airway wall by inflammatory cells, 
especially eosinophils have long been recognized in fatal cases.27 28 29 Endobronchial 
biopsies in adult asthmatics have continned that extensive inflanunatory changes are 
also present in non-fatal asthma and even in mild asthmatics. 30 31 32 Infiltration of 
the lamina propria by inflammatory cells, especially eosinophils, mast cells and lympho-
cytes, epithelial shedding and collagen deposition beneath the basement membrane are 
common findings. Due to ethical difficulties in using invasive techniques as bronchial 
biopsies and broncho-alveolar lavages, only limited studies in children have been perfor-
medY As in adults, in children with asthma increased numbers of eosinophils and 
increased levels of activation markers, such as eosinophilic cationic protein and mast 
cell tryptase have been found in alveolar lavage fluid. 34 35 
Although the underlying immunological mechanisms are not yet fully understood, 
activated T -lymphocytes, by producing cytokines, seem to orchestrate the chronic 
inflammation in atopic asthma.36 Antigens are presented to T -lymphocytes by antigen 
presenting cells, especially dendritic cells and T-cells are stinmlated, resulting in 
cytokine production. Two patterns of cytokine production have been distinguished. Th-l 
cells synthesize IL-2, interferon-gamma (IFN-'Y) and granulocyte macrophage-colony 
stimulating factor (GM-CSF), wllereas Th-2 cells synthesize IL-3, IL-4, IL-5 and IL-
10. 36 37 In asthma there is evidence for a T-cell response switch to the Th-2 
phenotype. 38 IL-4 causes an isotype switch of the B-cells to produce IgE." IL-5 
causes recruitment and activation of eosinophils. 4o Activation of eosinophils results in 
the secretion of several toxic proteins such as major basic protein (MBP). eosinophilic 
cationic protein (ECP), eosinophil-derived neurotoxin (EDN) and eosinophilic 
peroxidase (EPO), which are toxic to the ainvay epithelium, causing epithelial 
shedding.'1 Furthermore, eosinophils are able to secrete lipid mediators (e.g. 
prostaglandins, platelet activating factor, leukotriens), oxygen radicals, neuropeptides 
(substance P, vasoactive intestinal peptide) and cytokines (IL-3, IL-5, GM-CSF and 
tumor growth factor-61)." This activation process of eosinophils is now regarded as 
the basis of the eosinophilic inflammation in asthma,o 
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1.3 Definition of asthma in childhood 
The knowledge that inflanunatory processes underlie the clinical expression of asthma, 
forced to a new operational definition of asthma in the National Heart, Lung, and Blood 
Institute consensus report. 12 II Asthma is a chronic inflammatory disorder of the airways 
in which many cells playa role, including mast cells and eosinophils. In susceptible 
individuals this inflalmnation causes symptoms which are usually associated with 
widespread but variable airflow obstruction that is often reversible either spontaneously 
or with treatment, and causes an associated increase in airway responsiveness to a 
variety of stimuli". In daily clinical practice, especially in children, the diagnosis of 
asthma will still be based on the clinical characteristics of symptoms of wheeze, 
dyspnea and cough in combination with reversible airway obstruction and airway 
responsiveness.lO 44 Especially in infants and young children no clear distinction can 
be made between asthma and wheezing-associated lower respiratory ilInesses. 45 
Martinez et al. recently described two distinct manifestations of infant wheezing and 
suggested that early-onset asthma is associated with increased prevalence of allergic 
markers, bronchial hyperresponsiveness and deterioration in lung function during the 
first 6 years of life, while transient wheeze was associated with a small ainvay diameter 
at birth and maternal smoking during pregnancy. 46 
1.4 Treatment of asthma: consensus reports 
Several international consensus reports have focused on the management of asthma in 
adults 11 12 13 as well as chiidren91O• Apart from medication regimens these reports 
promote allergen avoidance in allergic patients, control of air pollution especially indoor 
(such as tobacco smoke) and avoidance of drugs which may aggravate asthma (such as 
aspirins). Drug therapy is based on a stepwise approach according to the severity of the 
disease. Severity of the disease may be assessed by taking into account the frequency 
of symptoms, nocturnal symptoms, peak flow variability and use of bronchodilators. 
All consensus reports aim to establish control of asthma in tenns of minimal possible 
symptoms, preferably no exacerbations, minimal need for additional bronchodilators, 
minimal or no peak flolV variability and nonnal or best personal lung function. This 
should be achieved with no or minimal adverse effects from medication. Astluna 
management plans, which include an inlportant role for the patients self-management, 
are part of the consensus reports. All consensus reports focus on the inflammatory 
process which underlies the disease and advocate anti-inflammatory treatment at least 
for moderate and severe asthma. Whereas in most adult reports inhaled corticosteroids 
are the first prophylactic treatment, consensus reports on childhood astlnna do make 
room for cromoglycate in mild to moderate asthma. Comparing the different consensus 
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reports at the more severe end of the asthma spectrum, there is no evident consensus 
on the place of long-acting firagonists. So far, it is not clear whether an increase in 
inhaled corticosteroids, addition of long-acting Bragonists or even introduction of 
theophyllines is the fIrst step after a moderate dose of inhaled corticosteroid fails to 
control asthma. 
1.5 Treatment of asthma: inhaled corticosteroids and Jl,-agonists 
Inhaled corticosteroids are regarded as the most effective anti-inflammatory drugs for 
the treatment of asthmaY Inhaled short-acting fi2-agonists are the most effective bron-
chodilators for short-term relief of symptoms.48 49 Both are described in more detail. 
As this thesis focusses on salmeterol, a long-acting B2-agonist, phanl1acoIogy and 
clinical effects of these class of dmgs will also be summarized here. 
1.5.IIl/haled COlticosleJ'oids 
PHARMACOLOGY 
Glucocorticosteroids diffuse into the cell and bind to the glucocorticoid receptor within 
the cytoplasm. Activation of the receptor results in dissociation of heat shock proteins 
and translocation of the resulting complex into the nucleus, where it binds directly to 
glucocorticoid responsive elements on DNA in the promoter region of steroid sensitive 
genes. 50 Depending on the gene and the cell type, activation of the glucocorticoid 
responsive elements can cause up-regulation or down-regulation. 50 51 One example of 
downregulation is the blocking effect of glucocorticosteroids on the transcription of 
several cytokines. 47 52 Alternatively, the steroid receptor complex may directly bind 
with pro-inflammatory transcription factors as activating protein-l (AP-I) and nuclear 
factor-KB (NF-KB) and thereby having a modulating effect on gene transcription." 
Glucocorticoids have suppressive effects on inflammatory cells as eosinophils and mast 
cells, probably partly by reducing their survival. 47 54 Glucocorticosteroids reduce the 
cytokine production by T-Iymphocytes as well as airway epithelial cells." Furthennore 
they may inhibit plasma exudation56 and mucus secretion. 57 
CLINICAL ASPECTS 
Although clinical effects on airway responsiveness" and the late asthmatic reaction 
after allergen challenge59 are measurable after a single dose of an inhaled corticos-
teroid, from a clinical point of view effects during long-tenn treatment are more 
interesting. Several long tenn studies, ranging from I to 2.5 years, have revealed 
positive effects on symptoms, exacerbations, peak flow rates, airway caliber and airway 
responsiveness with twice daily dosing of either beclomethasone or budesonide.5 192021 
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However, the time course for the effect parameters is different, whereby symptoms and 
peak flow rates improve more rapidly than airway responsiveness. For airway 
responsiveness to histamine a plateau seemed to be reached only after 22 months of 
treatment with budesonide. 4 Prolonged treatment with inhaled corticosteroids also 
reduces airway responsiveness to other bronchoconstricting stimuli than histamine, such 
as exercise,60 dlY air hyperventilation,61 methacholine,62 metabisulfite63 , the late 
asthmatic reaction to allergen60 and the allergen-induced increase in airway 
responsiveness. 64 Not only the position of the dose response curve is influenced by 
inhaled corticosteroids, but also the maximum degree of airway narrowing. 6S Ainvay 
inflammation is modified, as has been shown by bronchial biopsy studies which show 
a reduction in the number of inflammatory cells as well as in the activation of these 
cells after treatment with inhaled corticosteroids for several months. 66 61 Despite 
clinical improvement, even long-tenn use of inhaled corticosteroid therapy does not 
cure the disease, in that most of the patients do not become symptom free and the 
majority keeps lung function abnormalities.' Furthennore, stopping or reducing inhaled 
corticosteroid treatment rapidly reverses symptoms and increases airway responsi-
veness. 22 23 24 Side effects on the hypophyseal-pituitary-adrenal axis, on growth and on 
bone density are considered unlikely when daily doses of inhaled corticosteroids are 
below 400-800 I'g, but individual susceptibility may vary. 68 
Inhaled corticosteroids are now recommended as prophylactic treatment in adult asthma, 
which is not well controlled with a 6r agonist on demand. II 12 13 In children these are 
recommended when prophylactic therapy with cromoglycate fails or in case of severe 
symptoms.9 iO 
1.5.2 Sholt-acting .fJ,-agonists 
PHARMACOLOGY 
Selective fi,-agoolsts, as salbutamol, terbutaline and fenoterol bind to the fi,-receptors 
in ainvay smooth muscle, consisting of seven transmembrane a-helices with a binding 
cleft between them. Binding to the receptor results in activation of the a-unit of the 
receptor-associated stinmlating G-protein. Activation of this alpha-unit in tum activates 
the cell surface-associated enzyme adenylyl cyclase (AC), which results in conversion 
of ATP to cyclic 3'-5'-adenosine monophosphate (cAMP). cAMP activates protein 
kinase A (PKA), which in airway smooth muscle inhibits myosin light chain 
phosphorylation, inhibits phosphoinositide hydrolysis and promotes Ca'+ INa+ exchange, 
thus resulting in a fall in intracellular Ca'+ .69 This leads to relaxation of airway 
smooth muscle. fi,-agonists, already in low doses, may also relax airway smooth muscle 
independent of cAMP via direct coupling between the receptor-activated stimulating G 
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protein and a large conductance Ca'+-activated potassium channel, leading to cell 
hyperpolarization. 69 Furthennore fi2-agonists may influence gene transcription through 
elevation of cAMP and activation of PKA, which mediates phosphorylation of cAMP 
responsive element binding protein (CREB) within the nucleus. CREB binds to a cAMP 
response element (CRE) in the upstream promotor region of a responsive gene and in 
this way short term exposure to a fi,-agonist may exert positive feedback on the 
transcription of the Brreceptor gene.69 70 Long-tenn exposure to Bragonists however 
results in reduced gene transcription and is associated with a reduction in CREB activi-
ty.71 Apart from the effects on airway smooth muscle, short-acting fi2-agonists have 
also an effect on mast cells, by reducing the release of mediators72 and may inhibit 
microvascular leakage.73 
CLINICAL ASPECTS 
After a single dose short-acting fi,-agonists result in bronchodilatation up to 4-6 hours 
after inhalation. They also protect against bronchoconstricting stimuli as methacholine, 
histamine, exercise, hyperventilation with dry cold air and inhibit the early asthmatic 
reaction after allergen challenge.74 75 Recently, also an inhibition of the late asthmatic 
reaction was found with a higher dose of salbutamo!.76 Although salbutamol results in 
a rightward shift of the dose-response curve to methacholine, it was found that with 
higher doses of methacholine this protection is overcome and there is an even steeper 
fall in lung function.77 The protective effects of short-acting fi,-agonists may be due 
to functional antagonism on airway smooth muscle. However, some evidence exists that 
separate mechanisms may be involved." 
Chronic continuous use of firagonists has been related to worsening of asthma 
controp9 and to a reduction in lung function,80 compared to the use of firagonists on 
demand. Also an association has been made between the use of inhaled Bragonists and 
asthma mortality rates in several epidemiological studies.81 82 83 84 85 An unresol-
vable problem of these studies is the confounding by severity of the disease. 86 Further-
more, despite the increase in sales of firagonists, no increase in asthma mortality was 
found in the past two decades in several European countries.87 After cessation of treat-
ment with a short-acting 62-agonist for several weeks a rebound increase in airway 
responsiveness and fall in FEV1 was noted, lasting up to 59 hours. 88 89 Regular use 
of inhaled fi,-agonists induces tolerance to the bronchoprotective effects of several 
stimuli as histamine, methacholine, AMP I allergen and exercise':X:" while tolerance to 
the bronchodilator effect has not been convincingly established so far and seems not to 
be of clinical importance. 90 91 Loss of protection is greater for AMP than for 
methacholine, suggesting that 6,-receptors on mast cells may be more susceptible to 
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tolerance than Brreceptors on ainvay smooth muscle.92 Corticosteroids do not prevent 
the development of tolerance. 93 In addition to tolerance to the bronchoprotective 
effects, it was found that after regular use of salbutamol for 1-2 weeks the early as well 
as late response to allergen was increased, as well as the allergen-induced airway 
responsiveness. 9-t 95 The clinical relevance of the development of tolerance remains 
unclear, but theoretically the enhanced response to allergen may result in increased 
airway inflammation. This may explain the increased numbers of eosinophils found in 
bronchial biopsies after regular treatment with salbutamol. 96 
Short-acting Bragonists are now advised as rescue medication in all steps of the asthma 
treatment plan in the consensus reports. 9 JO 11 12 13 
1.5.3 Long-acting fJ,-agollists 
PHARMACOLOGY 
Two long-acting fi,-agonists are now available, salmeterol and formoterol. Their long 
duration of action distinguishes these drugs from short-acting B1-agonists. Both drugs 
are selective fi2-agonists. 97 Moreover, salmeterol was found to reassert its relaxing 
effect on airway smooth muscle after adding a 6-antagonist and subsequently wash-out 
of this antagonist. 98 The underlying mechanism of this action has been hypothesized 
as the result of the binding of the inactive long aliphatic tail to an Uexosite" near or in 
the 62-receptor. 97 Recently the underlying mechanism for the long dlll"ation of action was 
explained in the so called "plasmalemma diffusion microkinetic model" . 99 According 
to this model a moderate (formoterol) and highly (salmeterol) lipophilic molecule may 
approach the 6,-receptor in ahway smooth muscle by entering the plasmalemma lipid 
bilayer and once having partitioned into the bilayer, remain available to interact with 
the fi2-adrenoceptor active site" This model may also explain the difference between 
fOlmoterol and salmeterol in onset of action; formoterol having a more rapid onset of 
bronchodilator effect. 100 The faster onset of formoterol is based on the moderate 
lipophilicity, making it possible also to rapidly diffuse to the active site of the fi,-
receptor by the aqueous biphase." The partitioning of salmeterol as well as formoterol 
has been demonstrated in vitro. 99 101 Apart from their effects on airway smooth 
muscle, salmeterol and fonnoterol are able to inhibit the release of mediators from mast 
cells, such as histamine, prostaglandins and leukotriens.97 102 Furthermore, inhibition 
of vascular permeability and inhibition of activation of eosinophils and neutrophils have 
been found in animal models and human cells in vitro. 97 103 These effects are fi;c 
receptor mediated. Salmeterol also has inhibitory effects on the release of Ihromboxane 
B, from human airway macrophages and blood monocytes in vitro; these effects are not 
or only partially mediated by B,-receptors and are probably due to the lipophilic 
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properties of the molecule.l()j So far, no inhibition of T-lymphocytes could be 
detected, as was measured by the serum level of the soluble interleukin-2 receptor after 
two weeks of treatment with salmeteroi. 105 
CLINICAL ASPECTS 
The clinical aspects of salmeterol and formoterol are described in more detail in chapter 
3. 
Single doses of salmeterol as well as forulOterol give prolonged bronchodilation, up to 
12 hours after inhalation. 106 107 Protection against various bronchoconstricting 
stimuli as methacholine,IOS histamine,l09 exercisellO 111 and hyperventilation with 
dry cold airll ' is also prolonged compared to short-acting B,-agonists. Salmeterol as 
well as formoterol are able to block the early and partially the late asthmatic reaction 
to allergen. 113 114 1I5 These blocking effects are most likely due to functional 
antagonism on airway smooth muscle. Used on a twice daily base for several weeks to 
months, compared to placebo or salbutamol, these drugs result in better symptom 
control and higher peak flow rates. 1I6 117 118 No deterioration of asthma or 
increase in exacerbations has been noted during long-term treatment.]]9 A surveillance 
study could not reveal an increased number of deaths yo Tolerance to the protective 
effect to methacholine, 121 exercisel22 and allergen123 has been described and seems 
to develop within several days after starting therapy.124 However, there remains a 
residual protective effect during treatment. 125 As with short-acting fi2-agonists, 
corticosteroids do not prevent the development of tolerance. 126 127 128 So far, no 
rebound increase in airway responsiveness has been noted after cessation of treatment. 121 129 
Long-acting B,-agonists should not be considered as anti-inflammatory drugs. Eight 
weeks of treatment with salmeterol did not affect the total cell count, cellular profIle, 
tryptase or albumine concentrations in bronchoalveolar lavage fluids yo Consensus 
reports place these drugs after the introduction of inhaled corticosteroids.9 10 II 12 13 
Recently two studies in adult asthmatic patients revealed better symptom control and 
peak flow rates with the addition of salmeterol to a moderate-high dose of an inhaled 
corticosteroid compared to doubling the dose of an inhaled corticosteroid. l3l 132 
1.5.4 illferaCfiolls between cOlticosteroids Gndflragonists 
Glucocorticoids are able to upregulate B,-receptors and prevent down-regulation of B,-
receptors in aitway smooth muscle and other cell types, probably by receptor complex 
binding to a glucocorticoid responsive element within the promotor region of the B,-
receptor gene. 70 133 In rat lung salbut.mol decreased the binding of the glucocorticos-
teroid to the glucocorticosteroid responsive element, due to an interaction between the 
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glucocorticoid receptor and CREB. 134 High doses of Bragonists are able to activate 
CREB and so inhibit the binding of an activated glucocorticosteroid receptor and have 
functional anti-glucocorticoid activity. 70 
Clinically there is no evidence for preventing down-regulation of B,-receptors by inbaled 
corticosteroids; in contrast, there is now evidence that inhaled corticosteroids are not 
able to protect against tolerance to the B-agonist effect on bronchoconstricting stimuli. 126 
127128 It was shown that oral terbutaline caused desensitization of B2-receptors in human 
alveolar macrophages, which was not influenced by either inhaled or oral corticosteroid 
treatment. 135 One study has suggested a negative effect of continuous administration 
of il,-agonists on the protection by inbaled corticosteroid. After treatment with 
terbutaline and budesonide in combination less protection against allergen induced 
bronchoconstriction was found compared to budesonide treatment alone. '36 A recent 
study from the same department, however, could not confirm these results for the 
protection against histamine and adenosine monophosphate induced bronchoconstricti-
on. 137 
1.6 Aims of the study 
The aim of our studies was to investigate the effect of salmeterol after a single dose and 
during prolonged treatment on several outcome parameters of asthma in children. 
Primary outcome parameters were airway caliber, as measured by FEV, and ainvay 
responsiveness, as measured by PD20 methacholine. In the long tenn studies secondary 
outcome parameters were symptom scores, peak flow rates, use of additional short-
acting Bragonists and exacerbations of asthma. 
Chapter 2 gives a review of the literature on the effects of short- and long-acting B,-
agonists on airway responsiveness. 
Chapter 3 describes in more detail the clinical effects of long-acting .B2-agonists. 
In chapter 4 the bronchodilator and bronchoprotective effect against methacholine 
induced bronchial obstruction of a single dose of salmeterol are compared to placebo 
in children with mild to moderate asthma. 
In chapter 5 the bronchodilator and bronchoprotective effect of salmeterol after a single 
dose and after 4 months treatment are compared with salbutamol in children with mild 
to moderate asthma, who were not on treatment with inhaled corticosteroids. 
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In chapter 6 one year treatment with twice daily salmeterol is compared to treatment 
with a moderate dose of beclomethasone (400 I'g daily) in children with mild to 
moderate asthma. who were not already treated with inhaled corticosteroids. 
In chapter 7 the addition of sahneterol to a moderate dose of beclomethasone (400 I'g 
daily) is compared to beclomethasone alone in the same dose and to a doubling dose of 
beclomethasone in children with mild to moderate asthma, who were already on 
treatment with an inhaled corticosteroid 
Chapter 8 gives a summary on previous chapters and a general discussion. 
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Effects of Il,-receptor agonists on airway responsiveness 
2.1 Summary 
Ainvay hyper-responsiveness is olle of the characteristics of astlima. If may be 
distinguished by ainvay hypersensitivity Gnd Gil increase of the maximal response 
plateau. Short-acting fi2-agollists have all acute protective effect Oil ainvay sensitivity, 
which is shOltel' in duration than the hl'oncJ/Odilating effect, without affecting the 
maximal response plateau. Long-tel1ll treatment has no beneficial eifect on airway 
responsiveness. A diminishment oJfhe protection 10 methacholine- and histamine-induced 
ai/way obstruction and a rebound increase of this after cessation of continuous 
treatment have been rep011ed. 
Single doses of long-acting fi,-agonists give a prolonged protection against 
methacholine- and histamine-induced ainvay sensitivity of at least 12 hours. A small 
decrease in the maximal response plateau has been noted. During /ong-tentl treatment 
tolerance to the protecting effects develops, although significant protection remains alld 
the bronchodilatillg effect is not influenced, So jar, IlO rebound increase ill ainvay 
sensitivity has been rep011ed after cessation of continuous treatment. 
2.2 The role of airway responsiveness and airway inflammation in asthma 
Asthma is characterized by a variable degree of airway obstruction and airway hyper-
responsiveness to several stimuli.' Although it seems likely that airway hyper-
responsiveness and airway inflammation are closely related, the underlying mechanism 
remains unclear. Chronic ainvay inflamm.ation is the result of epithelial tissue injury. 
extensive mediator release from inflammatory cells and nerve endings, increased 
vascular permeability. cell migration into the exudate and repair phenomena, The repair 
phase of the inflammatory response consists of basement membrane thickening, goblet 
and squamous cell metaplasia. connective tissue deposition and smooth muscle 
hypertrophy.' Biopsy studies in patients with stable asthma and airway hyper-
responsiveness reveal chronic inflammatory changes of the ainvay wall. 3.4,5 Although 
a correlation was found between epithelial damage and the degree of airway 
responsiveness,3,4 this could not be confirmed in a study comparing biopsies from 
astlnna patients with airway hyper-responsiveness with biopsies from healthy individuals 
without airway hyper-responsiveness, 6 
Airway hyper-responsiveness can be distinguished in two components: airway 
hypersensitivity and excessive airway narrowing, which are probably the result of 
distinct underlying mechanisms.7 It has been postulated that the maximal degree of 
airway narrowing detennines the degree of obstruction and thereby the severity of 
symptoms. In patients with mild asthma there is a shift of the dose-response curve for 
methacholine to the left which reaches a plateau; moderate asthma is characterized by 
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a more pronounced leftward shift, but without a plateau, and the maximal degree of 
airway narrowing is higher than the plateau in patients with mild asthma (Figure 2.1).' 
There is a general relationship between the degree of ainvay sensitivity and the severity 
of asthma symptoms in groups of patients, but within subjects this relationship is rather 
weak.9 For individual patients a direct correlation was found between the degree of 
airway sensitivity to a non-specific stimulus and the amount of allergen which could be 
tolerated. lO•ll The prognostic value of airway hyper-responsiveness was studied in adults 
as well as in children. In adults with chronic obstructive lung disease, airway sensitivity 
is associated with progressive loss of pulmonary function. 12 In children airway 
sensitivity is considered to be a risk factor for the outcome of childhood asthma into 
aduIthood.13 Treatment which aims at suppression of airway hyper-responsiveness seems 
therefore appropriate. 
Airway responsiveness is usually measured to histamine or methacholine, using the 
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Table 2.1 Acute protection of short-acting B2-agonists against airway sensitivity to histamine or methacholine. 
Reference Drug Route Dose Interval Test Mean change 
("g) (minutes) in PC20 or 
PDw (DD) 
Casterline et al salbutamol IN 170 0 histamine +3.6 (PD) 
(14) 
Cockcroft et a1 salbutamol PO 4000 60 histamine + 1.1 (PC) 
(IS) IN 200 IS histamine +3.6 (PC) 
DeCotiis et al terbutaline SC S/kg NS* methacholine +2.4 (PD) 
(16) 
Bandouvakis fenolerol IN 800 45 histamine +3 (PC) 
et al(17) methacholine +4 (PC) 
Salome et al fenolero! IN 400 15 histamine +2.4 (PD) 
(18) PO 5000 90 histamine +0.5 (PD) 
IN 400 15 methacholine +3.8 (PD) 
PO SOOO 90 methacholine +1.5 (PD) 
Chung et al(19) salbutamol IN 200 30 histamine +2.S (P035)" 
Salome et al fenolerol IN 100 15 histamine + 1.8 (PD) 
(20) 200 15 histamine + 1.9 (PD) 
400 IS histamine +3.1 (PD) 
Chullg et al(21) salbutamol IN 200 30 methacholine +3 (PD35) 
Ahrens et al salbutamol IN 90 30 histamine +3 (PD) 
(22) 120 histamine + 1.1 (PD) 
240 histamine 0 (PD) 
180 30 histamine +4.3 (PD) 
120 histamine +2.7 (PD) 
240 histamine +0.7 (PD) 
metaproterenol IN 1300 30 histamine +2.6 (PD) 
120 histamine + 1.3 (PD) 
240 histamine 0 (PD) 
2600 30 histamine +3.6 (PD) 
120 histamine +2 (PD) 
240 histamine 0 (PD) 
Joad et al salbutamol IN 200 30 histamine +2.8 (PD) 
(23) 240 histamine 0 (PD) 
Britton et al salbutamol IN 5 15 histamine +0.3 (PD) 
(24) 30 IS histamine + 1.1 (PD) 
200 15 histamine + I.S (PD) 
1000 IS histamine +3.0 (PD) 
Salome et al fenoterol IN 200 5 histamine +3.6 (PD) 
(2S) 180 histamine + I.S (PD) 
360 histamine +0.6 (PD) 
salbutamol IN 200 S histamine +3.8 (PD) 
180 histamine + 1.9 (PD) 
360 histamine +0.2 (PD) 
Phillips et al salbutamol IN 2500 40 histamine +3.2 (PC) 
(26) 40 methacholine +2.9 (PC) 
Higgins et al salbutamol IN 1855*** 60 histamine +2.3 (PD) 
(27) 
* NS = Not stated ** PDJ5 = PD3ssGaw *** Cumulative dose 
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dosimeter method or tidal breathing technique. Values are expressed as provocative 
dose (PD) or provocative concentration (PC) at which a certain (mostly 20%) decrease 
in baseline FEV1 or specific airway conductance (sGaw) occurs. Changes after drug 
administration can be expressed as doubling doses (DD). 
The effects of B2-agonists on airway responsiveness will be considered separately on 
ainvay sensitivity as well as on the maximal degree of airway narrowing. A distinction 
will be made between the effect after a single dose (acute protection) and the effect 
during long-term treatment. For acute protection the effect on allergen-induced airway 
hyper-responsiveness will also be mentioned. 
2.3 Short-acting Jl,-agonists 
2.3.1 AClIte protection after a single dose 
Numerous studies have examined the effect of a single dose of a short-acting Jl,-agonist 
on airway sensitivity (Table 2.1). A shift of the dose-response curve of histamine or 
methacholine to the right was found.!4-26 The maximum increase in PD20 or PC20 varied 
from 0.3 to 4.3 DD and was usually reached within 30 minutes after drug inhalation. 
The effect was more pronounced when the drug was inhaled than after oral 
administration. 15 18 After inhalation, a dose relationship has been found in several 
studies.2o,22.24 Few data exist on the duration of the protective effect. Salome et a1. found 
that this was less than 3 hours in all subjects, whereas in most subjects the 
improvement in FEV! was well maintained 4 hours after drug administration.20 
Similar results were obtained by Ahrens et al. 22 and Joad et al. 23 This difference in the 
duration of the bronchodilating and protective effects suggests that the protection is not 
only a result of smooth muscle relaxation. but is also detennined by other mechanisms. 
This is supported by in vitro studies in which relaxation of guinea pig trachea with 13-
agonists did not affect the concentration-response relationship to carbachol. 28 
Data on the effect of short-acting Jl,-agonists on the maximal degree of airway 
narrowing are limited. Bel et a1. did not find a protection against excessive airway 
narrowing after sinOe doses of 200 and 400 I'g salbutamol, despite an effect on the 
position of the dose-response curve.29 On the contrary, a steepening of the slope of the 
dose-response curve was found. 
Short-acting Jl,-agonists were generally held not to influence the late asthmatic reaction 
and the allergen-induced increase in ainvay responsiveness. However. two recent 
studies revealed an inhibition of the late asthmatic reaction after inhalation of single 
doses of salbutamol of 2.530 and 0.5 mg. 31 Two-and-a-half mg salbutamol also protected 
against the allergen-induced increase in airway sensitivity up to 7.5 hours after 
administration. Whether this is the result of functional antagonism or of other properties 
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Table 2.2 Long-term effect of short-acting inhaled Gragonists on airway sensitivity to histamine or 
methacholine. 
Reference Drug and Daily Duration Test Interval Mean change 
frequency dose in PC211 or 
(pg) PD20 (UD) 
Adults: 
Peel et al salbutamol 800 1010 histamine >6 h -n.3(pC) 
(32)n~8 q.Ld. 2 wk +O.5(PC) 
Kraan et al terbutaline 2000 2 wk methacholine >12 h -0.8(pC) 
(33)n~17 q.i.d. > 12 h -0.5(pC) 
2 wk +O.I(PC) 
4 wk -0.3(pC) 
Van Schayck salbutamol 1600 12 010 histamine >8h -0.3(PC) 
et al(34) q.i.d. 
n = 15 
Wiebicke et al salbutamol 800 3 wk histamine >6h +0.6(pClOO)* 
(35) n ~ 12 q.i.d. methacholine >6h O(PCloo)' 
Haahtela et al terbutaline 750 22 010 histamine 6h +O.3(PCI5)** 
(36) n ~ 43 b.Ld. 
Vathenen et al terbutaline 2150 2wk histamine 23 h -1.5(PC) 
(37) n ~ 8 t.i.d. 
Sears et at fenoterol 1600 24 wk methacholine >6 h O.6(pC)*** 
(38) n ~ 64 q.i.d. 
Kerstjens et at terbutaline 2000 24mo histamine >8h O(PC) 
(39) n ~ 91 q.Ld. 
Children: 
Kerrebijn et al terbutaline 1500 1 rna methacholine 12 h -0.9(PD) 
(40) t.i.d. 3 rna 12 h -0.8(pD) 
n = 7 6mo 12 h -0.8(PD) 
Raes et al fenoterol 600 1 rna histamine 12 h +O.I(PD) 
(41) t.i.d. 2 mo 12 h +0.2(PD) 
n = 8 3 rna 12 h + !.l(PD) 
4 mo 12 h + 1.9(PD) 
\Vaalkens et al terbutaline 2000 4 wk histamine > 12 h -0.5(PC) 
(42) q.i.d. 8 wk > 12 h -O.I(PC) 
n = 12 
Van Essen- salbutamol 600 22 mo histamine > 8 h O(PD) 
Zandvliel et al t.i.d. 
(43) n ~ 58 
* PC[oo = provocative concentration which causes an increase in sRaw by 100% 
** PC IS = provocative concentration which causes a decrease in FEV l by 15% 
*** Difference between regular and on demand treatment 
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Table 2.3 Acute protection of long-acting Bl-agonists against airway sensitivity to histamine or 
methacholine. 
Reference Drug Dose Test Interval Mean change 
(pg) (bours) in PCzo or 
PD" (DD) 
Derom et at salmeterol 50 methacholine 1 +2.4 (PC) 
(46) 12 + 1.6 (PC) 
12 adults 100 1 +3.2 (PC) 
12 +2.4 (PC) 
Campos salmeterol 50.* histamine 1 +2.7 (PC) 
Gongora et al(47) 12 + 1.8 (PC) 
12 adults 50.** 1 +2.4 (PC) 
12 + 1.5 (PC) 
Cheung et al salmeterol 50 methacholine 1 +3.3 (PC) 
(48) 
12 adults 
Verbcmc salmelerol 50 methacholine +3.8 (PD) 
et al(49) 12 +2.0 (PD) 
20 children 24 + 1.2 (PD) 
Simons et al salmeterol 25 methacholine 0.5 +2.0(PC) 
(50) 12 +2.I(PC) 
20 children salmctcrol 50 0.5 +2.8(pC) 
12 +2.5(PC) 
Maconochie salmeterol 12.5 histamine I +1.5(pC)*** 
et al (51) 12 +0.9(PC)*** 
8 adults 50 1 + 1. 7(pc)*** 
12 +0.8(pc)*'* 
100 1 +2.6(PC)*** 
12 +2.0(pc)*** 
Rabe ct al salmeterol 50 methacholine 0.5 +3.6(PC) 
(52) 12 +2.5(pC) 
12 adults 24 + 1.9(PC) 
Soler et al salmeterol 50 histamine 14 + 1.1(PD) 
(53) 13 adults 
Nix et al(56) fomlOterol 12 methacholine 2 + 1.1 (PC) 
12 adults 5 + 1.5 (PC) 
Ramsdale et al formoterol 12 methacholine 0.5 +3.8 (PC) 
(57) 12 +2.6 (PC) 
16 adults 24 0.5 +4.3 (PC) 
12 +3.0 (PC) 
Becker et al formoterol 12 methacholine 0.5 +2.9 (PC) 
(58) 12 + 1.7 (PC) 
16 children 24 0.5 +3.6 (PC) 
12 +2.1 (PC) 
Von Berg et al fomtoterol 12 histamine 2 +3.3 (PDrool**** 
(59) 8 +2.7 (PDlool**** 
5 children 
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Wong et al formoterol 24 histamine 24 + 1.2(PC) 
(54) 6 adults 
Sovijiirvi formoterol 12 histamine 3 + 1.8(pO)*** 
et al (55) 12 adults 
Rabe et a1 fonnoteroI 12 methacholine 0.5 +3.5(PC) 
(52) 12 +2.5(PC) 
12 adults 24 + 1.1(PC) 
* metered dose inhaler 
** dry powder inhaler 
*** PC[5 or POlS histamine 
**** PD[OO = provocative dose which causes an increase in sGaw by 100% 
of the drug is still the subject of debate. 
2.3.2 Protection during /ong-tel1ll treatment 
Table 2.2 summarizes the results of studies on airway sensitivity during long-term 
treatment with short-acting inhaled B,-agonists in adults and children."'" The duration 
of these studies varied from 2 weeks to 2 years. No significant changes in airway 
sensitivity were found after treatment periods from 2 weeks to 6 months by Peel et alY 
and Wiebicke et al." in adults and by Raes et al. 41 and Waalkens et al. 42 in children. 
The slight increases in airway sensitivity reported by Kraan et al." and Kerrebijn et 
al. 40 are within the intra-subject reproducibility of the measurement and may be the 
result of selecting patients in a stable condition, so that the risk of deterioration is 
greater than the chance of improvement. Although statistically significant, the change 
in airway sensitivity in the 12 months study by Van Schayck et al. is small and unlikely 
to be of clinical importance.34 Two long-term studies (22 and 24 months) in adult 
astbmatic patients comparing treatment with a il,-agonist alone and in combination with 
an inhaled corticosteroid did not show an increase in ainvay sensitivity in the 13r agonist 
group.J6·" However, the results in both studies may have been influenced by the high 
drop-out rate (10143 respectively 44/91) in the B,-agonist only group, mainly because 
of symptoms. A 22-month study in children did not reveal an increase in airway 
sensitivity during treatment with 200 I'g salbutamol 3 times daily, but in this study, too, 
there was a considerable drop·out rate because of symptoms.43 
In two separate studies37,44 a rebound increase in airway sensitivity of 1.5 and 1.65 DD 
was found 23 and 59 hours after the cessation of maintenance treatment with a 3,-
agonist for periods of 2 and 3 weeks. 
Vathenen et al." as well as O'Connor et al. 45 reported a reduction of the protective 
effect of terbutaline against histarnine- and methacholine-induced airway obstruction 
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Table 2.4 Long-tenn effect of inhaled long-acting fi2-agonists on airway sensitivity to histamine or 
methacholine 
Rererence Drug Dose Duration Test Interval M,mdmge 
(b.i.d) (pg) QlOurs) in PC10 or 
PD" (DD) 
Dahl et al salmeterol 50 4 weeks histamine NS +2.2(PC) 
(68) n~12 
Roberts et salmeterol 50 6 weeks methacholine NS +2.2(PC) 
a1 (69) 
n=12 
Cheung et alsalmeterol 50 methacholine +3.3(PC) 
(48) n~ 12 4 weeks 1 + 1.0(PC) 
8 weeks 1 + 1.0(Pc) 
Beach et al salmeterol 50 6 weeks methacholine 24 +O.O(PD) 
(70) n~ 10 72 +0.2(PD) 
Booth et al salmeterol 50 methacholine 12 +0.9(PD) 
(71) n~1O 4 weeks 12 + I.2(PD) 
8 weeks 12 +0.7(PD) 
Meijer et al salmeterol 50 methacholine 8 + 1.9(PC) 
(72) n~20 1 week 8 +1.7(pc) 
children 8 weeks 8 + I.2(PC) 
16 weeks 12 + I.l(PC) 
Bhagat et al salmeterol 50 methacholine +3.3(PC) 
(73) 1I~1O 2 days +2.4(PC) 
3 days +2.0(pC) 
4 days + I.5(PC) 
5 days 24** + 1.9(pC) 
Kalra et al salmeterol 50 methacholine 1 +2.8(PC) 
(74) n~8 2 days + 1.8(pC) 
3 days + 1.9(pC) 
4 days + 1.6(PC) 
5 days 24** + 1.7(PC) 
Yates et al salmeterol 50 methacholine 15*** +2.4(pc) 
(75)n~12 1 week 15*** + 1.0(PC) 
salmeterol + budesonide50 methacholine 15*** +3.4(PC) 
*** 1 week 15*** +2.3(PC) 
Booth et al salmeterol 50 methacholine 1 +3.3(PD) 
(76) n~22 4 weeks 1 +2.0(PD) 
8 weeks 1 +2.0(PD) 
Verbeme salmeterol 50 methacholine 12 + 1.7(PD) 
et al (77) I month 12 +0.6(PD) 
n=15 children 2 months 12 + 1.0(PD) 
3 months 12 +0.6(pD) 
4 months 12 +0.8(pD) 
Cheung ct salmeterol 50 histamine 1 +3.4(PC) 
al (78) 2 weeks 1 + 1.5(pC) 
n=12 4 weeks 1 + 1.5(PC) 
salmeteroi + Iheophilline histamine 1 +3.5(PC) 
38 
Chapter Two 81·agonists and Airway ResponsiYeIles5 
***** 2 weeks I + 1.8(PC) 
4 weeks I + 1.7(PC) 
Milot et salmeterol 50 methacholine I +3.3(PC) 
a1 (79) 12 +2.5(PC) 
n=26 4 weeks I + 1.7(pc) 
12 + 1.l(PC) 
salmeterol + ics methacholine I +2.4(PC) 
***** 12 + 1.2(pc) 
4 weeks I + 1.4(PC) 
12 +0.3(PC) 
Woolcock salmeterol 50 8 weeks histamine NS* +0.8(POPD) 
e' a1 (80) 24 weeks NS* +0.8(POPD) 
n=140 salmeterol 100 8 weeks histamine NS* +0.6(K"IPD) 
24 weeks NS* +0.6(K"IPD) 
Wong et al salmeterol 50 4 days methacholine 0.25 + 1.6(PC) 
(81) n~14 
Weersink et salmeterol 50 6 weeks methacholine 7 (day) + 1.5(PC) 
al (82) n~16 7 (night) +2.4(PC) 
Yales et at fomlOteroi 24 methacholine 12 + 1.9(pC) 
(83) n~17 2 weeks 12 +0.5(PC) 
* NS = Not stated 
** 10 minutes after pretreatment with 200 pg salbulamol 
*** 15 minutes after pretreatment with 200 pg salbutamol 
**** salmeteroi plus budesonide 800 pg b.Ld 
***** salmelerol plus theophylline (mean serum level 9.9 ± 1.1 mg/l) 
****** salmeterol plus inhaled corticosteroid treatment 
after 14 and 7 days maintenance treatment compared with the first treatment day, 
despite a well-maintained bronchodilating effect. The latter study reported a greater 
reduction in the protection of bronchoconstriction induced by adenosine monophosphate 
than by methacholine, suggesting a more pronounced tolerance to the mast-cell 
stabilizing effects of a Jl,-agonist than to the effects on bronchial smooth muscle. The 
clinical implications of the rebound phenomenon and the development of tolerance to 
non-bronchodilating effects of short-acting Il,-agonists are not yet clear. 
2.4 Long-acting Jl,-agonists 
2.4.1 Acute protection after a single dose 
Several studies have been published on the effects of single doses of salmeteroI4~52 and 
fonnoteroP2.54-59 on methacholine- and histamine-induced airway obstruction. The results 
are summarized in Table 2.3. Except in the study by Cheung et aJ. only the position of 
the dose-response curve (airway sensitivity) was studied. The peak increase in PD20 or 
PC,o varied between 1.1 and 3.8 DD for salmeterol and between 1.2 and 4.3 DD for 
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formoterol. Several studies suggest that the magnitude of the protection is dose-related 
for both salmeterol and formoterol. 4650515758 The duration of protection at least lasts up 
to 12 hours after inhalation.46 47 5051535758 Three studies described a protective effect up 
to 24 hours after inhalation of either 50 I'g salmeterol or 12 and 24 I'g fonnoterol"" 
54 In the study in children, the maximum protective effect was reached one hour after 
inhalation (3.8 DD) and gradually decreased, being 2.0 DD at 12 hours and 1.2 DD at 
24 hours. Nearly half of the children had PD20 measurements within the normal range 
up to 12 hours after inhalation." Tn this study the effect on FEV, at 24 hours was no 
longer significantly different from that after placebo, although a residual bronchodilation 
seemed to persist. Comparable data were found in a study in adults with asthma for 
salmeterol as well as fonnoterol. 52. 54 
After a single dose of 50 I'g salmeterol a small decrease (3.2%) in the maximal 
response plateau was observed. 48 
The first study of salmeterol on allergen induced obstruction described an inhibition of 
the early and late phase reaction over 34 hours, together with an inhibition of the 
allergen induced rise in airway sensitivity to histamine.60 Comparing the results after 
allergen challenge with those after saline, the authors conclude that the inhibition was 
not the result of prolonged bronchodilation or functional antagonism, but was due to 
other, anti-inflammatory mechanisms. Others have argued against this conclusion 
because, although airway sensitivity started at a higher baseline as a result of the 
bronchodilating effect of salmeterol, it showed a progressively lower increase during 
the late phase after allergen challenge.6l Several studies now have been published 
regarding the effects of salmeterol62 63 64 65 and formoterol66 67 on the early and late 
responses after allergen challenge and the effects on blood and sputum eosinophils and 
activation markers. Except the study by Pedersen et al,63 which showed minor effects 
on serum eosinophilic cationic protein and serum eosinophil protein X, none of these 
studies revealed anti-inflanunatory effects of either salmeterol or formoterol. The 
overall conclusion from these studies is that sahneterol and formoterol are able to 
partially inhibit the late-asthmatic reaction due functional antagonism on airway smooth 
muscle, without affecting the anti-inflammatory response. 
2.4.2 Protection during long-term treatment 
Several studies, lasting from a few days to 24 weeks, have investigated the effects of 
salmeterol and formoterol on airway responsiveness during continuous treatment.4868-83 
(Table 2.4) Depending on the interval between the last dose of the long-acting fi,-
agonist and the time of measurement these studies show protection against 
methacholine- and histamine induced bronchoconstriction varying between 0.6 and 2.4 
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DD Up to 12 hours after the last dose. Cheung et al. 48 were the first to publish the 
development of tolerance to the bronchoprotective effect of salmeterol during treatment 
with twice daily 50 p..g salmeterol for several weeks, despite the maintenance of the 
bronchodilating resporue. One hour after inhalation of salmeterol the protection dropped 
from 3.3 DD after the first dose to 1.0 DD after 4 and 8 weeks of continuous 
treatment. Except from the study by Booth et aI., 71 other studies have confirmed the 
development of tolerance for salmeterol as well as for foonoteral. 73.79. 8) From the data 
now available, this seems to establish within the first days of treatment,?) after which 
residual protection (between 1 and 2 DD) remains for at least four months. 77 Inhaled 
corticosteroids and theophylline do not prevent the development of tolerance.74.7618 83 
Three studies also showed tolerance for the bronchoprotection by salbutamol after 
regular salmeterol treatment. 7)·75 So far, the clinical relevance of this is not yet clear. 
Tolerance has also been described for the inhibition of salmeterol on indirect stimuli 
such as exercise, 84 cold air citallenge85 and allergen-induced bronchoconstriction86 during 
continuous treatment for several weeks. After stopping maintenance treatment with 
either salmeteroI or formoterol no rebound increase in ainvay responsiveness has been 
found.48 59 69 70 83 
2.5 Conclusion 
Airway hyper-responsiveness is an important characteristic of asthma, which may be 
related to the severity of asthma symptoms and the long-term outcome of asthma. It can 
be distinguished in ainvay sensitivity and the maximal response plateau. It is attractive 
to hypothesize that treatment regimens that aim at reducing ainvay responsiveness will 
contribute to a better long-term outcome of asthma. Short-acting B,-agonists as well as 
two recently developed long-acting fi,-agonists, salmeterol and formoterol, have an 
acute protective effect on airway sensitivity, reflected in a right-ward shift of the dose-
response curve, induced by non-specific stimuli such as histamine and methacholine. 
For short-acting B,-agonists the duration of protection is only about 3 hours; for the 
long-acting fi,-agonists it may last 12-24 hours. No effect on the maximal degree of 
airway narrowing will occur, although after a single dose of salmeterol a small decrease 
in the maximal response plateau was noted. 
Maintenance treatment with short-acting B2-agonists will not decrease airway sensitivity; 
in fact, some studies have reported a small increase. The clinical relevance of this has 
been discussed over several years now, but so far continuous treatment with short-acting 
B,-agonists has not been unequivocally related to deterioration of asthma. However, 
international guidelines do recommend to use these drugs on an as needed basis. Several 
studies with the long-acting B,-agonists salmeterol and formoterol now have shown that 
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tolerance develops to the bronchoprotective effects after direct stimuli as histamine and 
methacholine as well as after indirect stimuli. This develops within several days after 
the start of continuous treatment, but residual protection remains. Tolerance can not be 
prevented by inhaled corticosteroids. Furthermore, continuous use of long-acting 62-
agonists also resulted in less bronchoprotection by inhaled salbutamol. Theoretically, 
this might have clinical implications when short-acting .B2-agonists are used 
intennittently together with a continuous long-acting .B2-agonist. As far as tolerance to 
the bronchodilator effect is concerned, this is less evident, although long-acting 62-
agonists may show a relatively small shift of the dose-response curve for short-acting 
B2-agonists to the right without effecting the maximum bronchodilation.87 88 There are 
no adverse clinical effects during prolonged treatment with long-acting firagonists, such 
as an increase in number or severity of exacerbations.89 
After treatment with a short-acting Bragonist for 1 or 2 weeks a rebound increase in 
airway sensitivity was found. This has not been found after discontinuation of treatment 
with long-acting B,-agonists. 
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The role of inhaled long-acting bronchodilator therapy 
3.1 SUnmlal'Y 
Inhalation of a single dose of salmeterol or fOl11lOterol results ill prolonged 
brollchodilatioll for at least 12 h alld also protects agaillst various brollchocollstrictillg 
stimuli. such as methacholille, exercise alld allergells. This suggests that twice daily 
sa/meretal and !ol7Jloterol may result ill reduced asthma symptoms and improved lung 
jUllction during chronic freatmelll. 
Studies of twice daily treatmellf with sa/me/erof for up to 12 months have showll Gil 
improvement in symptoms Gnd peakjlow measurements, and 110 increase ill exacerbation 
rate or worsening of asthma has beenllo/ed. Although some reduction of the protection 
against methacholine-induced brollc/IOCOllstriCtiOll was found ill adults and children 
during long-fenn treatment with sa/metel'ol a/one, significant protection remained alld 
showed no fW1her reduction over time. Inhaled corticosteroids are the mainstay of 
asthma treatment ill children with moderate-to-severe asthma, according to illfemational 
cOllsensus rep0l1s. Results from a recently published adult stltdy found that the addition 
of salmeterol to low-dose inhaled corticosteroid compared favourably with increasing 
the corticosteroid dose. 
F1lI1her studies are required to detel7l1ille the place of long-acting brollchodilators in the 
management of childhood asthma. 
3.2 Introduction 
Childhood asthma leads to considerable morbidity, but in Western Europe, at least, 
mortality rates are very low. Hospital admissions for asthma have increased, especially 
in the young age group.l Most children with asthma suffer from exercise-induced and/or 
nocturnal symptoms and frequently miss school because of their asthma. 2 Attention 
should be paid not only to preventing the disease and provocating stimuli, but also to 
effective symptom control. Inflammatory changes in the airway wall mucosa are 
regarded as the pathophysiological basis of the disease3 and, according to recent reports, 
inhaled corticosteroids are the mainstay of asthma treatment, particularly for children 
with moderate-to-severe asthma. 4 5 It might, therefore, be hypothesized that early 
intervention in the inflammatory process in young children with astluna prevents 
deterioration or, eventually. completely reverses the disease. 
So far, the study with the longest follow-up has shown an improvement of symptoms, 
ainvay obstruction and bronchial responsiveness during 3 yrs of treatment with an 
inhaled corticosteroid (budesonide, 600 Jlg day) plus a short-acting fi,-agonist three 
times daily in children with mild-to-moderate asHuna.' 7 During the study period, 60% 
of the children achieved a period of symptomatic remission, which was defined as a 
symptom-free period during which no additional bronchodilator therapy was required 
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lasting for at least 8 months. Nearly 70% of children relapsed from their remission 
during the study, however, and less than 50% of the children with a symptomatic 
remission at the end of the study period had forced expiratory volume in one second 
(FEV,) values and histamine responsiveness in the nonnal range. In a follow-up study 
in which the inhaled corticosteroid therapy was tapered off, there was a rapid reappea-
ranee of symptoms and deterioration in lung function. 8 Thus, with current medication 
regimens, it seems impossible to cure asthma. Moreover, most children are not 
symptom-free and show lung function abnormalities. 
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Figure 3.1 
Bronchodilator action of a single dose of sahneterol ( .......... ), 50 ~lg, 
compared with placebo (-0-) in children. *p ~O.OO I 
Recently, two inhaled long-acting bronchodilators, salmeterol and fonnoterol, have 
become available. Their long duration of action makes twice daily dosing possible, 
which may reduce symptoms and improve lung function over the 24 h period. 
3,3 Clinical studies 
3.3.1 Single dose studies 
The first study of sahneterol in adults with asthma showed that a single dose produced 
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Effect ofsalmcterol (--), 50 ~lg, compared with placebo ( .... -.), on 
exercise-induccd bronchoconstriction in children with asthma. Exercise 
challenges were perfonned: a) I hour; b) 5 hours; c) 9 hours after 
administration of salmeterol or placebo. 
bronchodilation, determined from measurements of peak expiratory flow rates lasting 
up to 12 h after dosing.' The duration of the bronchodilatory effect has also been 
investigated in children with asthma. Single doses of salmeterol, 25 and 50 "g, 
produced significant bronchodilation lasting for up to 12 h after inhalation, and the 
effect had not completely disappeared 24 h after dosing (Fig. 3.1), \0 II The onset of the 
effect was slower for salmeterol than for salbutamol; however, 30 min after inhalation, 
the effect of both treatments was equaL From 3-12 h after inhalation, the effect of 
salmeterol was superior to salbutamoL \0 Single doses of fomlOterol, 12 "g and 24 "g, 
also produced long-lasting bronchodilation in children, 12 
The duration of protection against exercise-induced bronchoconstriction has been studied 
in 13 children with asthma for up to 12 hours after inhalation, 13 14 Salmeterol, 50 "g, 
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reduced the exercise-induced fall in FEV! in all children at all time points (Figure 3.2). 
Formoterol showed significant protection up to 12 h after dosing.!4 Protection against 
methacholine-induced bronchoconstriction has been investigated in two paediatric cross-
over studies, with 20 children in each study. 10 11 Twelve hours after inhalation of 
salmeterol airway responsiveness to methacholine was reduced by about two DD, and 
24 h after in11alation there was still significant protection of more than one DD (Figure 
3.3). These results are comparable with the results from adult studies for protection 
against exercise l5 16 and methacholine. 17 18 In adults, long-lasting protection has also 
been found against bronchoconstriction caused by allergens, 19 20 histamine2 ! and hyper-
ventilation.22 No data for these bronchoconstrictors are available in children. 
In conclusion, single doses of salmeterol in children result in prolonged bronchodilation 
and protection against bronchoconstrictors, such as methacholine and exercise. 
3.3.2 Multiple dose sludies 
Salmeterol and fOlIDoterol are recommended for use as regular preventive therapy. 
Results for continuous treatment are, therefore, more relevant clinically than single dose 
studies. Data from paediatric patients are beginning to appear. 
A double-blind, parallel-group multicentre study of 847 children with asthma has com-
pared the effect of salmeterol, 25 and 50 flg b.Ld., with salbutamol, 200 flg b.Ld., 
during 12 months of treatment. 2J Treatment was given either by a metered-dose inhaler 
(MDI) or by a dry powder inhaler (Diskhaler™). More than half of the study population 
was receiving in11aled c0l1icosteroid treatment and another 18% were using sodium 
cromoglycate when they entered the study. These treatments were unchanged during the 
study period. 
Mean morning and evening peak flows improved in the first week of treatment with 
salmeterol and were sustained during the 3 month observation period. Salmeterol, 50 
flg b.Ld., was significantly better than salbutamol, 200 flg b.Ld., in terms both of 
morning and evening peak flow rates. Children receiving sahneterol, 50 flg b.Ld., had 
slightly more symptom-free nights and more days without rescue bronchodilator therapy 
compared with the salbutamol groups. There were no changes in the rate of asthma 
exacerbations during the 12 month period in either treatment group. The Diskhaler™ 
and MDI were equally effective for the same dose. 
In another study, sahneterol, 100 flg b.Ld., was added to inhaled corticosteroid treat-
ment in 11 children with severe asthma who attended a residential school for asthma. 
A significant improvement in morning and evening peak flow rates and FEV I values 
was seen in the salmeterol group during the 8 weeks of treatment. 24 There was a trend 
for improvement in all symptom parameters. 
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The effect of long-tenn treatment with salmeterol on airway responsiveness has been 
studied in a double-blind, parallel-group study comparing salmeterol, 50 I'g b.i.d., with 
salbutamol, 200 I'g b.i.d., in 30 children." Throughout the 4 month treatment period, 
a constant significant protection against methacholine challenge was observed with 
salmeterol compared with baseline values and salbutamol. The protective effect during 
chronic treatment, however, was significantly less than the effect after the first dose of 
salmeterol (0.7 and 1.7 DD, respectively). This reduction of protection has also been 
observed by Cheung et al26 in adults with asthma, but was not seen in another study by 
Booth et al27 • It is of interest that both studies which showed a reduction of protection 
were performed in asthmatics not receiving concomitant inhaled corticosteroid therapy, 
whilst in the study in which the protective effect was maintained27 , most of the partici-
pants were receiving maintenance treatment with inhaled corticosteroids. The clinical 
relevance of this effect is not yet clear. Tolerance to the protective effect against 
exercise-induced bronchoconstriction has also been shown.28 Recently, for salmeterol, 
sub-sensitivity was suggested after two weeks of treatment. However, this study has 
been extensively criticized for methodological reasons. 29 
In summary, salmeterol, 50 p..g b.i.d., has been shown to reduce symptoms and improve 
lung function in children with asthma. The protection against methacholine challenge 
is less during prolonged treatment than after a single dose. Significant protection seems 
to remain and there are no signs of further deterioration over periods of several months. 
3.4 Adverse events 
The most conmlOnly reported adverse events in children receiving long-term treatment 
with salmeterol, 50 I'g b.i.d., were upper respiratory tract infections and related 
symptomsY 25 Pharmacologically predictable adverse events, such as tremor, ta-
chycardia and palpitations, were low, as was headache. No clinical significant effects 
on heart rate and rhythm were noted during 24 h electrocardiographic monitoring.30 
3.5 Place in asthma treatment 
3.5.1 In general 
The data now available for children are similar to those for adults and show a reduction 
of asthma symptoms and improvement in lung function, as detennined by measurement 
of peak flow or FEV l' A reduction in protection against methacholine challenge has 
been observed in one paediatric and one adult study but its clinical relevance, if any, 
is unclear. Tolerance to nonpulmonary effects, such as tremor, increased QTc interval 
and elevated blood glucose, has been observed after 2 weeks of treatment with 
salmeterol in healthy individuals.'l There are no data to suggest that an increase in 
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exacerbation rate or worsening of asthma control may occur during continuous 
treatment with salmeterol. There is still some debate about the continuous use of short-
acting fi2-agonists, J2 and a rebound increase in airway responsiveness has been described 
for these agents. 34 35 The data available for salmeterol show that a clinically important 
rebound phenomenon is unlikely. 25 26 35 
3.5.2 Exercise-il/duced asthma 
Exercise-induced asthma is thought to occur in up to 90% of asthmatic patients and is 
particularly common in children because of their heightened and often unstructured 
levels of physical activity. Its psychosocial effects are also more pronounced in 
childhood because of the importance of physical activity. whether as organized sport or 
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play, to the development of the child and the importance society places on perfomling 
well. While short-acting bronchodilators have demonstrated effectiveness in relieving 
exercise-induced symptoms and can also be used before exercise to reduce its effects,36 
the extended duration of action of the long-acting bronchodilators suggests that they 
may be particularly well suited for the management of exercise-induced asthma. 
The effects of long-acting bronchodilators in exercise-induced asthma have been clearly 
demonstrated for sahneterol in a large study involving 161 adults37 and in two smaller 
studies in children. In one double-blind cross-over placebo-controlled study in 13 
children who suffered from exercise-induced asthma, salmeterol was demonstrated to 
have a protective effect during exercise tests for up to 9 It after inhalation. 13 In a similar 
study involving 17 children, salmeterol was found to protect 65 % of children for 6.5 
It after inhalation. 38 In contrast, salbutamol provided protection against bronchospasm 
for 30 min but not at 2.5 h or longer. 
Similar results have been shown for fomlOterol (12 I'g) in a study of 15 asthmatic 
children (aged 6-12 years) with exercise-induced bronchoconstriction. 14 Formoterol was 
found to be significantly better in limiting exercise-induced bronchoconstriction than 
both salbutamol (200 I'g) and placebo in exercise tests perfonned 3 and 12 hours after 
dosing. 
3.5.3 Allfi-ilif/ammaIOl}' effecls 
Although anti-inflammatory effects of salmeterol have been well described in vitro,39-42 
no influence on chronic ainvay wall inflammation could be detected after 6 or 8 weeks 
of b.Ld. treatment with salmeterol in adults with asthma.4243 In the absence of studies 
comparing long-acting bronchodilators with prophylactic treatment using inhaled 
corticosteroids or sodium-cromoglycate, it would be best to use these drugs only in 
addition to inhaled corticosteroid treatment. One should also realize that most patients 
in the previously mentioned long-teon studies were receiving prophylactic treatment. 
The most urgent question at this time seems to be whether patients who are poorly 
controlled with a conventional dose of inhaled corticosteroids would gain more benefit 
from the addition of a long-acting bronchodilator to the conventional dose of inhaled 
corticosteroid than increasing the dose of inllaled corticosteroid. This is an important 
issue, particularly in children where the potential risks of inhaled corticosteroids may 
be more significant than in adults. 
Recently, two adult studies have addressed this question. Greening et al" studied 429 
adults with asthma who still had symptoms despite maintenance treatment with inhaled 
beclomethasone dipropionate (BDP), 200 I'g b.Ld. Patients were randomized to receive 
either salmeterol, 50 I'g b.Ld., in addition to BDP, 200 I'g b.Ld., or a higher dose of 
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inhaled corticosteroid (BDP, 500 I'g b.Ld.) for a 6 month period. Mean morning and 
evening peak flows were higher in the salmeterol treated group; there was also a 
significant reduction in diurnal variation. Use of rescue bronchodilator and daytime and 
nighttime symptoms were lower in the salmeterol group. 
Another study by Woolcock" has compared the addition of salmeterol in two doses, 50 
I'g and 100 I'g b.Ld., to BDP, 500 I'g b.Ld., with BDP, 1000 I'g b.Ld. Both salmeterol 
groups were superior regarding monting and evening peak flow measurements and 
certain symptom scores34 • Ainvay responsiveness was measured in part of the study 
population; no changes of more than one DD from baseline were detected in either 
treatment group. Both studies lack a control group in which the inhaled corticosteroid 
dose was not increased. 
3.6 Conclusion 
Further studies in asthmatic children will be necessary to define the place of long-acting 
bronchodilators in the treatment of childhood asllnna. It may well be that children, 
especially those who usually have good reversibility of bronc hoc on stricti on, may benefit 
more from adding a long-acting bronchodilator to a conventional dose of inhaled 
corticosteroids than from increasing the dose of inhaled corticosteroid. 
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Effect of a single dose of inhaled salmeterol on baseline airway caliber 
and methacholine-induced airway obstruction in asthmatic children 
4.1 Summary 
Sa/meteral is a new inhaled selective fi2-adrenergic receptor agonist with a long 
duration of action. We studied the duration of the bronc/lOdilation alld the protective 
effect against methacholine-induced ainvay obstruction of a single dose of salmeterol 
ill a double-blind, randomized, placebo-controlled cross over design. 
Sevellleen boys and 3 girls with mild-to-moderate asthma participated in the study. On 
two separate days either 50 p.g salmeterol 01' placebo was inhaled. FEV/ alld PD,o 
methacholine were determined before and I, 4, 8, 12 and 24 hours after inhalation. 
Salmeterol resulted in a significant bronchodilation compared with placebo up to 12 
hours (p=0. 0001). At 24 hours there was a residual effect that approached significance; 
mean FEV/ being 8.3% ± 2.4 above baseline (p=0.06). Significalll protection against 
ainvay sensitivity to methacholine after salmeterol inhalation was found at all time 
poillls (p < 0.005). Twenty-foul' hOllrs after administration mean PD,o was still 1.22 ± 
0.29 DD above baseline. No impOltanf adverse effects were noted. 
We conc/ude that a single dose of 50 p.g salmeterol in children with asthma gives a 
long-lasting brollchodilatioll, exceeding 12 hours, which is comparable 10 the results ill 
adult studies. The duration of the protection against ainvay sensitivity to methacholine 
exceeds 24 hours. 
4.2 Introduction 
Asthma is characterized by a variable degree of airway obstruction and airway 
hyperresponsiveness to several stimuli. 1 Persistent airway obstruction and airway 
hyperresponsiveness predispose to chronic symptoms and constitute a risk factor for the 
continuation of childhood asthma into adulthood. 2,3 Ainvay hyperresponsiveness can 
be characterized by an increase in airway sensitivity and by an increase in maximal 
response.4 
Currently available short-acting inhaled fi,-agonists, like salbutamol, are strong 
bronchodilators. Their bronchodilating effect lasts for approximately 4 to 6 hours.5 
After inhalation of therapeutic doses, protection against histamine-induced airway 
responsiveness and other acute challenges, such as allergen, exercise, and cold air, lasts 
less than 4 hours,5,6 They do not influence the maximal degree of airway narrowing; 
moreover, a steepening of the dose-response curve for methacholine and histamine has 
been reported. 7 
Salmeterol xinafoate (Glaxo, England) is a new selective fi,-agonist with a long duration 
of action on smooth muscle contractility in vitro. 8 Its long-lasting bronchodilating effect 
in vivo has been established in several studies in adult asthmatic patients,,· l0,l1 More 
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than one half of the maximum bronchodilation remains 12 hours after administration.9 
In healthy volunteers, protection against histamine-induced ainvay obstruction lasted 12 
hours after inhalation of 200 I'g salmeterol. 12 In adult asthmatic patients protection 
against methacholine- and histamine-induced airway obstruction remained for at least 
12 hours after salmeterol doses of 50 and 100 I'g and appeared to be dose-related. IO.II 
The aim of our study was to establish the duration of the bronchodilating effect and the 
degree and duration of the protection against airway sensitivity to methacholine of a 
single dose of 50 I'g salmeterol in children with mild-to-moderate asthma. 
4.3 Material and methods 
4.3.1 Patieflls 
Twenty children with mild-to-moderate asthma, 17 boys and 3 girls, were studied. The 
patient characteristics are summarized in Table 4.1. The children were selected from 
the outpatient department of Pediatric Respiratory Medicine, Sophia Children's 
Hospital, University of Rotterdam. The following inclusion criteria were fulfilled at a 
prestudy visit: (I) mild-to-moderate asthma according to American Thoracic Society 
criteria,l that is, reversible ainvay obstruction with an increase of at least 15 % in forced 
expiratory volume in one second (FEY1) after inhalation of a bronchodilator, (2) age 
between 7 and 16 years, (3) baseline FEY1 greater than 60% predicted, (4) airway 
hyperresponsiveness to methacholine, that is, the dose of methacholine to produce a 
20% fall in FEY1 (PDlO) equal to or less than ISO I'g, I3 (5) ability to produce 
reproducible lung function tests, that is, coefficient of variation in three consecutive 
measurements of FEV 1 less than 5 %. All children were atopic to one or more inhaled 
allergens. Their asthma had been stable for at least I month, with no respiratory tract 
infections. Maintenance treatment, which had not been changed during the previous 6 
months, consisted of inhaled corticosteroid (12 children), disodium cromoglycate (3 
children), or both (3 children). All patients used a ll,-agonist on demand. 
4.3.2 Study design 
The study was double-blind, randomized, placebo-controlled, and crossover. The 
children visited the lung function laboratory on two separate occasions within 4 weeks; 
the interval between visits being no shorter than 3 days, preferably approxinlRtely I 
week. They arrived at 8 AM, having abstained from inhaled bronchodilators for at least 
12 hours. After a short rest (IS minutes), baseline heaI1 rate, blood pressure and FEY1 
were measured. Then a methacholine provocation test was performed. At least I hour 
after the last concentration of methacholine, when FEY1 had returned to within 10% of 
baseline, the study medication was inhaled. Tltis consisted of either placebo or 50 I'g 
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Table 4.1 Patient characteristics at entry of the study. 
Subject Age Sex FEV. FEV1IFVC PD20 Maintenance 
QT) (%pred.) (%) (pg) treatment 
I 9 M 94 77 19 B CS 
2 10 M 103 86 80 BCS 
3 10 M 86 76 83 BS 
4 14 M 65 64 25 BCS 
5 13 M 76 90 109 B 
6 9 M 82 78 94 BS 
7 13 M 57 60 3 BS 
8 16 M 88 79 24 BS 
9 12 M 103 77 14 BS 
10 16 M 61 52 26 BS 
II II M 81 63 19 BS 
12 12 M 90 86 35 BC 
13 10 M 81 69 16 BS 
14 II M 88 83 47 BS 
15 16 M 99 78 123 B 
16 12 F 85 77 41 BC 
17 8 M 90 74 42 BS 
18 7 F 89 69 16 BS 
19 10 F 71 70 7 BC 
20 9 M 81 66 22 BS 
Mean 11.8 84 74 30* 
SD 2.7 12.7 9.6 
M, male; F, female; B, inhaled 1l2-agonist on demand; C, inhaled disodium cromoglycate; S, inhaled 
corticosteroid. 
* Geometric mean 
salmeterol, administered as two puffs from a metered dose inhaler in conjunction with 
a Volumalic (Glaxo) spacer device. The two puffs were given one by one. 
After each puff the child had to take five breaths of sufficient magnitude to move the 
valve of the Volumatic. 14 During the study days no other bronchodilators were allowed 
except the study m.edication. Inhaled corticosteroid and/or disodium cromoglycate were 
continued as before entry into the study. On both study days they were inhaled at the 
same time of the day for all patients. 
Repeated measurements of heart rate, blood pressure, and FEV I as well as repeated 
methacholine provocation tests were perfomled 1, 4, 8, 12 and 24 hours after 
administration of the study medication. During the day the children stayed in the 
laboratory of the outpatient department of pediatric respiratory medicine, during the 
night they slept in the hotel accommodation of the hospital together with one of their 
parents. 
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The study was approved by the medical ethics committee of the University 
Hospital/Sophia Children's Hospital Rotterdam. Informed consent was obtained from 
all patients and their parents. 
4.3.3 LUllg jUllction measuremellts 
All FEV 1 measurements were performed on a spirometer with a digital volume 
transducer (Vicatest-P2, Mijnhardt, Zeist, The Netherlands). Reference values used 
were those of the European Community for Coal and Steel." Before each 
methacholine provocation, FEV 1 was measured in triplicate; the best value was taken. 
Methacholine provocation was perfOlmed according to standardization 
recommendations. 16.17 Aerosol-dispersed methacholine bromide in unbuffered saline 
was given in doubling concentrations (0.125 to 32 mg/rnl). The aerosol was generated 
by a DeVilbiss 646 (De Vilbiss Co., Somerset, PA, USA) nebulizer, which was 
operated with 3 ml solution in the nebulizer cup. The nebulizer was attached to a 
Rosenthal-French dosimeter (Laboratory for Applied Immunology, Fairfax, Virginia, 
USA) driven by air at 137.8 kPa (20 psi). The aerosol was delivered directly into the 
mouth through a mouthpiece. The patient inspired slowly from functional residual 
capacity to total lung capacity. During inspiration the dosimeter was triggered for 0.6 
seconds. After the inspiration had been completed, the child was asked to hold his or 
her breath for about 2 seconds. A total of 20 1'1 of aerosolized solution was delivered 
to the mouth in four consecutive breaths. Mouth doses were 2.5 to 640 I'g 
methacholine. In order to exclude reactions to the diluent, saline solution was inhaled 
before methacholine in a similar way. FEV1 was measured in triplicate 3 minutes after 
saline or methacholine inhalation. The interval between consecutive doses was 5 
minutes. The next methacholine dose was not given if FEV, had fallen below 80% of 
baseline. PD10 was calculated from a log dose-response plot with linear interpolation of 
data points. 
4.3.4 Statistical allalysis 
Wilcoxon's signed-rank test was used to compare active treatment with placebo after 
verifying that no significant treatment-order and period effects were present. i8 To 
allow for the multiplicity of testing at five time points, p values less than 0.01 (0.0515) 
were considered to be statistically significant according to Bonferroni's procedure. The 
effect of study treatment on FEV, was expressed as percent change from baseline FEV, 
on the same day. Logarithmic transfonnation was perfonned in all analyses of PD,o' 
The magnitude of the protection against methacholine-induced airway sensitivity was 
expressed in DD change from baseline PD20 on the same day. In patients who did not 
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reach a 20% fall in FEV, after the maximum dose of 640 I'g methacholine, PDlO was 
considered to be 640 I'g for statistical calculations. As in these cases, PDlO is known 
to exceed 640 I'g, and all but one of these occurred during active treatment; this will 
underestimate the treatment effect of salmeterol. Therefore an additional analysis was 
performed, with use of survival analysis tecimiques, allowing for such censored data. 
With these methods full use is made of the information that some PD20 values are 
known to exceed 640 I'g, instead of assuming them to be equal to 640 I'g. Because PD20 
values appeared log nonnally distributed, it was possible to make adjusted estimates 
(Le. which take account of the censored values) of the mean difference in DD at the 
different time points. 19 
4.4 Results 
Twenty children entered the study. Mean baseline values of FEV, and baseline 
geometric means of PD20 at the two different treatment days did not differ significantly; 
2.20 and 2.13 L (83% and 82 % predicted), respectively, 34.7 and 30.9 I'g,respectively, 
methacholine during placebo and active treatment. There were no effects of treatment 
order or period effects on FEY 1 and PD10 at all time points. 
During placebo administration two children had an exacerbation of their asthma at 8 and 
12 hours, respectively, after administration. Both children received salbutamol for relief 
of their symptoms. Measurements of FEV I and methacholine responsiveness within 12 
hours after the salbutamol dose were not perfonned. 
4.4.1 Effect 011 ainvay caliber 
Salmeterol gave a long-lasting bronchodilatation (Figure 4.1). Compared with placebo 
the effect on FEV, was highly significant at all time points up to 12 hours (p = 
0.0001). The maximum mean effect on FEV, was reached after 4 hours; the change 
from baseline being 18.6 % ± 2.5 % (mean ± SEM). However, after 1 hour 
bronchodilation was near its maximum (17.7 % ± 2.3 %). Twelve hours after inhalation 
of salmeterol mean FEV, was 10.8% ± 2.7% (p = 0.0001) above baseline, and after 
24 hours it was still 8.3% ± 2.4% above baseline. Compared with placebo this value 
was approaching significance (p = 0.06). After placebo administration mean FEV, 
decreased with a maximum of 6.9% ± 2.0% after 12 hours. Results of FEV/forced 
vital capacity (FVC)% were comparable to those of FEV,. Sahneterol inhalation 
resulted in a significant increase in FEV1/FVC% at 1, 4, 8 and 12 hours compared with 
placebo (p < 0.002). After 24 hours the mean FEV,/FVC% was respectively 0.77 and 
0.75 after salmeterol and placebo (p = 0.19). 
After salmetewl, individual results showed an increase in FEV, from baseline of at least 
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Figure 4.1 
Change in FEVt in percent change from baseline (SEM). 
Sahnctcrol, (-)~ placebo, ( ...... ). 
10% in 17 of 20 children. The maximum bronchodilating effect in these responders 
varied between 12% and 46%. Seven patienls had their peak effect after 1 hour, seven 
after 4 hours and three after 8 hours. Also the time period for which FEV! was more 
than 10% above baseline varied between patients. Eight of the 17 responders had FEV! 
values of more than 10% above baseline during 24 hours. In the remainder of 
responders FEV 1 values of more than 10% above baseline were maintained for up to 
12 hours in three patients, up to 8 hours in one, and up to 4 hours in five. 
4.4.2 Effect all ainvay sensitivity to methacholine 
The protection against methacholine-induced airway obstruction lasted for 24 hours. 
Figure 4.2 shows the geometric means of PD20 after salmeterol and placebo. The 
changes from baseline, expressed in DD are shown in Figure 4.3. Salmeterol resulted 
in a decrease in airway sensitivity to methacholine, with a maximum mean effect of 
nearly four DD 1 hour after inhalation, which gradually diminished to slightly more 
than one DD after 24 hours. Compared with placebo the protection of salmeterol was 
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Figure 4.2 
PDiO methacholine (geometric mean ± SEM). Salmeterol, (--); 
placebo, ( ...... ). 
Table 4.2 Number of patients in which PDlO exceeded 640 JLg methacholine 
Number or patients in which Unadjusted mean Adjusted mean 
Time PD20 exceeded 640 pg differences in PD20 differences in PD20 
(DD) (DD) 
I hour 10 3.7 (3.1-4.2) 4.S (3.8-S.2) 
4 hours S 3.7 (3.0-4.4) 4.1 (3.3-4.9) 
8 hours 3 3.2 (2.S-3.9) 3.5 (2.9-4.1) 
12 hours 2 3.0 (2.3-3.7) 3.2 (2.S-3.9) 
24 hours 1* 1.3 (0.S-2.1) 1.2 (0.4-2.0) 
Except the one marked (*). this occurred after salmeterol treatment. Unadjusted and 'adjusted mean 
differences (95% confidence intervals) in PDlO' expressed as DD, at different time points between 
salmeterol and placebo treatment are given. Unadjusted values were calculated, assuming PDl{) in these 
patients was 640 fig. Adjusted mean differences were calculated, using survival analysis techniques, 
laking account for the censored PDlO values, which actually exceed 640 Jig. 
highly significant at all time points (p < 0.0002 up to 12 hours, P 
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hours). After placebo administration no changes of more than one DO occurred. 
No PD20 was reached after the maximum methacholine dose, i.e. 640 p.g, in a 
substantial number of the children after salmeterol administration and in one patient 24 
hours after placebo. Because in these subjects PD20 was considered to be 640 p.g, the 
above mentioned treatment results underestimate the treatment effect. Taking into 
account that POlO actually exceeded 640 I'g in these patients, adjusted mean differences 
between salmeterol and placebo treatment were calculated (Table 4.2). 
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Figure 4.3 
PD20 changes from baseline (doubling doses ± SET"I). Salmeterol, (-); 
placebo,( """). 
One hour after administration of salmeterol 18 patients had PD20 values in the nonnal 
range, that is PD,o equal to or greater than 150 I'g methacholine. 13 For the other 
subsequent time points after 4, 8, 12 and 24 hours, respectively, 17, ll, 8 and 5 
children had their PD20 in the normal range. 
The peak response of the protective effect was measured at I hour after salmeterol 
administration in all subjects and varied between 2.2 and 6.1 DO. In only five patients 
the protective effect became less than one DO within 24 hours. 
No correlation was found between the degree of the protective effect and the degree of 
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respectively, p > 0.5). 
4.4.3 Adverse evellls 
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-0.14, -0.15, -0.12, -0.14 and 0.11, 
No adverse effects, like tremor or palpitations, were noted during the study. Two 
children complained of headache; one during placebo and one during salmeterol 
treatment. Heart rate, systolic and diastolic blood pressure during active treatment did 
not significantly differ between sahneterol and placebo. 
4.5 Discussion 
In adult studies 50 p.g sahneterol had been shown to be efficacious.'-l1 In a first study 
in children this dose was well tolerated. 20 
In this study the bronchodilating effect of 50 p.g salmeterol exceeded in most patients 
12 hours, although in a few patients it was less. Twenty-four hours after administration 
there was still a small but significant reduction of airway sensitivity to methacholine. 
Although at this thne point the bronchodilating effect of salmeterol was not significantly 
different from that after placebo, a residual effect on FEV I seemed to exist in 
approximately one half of the patients. The changes of FEV, and PD,o after placebo 
administration were small and likely to be caused by diurnal variation. 
In adult studies the peak level of FEV, after a single dose of 50 p.g salmeterol was 
comparable with that after 200 p.g salbutamoI. 1O•11 •21 Mean peak increases were 15 %, 
12% and 18%, respectively, which is comparable with the results in our study (18.6 % 
± 2.5%). The relatively small increase in FEV, may be due to the mild degree of 
airway obstruction at entry. Studies in adults report a significant bronchodilation after 
single doses of salmeterol 50 and 100 p.g up to 12 hours after inhalation. '-11 Our results 
are in keeping with those of Ulhnan and Svedmyr,' who found that one half of the 
bronchodilator effect remained after 12 hours. Another study showed almost identical 
mean FEV, values I and 12 hours after 50 I'g salmeterol. lO No data are available on the 
bronchodilating effect 24 hours after inhalation. 
The protective effect against methacholine-induced airway obstruction was studied in 
adult astlunatic patients by Derom et al. 11 Salmeterol, 50 and 100 p.g, gave a significant 
dose-related protection up to 12 hours after inhalation, whereas the effect of 200 p.g 
salbutamol was no longer significantly different from that of placebo at 4 hours. Twelve 
hours after salmeterol mean PC,o was 1.5 DD after 50 p.g and 2.4 DD after 100 I'g 
salmeterol, which is comparable with 2.0 DD in our study after 50 I'g. The peak effect 
was smaller, 2.4 and 3.3 DD, respectively, after 50 and 100 I'g salmeterol. In a study 
on histamine-induced airway obstruction, the peak effect was 2.7 DD, which is also less 
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than we obtained, but the protection 12 hours after inhalation of 50 j.!g salmeterol was 
again similar (1.79 DD). iO Whether these differences result from differences in patient 
characteristics or differences in pharmacokinetics between children and adults is 
unknown. Campos Gongora et al10 found 50 J-tg salmeterol four times as potent as 200 
j.!g salbutamol in regard to the protective effect against histamine-induced airway ob-
struction, whereas 50 J.tg salmeterol equaled the protective effect against methacholine 
of the same dose of salbutamol in another study. 11 No data are available on the effect 
of methacholine- and histamine-induced airway obstruction 24 hours after inhalation. 
In a recent saline challenge study 32 hours after 50 p,g salmeterol, there was no 
significant effect on either FEV1 or airway responsiveness to histamine.22 Malo et al. 21 
studied the effect of a single dose of 50 I'g salmeterol on hyperventilation with cold dry 
air up to 24 hours. The mean duration of the protective effect of salmeterol was 15.9 
hours, compared with 3.5 hours for salbutamol. However, 24 hours after inhalation 
only one patient showed a significant protection. In our study 24 hours after inhalation 
15 of the 20 children showed a clinically relevant protection against methacholine-
induced ahway obstruction, that is, more than one DD above baseline. So the duration 
and degree of the protective effect of salmeterol may be different for different stimuli, 
which is also known for short-acting Ih-agonists.5 
Non-bronchodilating properties of salmeterol have been suggested from in vitro studies 
on human lung fragments23 as well as from the study by Twentyman et al22 who 
revealed a complete inhibition of the rise in nonspecific airway responsiveness over a 
34-hour period after allergen challenge. Mechanisms other than bronchodilation and 
functional antagonism were held responsible for the protection of a short-acting fir 
agonist against several constrictor stimuli in guinea pig trachea preparations.24 The 
data in our study do not allow any conclusion on whether the long-lasting effect of 
salmeterol on airway sensitivity is the result of inhibition of smooth muscle contractility 
or of other non-bronchodilating properties. The fact that no correlation was found 
between the degree of the protective effect and the bronchodilating effect, which is also 
known for short-acting fi1-agonists,5 supports the view that mechanisms in addition to 
smooth muscle inhibition playa role. 
It is unlikely that our results have been influenced by the concomitant use of inhaled 
corticosteroids or disodium cromoglycate or both. No significant direct protective effect 
on methacholine-induced airway responsiveness of these drugs exists. 6 During both 
study days these drugs were administered at the same time point for all patients, so they 
only could have influenced the placebo and the active treatment in the same way. 
Because all patients were using their maintenance treatment for at least 6 months, it is 
unlikely that the chronic dosing effect has changed within the study period. It is in 
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agreement with tIils that no period effect was found. 
In this study 50 I'g salmeterol was shown to have a long-lasting bronchodilating effect 
and a prolonged duration of action against ainvay sensitivity to methacholine in children 
with mild-to-moderate asthma. So, twice daily dosing may result in a 24-hour 
protection. This is of considerable clinical importance because in general the tolerance 
to various external stimuli increases together with a decrease in airway sensitivity. 2S 
A direct correlation has been found between the degree of airway sensitivity to a 
nonspecific stimulus and the amount of allergen that can be tolerated. 26•27 However, 
for short-acting fi2-agonists a steepening of the dose-response curve is known, and 
maximal airway narrowing is not influenced. 7 Because we studied only airway 
sensitivity and not the effect on maximal airway narrowing after methacholine, we can 
not speculate on the potential hazardous effects of higher doses of allergen or other 
strong stimuli reaching the airways because of long-lasting better patency. Further 
studies will be necessary to determine this effect as well as the degree and duration of 
the protective effect of salmeterol against other stimuli in asthmatic children and to 
detemline the effect on the nonspecific airway responsiveness during long-term 
treatment. 
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Airway responsiveness after a single dose of salmeterol 
and during four months treatment in children with asthma 
5.1 Summary 
Inhalalion of a single dose of Ihe long-acling jJ,-adrenoceplor agonisl salmelerol 
protects against methacholine-induced ainvay obstnlction alld olher brollcJlOcollstricting 
slimuli for alleasl 12 hours. Hypolhelically. twice daily dosing of salmelerol may resuit 
in continuous protection. 
This sllldy was designed 10 invesligale Ihe proleclive effeCI of a single dose of salmelerol 
and of continuous nvice daily treatment on ainvay responsiveness to methacholine. 
In a double-blind. parallel sludy, salmelerol50 I'g b.i.d was compared with salbulamol 
200 "g b.i.d. 17lirly children with mild aSlhma, who had lillie or no bronchial ob-
struction and were hyperrespollsive to methacholine (PD10 :::;; 150 p.g) were allocated 
to receive either salmeterol or salbutamol. Ainmy responsiveness was measured before 
sludy elllry, 12 hours after a single dose and monthly dUling 4 mOlllhs of daily 
(rea/mem. Measurements were a/ways peifOl1lled at the same time of the day, 12 hours 
after the last dose of medicatioll was administered. 
No significant differences in FEV1 were found between treatments at any time point. 
PD20 significantly increased after the first dose of salmetero! was given (geometric mean 
100 "g). Geomelric mean PD20 values were signijicalllly beller dllling sallllelerol 
Irealmelllihan during salblllamolirealmelll, 52 and 25 "g respeclively (p=0.005). 
I1le protectioll provided by salmeterol during maintenance treatment was less than after 
Ihe firsl dose (p<0.001). However, proleclion did nol dimillish dllling Ihe 4 mOlllh 
treatment period and remained significant compared with baseline (p=O.003). 
5.2 Introduction 
Salmeterol xinafoate has a bronchodilating effect that lasts for at least 12 hours when 
administered as a single dose of 50 I'g in adults and children with asthma. I.2.3.4 
Protection against methacholine-induced2,3 and histamine-induced airway obstruction 
lasts for 12 up to 24 hours. Single-dose studies also show a prolonged protection against 
other bronchoconstricting stimuli, such as exercises, hyperventilation with dry cold 
air,' and allergen.' Theoretically, twice daily dosing of saImeterol can provide a 24-
hour protection against various bronchoconstricting stimuli and therefore decrease 
symptoms in patients with asthma. Studies comparing salmeterol 50 I'g twice daily with 
salbutamol 200 I'g four times daily during 12 weeks have indeed shown better symptom 
control in the group treated with salmeterol. 8.9.10 In patients with mild asthma a 
reduction of the acute protective effect of salmeterol against methacholine-induced 
bronchoconstriction from a 3.3 DD after the first dose to 1.0 DD after stopping 
maintenance treatment at 4 and 8 weeks was found. l! The bronchodilating effect did 
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not change during the study period. Another study in patients with mild-to-moderate 
asthma, of whom the majority were treated with inhaled corticosteroids, did not show 
this reduction in protection against methacholine-induced airway obstruction. 12 The 
two studies differ in the time point at which methacholine challenges were performed, 
respectively 1 and 12 hours after salmeterol; whereas in the study by Cheung et al11 
maintenance treatment was also stopped for 36 hours. A recent study in adult patients 
with symptomatic asthma, who were already being treated with a low dose of inhaled 
corticosteroids, showed a response more favourable in symptoms and peak flow values 
when salmeterol was added than when the inhaled corticosteroid dose was increased.13 
This study, however, does not include data on airway responsiveness. We investigated 
the protective effect of salmeterol against methacholine-induced bronchoconstriction 
after a single dose and during 4 months of maintenance treatment and compared this to 
the effect of salbutamol. 
5.3 Material and methods 
5.3.1 Pariellts 
Between July 1992 and January 1993, thirty children, aged 7 to 16 years, with mild 
asthma according to the American Thoracic Society's criterial4 , were recruited from 
the outpatient department for Pediatric Respiratory Medicine, Sophia Children's 
Hospital, Rotterdam. The patients had to be capable of perfomling lung function tests 
reproducible, i.e., a coefficient of variation in three consecutive measurements of FEV 1 
less than 5 %. Because airway responsiveness is partly determined by the degree of 
bronchial smooth muscle constriction,15 we selected children who had a consistent 
increase in airway responsiveness but little or no bronchoconstriction. They had to meet 
the following criteria: (I) a dose of methacholine that produced a 20% fall in FEV! 
(PDlO methacholine) equal to or less than ISO I'g (this being more than two standard 
deviations below the mean value in healthy children)!', (2) a baseline FEV! and FVC 
greater than 70% of predicted (reference values according to Zapletal et al I1) and (3) 
a FEV/FVC greater than 70%. The inclusion criteria had to be fulfilled at a prestudy 
visit. All patients were atopic to one or more inhaled allergens, as detennined by 
measurement of specific IgE in serum and/or positive skin test results. Their households 
were adapted to reduce house dust mite exposure, and keeping of domestic animals was 
discouraged. Asthma treatment before the study consisted of an inhaled 6,-agonist on 
demand only or in combination with maintenance treatment with disodium cromogly-
cate. Inhaled corticosteroids and maintenance treatment with oral corticosteroids were 
not allowed in the year preceding the study. Disodium cromoglycate was stopped 2 
weeks before the start of the run-in period. If during this period the symptoms of ast-
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hma increased significantly, the patient was excluded from the study. None of the 
children had acute episodes of asthma or respiratory tract infections for at least 1 month 
before entry into the study. 
Thirty children, 20 boys and 10 girls, were allocated randomly to treatment groups (15 
in each group). The baseline characteristics were the same for each treatment group 
(Table 5.1). Nine children in each treatment group had had disodium cromoglycate 
medication discontinued. The median duration of asthma was 5 and 6 years. 
respectively. for the salmeterol and salbutamol groups. The exacerbation rate was low 
in both groups, reflected by the mean number of prednisolone courses per patient in the 
previous year, respectively, 0.13 and 0.20. None of the children had been hospitalized 
for treatment of asthma in the year before entering the study. 
5.3.2 Study design 
The study had a double-blind, parallel group design and consisted of a 2-week run-in 
period, a 4-month treatment period and a 2-week follow-up period. The study was 
based on an intention to treat principle. At the first visit to the lung function laboratory, 
before the start of the run-in period. children were randomly allocated to receive either 
salmeterol 50 I'g twice daily or salbutamol200 I'g twice daily. During the run-in period 
no medication was given, except for salbutamol in case of symptoms. The first dose of 
the study drug was taken at the end of the run-in period, 12 hours before the second 
visit. Thereafter the 4-month treatment period started, and children took their study 
medication two times a day with an interval of approximately 12 hours. For acute relief 
of acute asthma symptoms, salbutamol was aHowed at a maximum dose of 200 Itg six 
times daily. Exacerbations of asthma were treated with a standard short course of 
prednisolone (starting with 30 mg on the first day and tapering off to 0 in I week 
according to a scheme that depended on body weight). Salbutamol and the study 
medication were administered as Rotadisks in combination with a DiskhalerR (Glaxo. 
Greenford, United Kingdom). All children were instructed in use of this inhalation 
device before entry into the study, and technique was checked at every visit. During the 
follow-up period after the study medication was stopped, salbutamol was used as 
needed. Children visited the lung function laboratory at the start and at the end of the 
run-in period, monthly during the treatment period, and at the end of the follow-up 
period. At each visit heart rate, blood pressure, FEV" PEF and airway responsiveness 
to methacholine were measured. All lung function measurements were performed 
between 8.30 and 9.30 am, 12 hours after the last dose of the study drug was given. 
To verify compliance with the last dose, patients were asked for the exact time of drug 
inhalation. If this was not 12 hours earlier, lung function measurements were 
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Table 5.1 Patient characteristics at entry of the study 
Salmeterol 
Subject Sex Age FEY, FVC FEV,' PD20 Medication Atopy" 
no.* (yl') (% pred) (% pred) FVC(%) (pg) 
1 M 9 93 97 80 34 B HD,C,D 
2 F 13 90 112 68 6 B HD, Gr, D 
3 M 7 106 107 84 23 BC HD 
4 M 11 99 90 92 75 B HD, Gr 
5 M 15 96 115 68 17 BC HD, Gr, C, D 
6 F 12 104 107 82 4 BC HD, Gr, C, D 
7 M 6 87 94 78 48 B HD, Gr, C 
8 M 11 74 82 75 16 B Or 
9 M 7 84 79 90 92 BC HD, Gr 
10 M 7 102 97 89 49 BC HD, Gr, C, D 
11 F 10 94 95 85 66 BC HD, Gr, C, D 
12 M 8 95 87 92 39 B HD,C,D 
13 F 12 99 99 85 136 BC Or 
14 M 10 97 96 85 54 BC HD, Or, C, D 
15 M 10 76 77 83 25 BC C 
Mean 10.3 93.0 95.5 82.5 32.4' 
SD 2.5 9.5 11.6 7.6 
rescheduled. Rescue salbutamol was allowed up to 8 hours before the measurements 
were taken. No FEV 1 measurements or methacholine provocation tests were perfonned 
within the first 4 weeks after prednisolone was taken. During the run-in and follow-up 
periods and during the first 2 weeks of every month of treatment, a record card was 
completed daily. Separate daytime and nighttime scores from 0 to 3 were given for the 
presence and severity of cough, wheezing and dyspnea. PEF was recorded in triplicate 
twice daily before inhalation of the study drug, with the use of a mini-Wright peak flow 
meter (Clemente Clarke International Ltd., Harlow, Essex, U.K.). The use of rescue 
salbutamol was also recorded. At the start and the end of the treatment period, blood 
samples were taken and analyzed for hematologic and biochemical parameters, and 
urine was analyzed for protein, glucose and blood. 
The study was approved by the Medical Ethics Committee of the University 
Hospital/Sophia Children's Hospital Rotterdam. Written informed consent was obtained 
from all patients and their parents. 
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Salbutamol 
Subject Sex Age FEV, FVC FEV/ PD", Medicationt Atopy·' 
no.* (yr) (% pred) (% pred) FVC(%) (pg) 
16 F 11 103 106 82 101 B HD 
17 M 7 111 121 80 28 BC HD,Gr,C 
18 M 11 103 113 76 123 B HD,Gr 
19 M 11 81 103 66 27 BC HD,Gr,C,D 
20 F 7 96 III 75 14 BC HD,Gr,C 
21 F II 84 89 81 24 BC HD,Gr,C 
22 M 12 91 84 90 83 BC HD,D 
23 F II 92 94 83 107 BC HD 
24 F 7 103 103 86 25 B HD,Gr,C 
25 F 7 87 81 93 20 BC HD,Gr,C,D 
26 M 12 82 86 80 27 BC HD 
27 M 12 77 82 78 26 B HD 
28 M 10 73 73 83 45 B HD 
29 M 8 96 88 91 41 B HD,C,D 
30 M 10 89 97 78 21 BC HD 
Mean 10.3 91.2 95.3 81.5 37.2* 
SD 2.0 10.9 13.6 7.0 
. Subject numbers do not indicate the sequence of entry into the study 
t B: inhaled 8r agonist on demand; C: inhaled disodium cromoglycale 
t Geometric mean 
.. HD: house dust mite; Gr: grass pollen; C: cat; D: dog 
5.3.3 Lung functioll111easurements 
FEV, was measured according to the European Community for Steel and Coal 
recommendations 18 with a water-sealed spirometer (Mijnhardt, Zeist, The 
Netherlands). The largest value from an envelope curve consisting of three to five 
attempts was recorded. Reference values of Zapletal et al 17 were used. PEF was 
measured in triplicate and the best value was recorded with the use of the patient's own 
mini-Wright peak flow meter. Methacholine provocation tests were performed with a 
modification of the dosimeter method of Chai, as described previously. 19 Nebulized 
methacholine bromide in unbuffered saline solution was given in doubling 
concentrations (0.125 to 32 mg/mI). The aerosol was generated by a DeVilbiss 646 
nebulizer (DeVilbiss Co., Somerset, PAl attached to a Rosenthal-French dosimeter 
(Laboratory for Applied Immunology, Fairfax, V A) and driven by air at 137.8 kPa (20 
psi) with a timing adjustment of 0.6 second. A total of20 1'1 of aerosolized solution was 
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delivered to the mouth in four consecutive breaths. Mouth doses were 2.5 to 640 I'g 
methacholine. Saline solution was inhaled before methacholine to exclude a non-specific 
response. The effect of each dose was determined by measuring FEV, in triplicate 3 
minutes after each administration. The PD20 methacholine was calculated from a log 
dose-response plot by linear interpolation of data points. 
5.3.4 Statistical allalysis 
FEV, results were expressed as percent predicted value according to reference values. '7 
All PD20 values were logarithmically transformed before analysis. For patients in whom 
a 20% fall in FEV, was not reached after the maximum dose of 640 I'g methacholine, 
PD,o was considered to be 640 I'g. As this only occurred in two patients, both in the 
sahneterol group, this has resulted in a slight underestimation of the effect of 
salmeterol. PD20 values were analyzed as geometric mean, as well as changes from 
baseline, expressed in DD. Comparisons of PD20 and of FEV, between and within 
treatment groups were done by using repeated-measures analysis of variance. 2o Com-
parisons of PDzo and of FEV, at and between specific time points were done using the 
t-test and the paired t-test, respectively. The percentage of days with symptoms and 
mean morning and evening PEF for individual patients were calculated from the daily 
record card for each study period. If the number of days scored on the daily record card 
was less than 7 (out of the required 14 days), the percentage of days with symptoms or 
peak flow values were considered inestimable for that item in that period and were not 
included in the analysis. Comparisons of the percentages of days with symptoms in 
various study periods were done by using Mann-Whitney U test. Comparisons of mean 
morning and of mean evening PEF at and between specific study periods were done 
using the t-test and the paired t-test, respectively. For all analyses, a p-value of 0.05 
(two-sided) was considered the linlit of significance. 
5.4 Results 
During the study, six prednisolone courses were given: three during salmeterol 
treatment (subject 2, one course and subject 7, two courses), and three during 
salbutamol treatment (subjects 18, 19 and 29). Two children (subjects 7 and 18), one 
in each treatment group, withdrew during the treatment period because of an increase 
in symptoms; it was considered unethical to continue administration of blinded 
medication. After withdrawal, both children began receiving inhaled corticosteroids. 
Measurements obtained from these subjects were included up to the last visit before 
withdrawal. Compliance with treatment schedules were checked by counting the used 
blister packs at each visit. The compliance gradually improved during the treatment 
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period in both treatment groups: from 1.11 to 1.76 blister packs/day for the group 
treated with sahneterol and from 1.10 to 1.90 blister packs/day for the group treated 
with salbutamol. 
5.4.1 Aillvay caliber 
Results of FEV 1 expressed in liters as well as percent predicted value, are listed in 
Table 5.2. At the beginning of the run-in period, FEY, was similar in both groups. 
Twelve hours after the first dose of either of the study drugs was administered, we 
found no significant change in FEY, compared with baseline values. At no time, either 
after the first dose was given or during the treatment period, were there any significant 
changes in FEV 1 within or between the two treatment groups. Two weeks after the 
discontinuation of salmeterol treatment, a small but significant (p=0.005) decrease in 
FEV1 occurred. However, the fall in FEVt after continuous treatment was stopped did 
not differ between the salmeterol and salbutamol groups (p=O.IO). 
5.4.2 Ainvay responsiveness 
Baseline PD20 methacholine values were similar in the salmeterol and salbutamol group 
(geometric mean, 32 and 37 I'g methacholine, respectively). There was a strong 
correlation between PD20 values at the different time points and baseline values of PD20 
within treatment groups. Therefore to reduce the variation caused by interindividual 
differences in baseline PD20, not only geometric mean PD20 values were analyzed but 
Table 5.2 Results of FEV l expressed in liters (mean ± scm) and as % predicted (mean ± scm) for both 
treatment groups at different time points 
Salmeterol Salbutamol 
liters % predicted liters % predicted 
Baseline 1.98 ± 0.t7 93.0 ± 2.5 2.00 ± 0.t3 91.2 ± 2.8 
Visit 2 (12 hours 
after first dose) 2.08 ± 0.22 95.5 ± 4.2 1.99 ± 0.12 90.3 ± 2.8 
Treatment period 
1 month 2.04 ± 0.19 94.3 ± 3.1 2.03 ± 0.14 90.3 ± 3.4 
2 months 1.97 ± 0.17 92.8 ± 2.9 2.06 ± 0.12 92.0 ± 2.4 
3 months 2.07 ± 0.19 93.2 ± 3.0 1.98 ± 0.12 88.0 ± 2.t 
4 months 2.02 ± 0.19 90.5 ± 4.t 1.96 ± 0.15 87.3 ± 3.1 
Follow-up 1.95 ± 0.18 85.7 ± 3.t 1.97 ± 0.14 86.2 ± 2.1 
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also changes in PD20 from baseline. The results of these analyses were similar. Figure 
5.1 shows both geometric mean PD2Il values and PD20 changes in DD. Table 5.3 shows 
individual data at each time point. 
At the end of the run-in period, 12 hours after the first 50 I'g dose of salmeterol was 
given, PD20 methacholine increased by 1.66 DD compared with baseline. After 
administering 200 I'g of salbutamol PD2Il fen with a 0.54 DD (p<O.OOI sahneterol vs 
200 
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60 
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10 
t ~l f~ h ~ 
single treatment period (months) folio\\,-
baseline dose 1 2 3 4 up 
I I I I 
1 
I I I 
Salmeterol:- 1.7(.3) 0.6(04) 1.0(04) 0.6(.3) 0.8(04) 0.0(.3) 
Salbutamol:- -0.5(.2) -0.3(.3) -0.5(.3) -0.6(.3) -0.5(04) -0.3(.2) 
Figure 5.1 
P020 methacholine (geometric mean ± SEM) at all titne points. Mean 
P010changes from baseline in DO (± SEM) for sahneterol and 
salbutamoI treatment are listed below the time points. 
Salmeterol, (-e-); salbutamol, (-0-). 
salbutamol). Geometric mean PD20 values at this time point were 100 and 26 I'g 
methacholine, respectively, for salmeterol and salbutamol (p=O.OOI). The individual 
results are plotted in Figure 5.2. 
During the treatment period no significant changes in geometric mean PD20 were found 
within both groups from I to 4 months. The geometric mean PD20 during the treatment 
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Fignre 5.2 
Individual results of P020 methacholine for both treatment groups at 
baseline period (visit I) and 12 hours after Ihe first dose of the study 
dmg was given (visit 2). 
period was 52 I'g methacholine for the salmeterol group, compared with 25 I'g 
methacholine for Ihe salbutamol group (p=0.005). The geometric mean PD20 was less 
during maintenance treatment with salmeteroJ than after the first dose was given 
(p<O.OOl), bUI still significant compared with baseline (p=0.003). Two weeks after 
maintenance treatment was stopped, geometric mean PD20 values were not significantly 
different between groups. For both treatment groups these values did not differ 
significantly from the values at the time of entry into the study. 
5.4.3 Daily record cards 
Symptom scores were generally low. Mean percentages of days with at least one 
symptom were 46% and 40%, respectively, for the salbutamol and salmeterol groups 
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Table 5.3 Individual data of PD20 (Jig methacholine) at different time points 
Saimctel'ol 
Subject no. Baseline Single dose Treatment period (months) Follow up 
I 2 3 4 
34 89 127 73 24 21 11 
2 6 14 * * 13 12 11 
3 23 13 20 26 41 35 13 
4 75 >640 428 504 103 221 199 
5 17 410 169 179 56 216 51 
6 4 32 18 28 21 11 8 
7 48 55 * 201 * * * 
8 16 20 19 19 
* 
21 32 
9 92 338 142 118 50 101 105 
10 49 208 59 51 63 68 48 
11 66 167 35 31 28 136 20 
12 39 108 10 101 65 13 50 
13 136 >640 101 117 >640 >640 69 
14 54 99 51 50 54 44 20 
15 25 97 23 46 44 * * 
Geometric 32 100 52 71 50 54 32 
mean 
during the mn-in period. For the group treated with salmeterol, these percentages were 
32%,25%,22% and 23%, respectively during the four consecutive treatment periods. 
These percentages did not significantly differ from the percentages for the group treated 
with salbutamol, which were 35%,34%,30% and 25%, respectively (all p>0.59). No 
significant differences were found when the various symptoms - cough. wheezing and 
shortness of breath - were analyzed separately. This applied also to the separate 
morning and evening symptom scores. Morning and evening PEF did not differ 
significantly within or between groups, although both tended to increase during 
salmeterol treatment. 
5.4.4 Adverse evellts 
During salmeterol treatment 17 adverse events were reported in 10 patients; during 
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Salbutamol 
Subject 110. Baseline Single dose Treatment period (months) Follow up 
2 3 4 
16 101 36 77 31 29 52 90 
17 28 13 35 11 34 60 58 
18 123 28 30 31 23 * * 
19 27 28 123 62 45 * 43 
20 14 9 10 9 10 10 16 
21 24 29 7 55 33 19 21 
22 83 80 174 183 140 37 75 
23 107 52 56 31 72 26 33 
24 25 37 29 17 16 13 13 
25 20 24 7 11 [3 10 [2 
26 27 28 20 [2 16 24 16 
27 26 20 20 15 21 5[ 22 
28 45 32 47 67 7 11 24 
29 41 9 * 11 8 9 20 
30 21 25 30 36 50 104 44 
Geometric 37 26 31 26 25 24 28 
mean 
* No measurements 
salbutamol treatment 36 adverse events were reported in 12 patients. Most adverse 
events were upper respiratory tract symptoms. Headache occurred slightly more often 
during salbutamol treatment (eight periods of headache in four patients) than during 
sahneterol treatment (one headache). There were no significant changes in systolic and 
diastolic blood pressure or heart rate in any group during treatment. 
5.5 Discussion 
The results of this study show that twice daily treatment with salmeterol in children 
with mild asthma results in continuous, stable protection against methacholine-induced 
bronchoconstriction. This protection, however, is less than the protection provided after 
a first single dose. After maintenance treatment was stopped for 2 weeks, no residual 
protection remained, indicating that there was no sustained reduction of airway 
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responsiveness. 
Salbutamol instead of placebo was used in the control group; otherwise, because of its 
bronchodilatory effect salmeterol could be recognized as the effective treatment. Twice 
daily treatment with salbutamol resulted in a slight but not significant fall (p~O.06) in 
PD20 during the 4 month period compared with baseline measurements; this was 
probably the result of withdrawal of disodium cromoglycate in more than half of the 
children before they entered the study. Some authors have suggested an increase in 
airway responsiveness and a deterioration of asthma as a result of regular B2-agonist 
treatment. 21.22 It is unlikely, however, that regular use of salbutamol is the 
explanation for the decrease of PD20 in the salbutamol group in our study, because the 
fall in PD20 was already present at the end of the run-in period in which children llsed 
salbutamol "as needed!!. 
We selected children with mild asthma, who were hyperrespol1sive but with little or no 
bronchoconstriction to avoid interference of airway caliber and PD20 . We chose to 
measure airway responsiveness 12 hours after the last dose of the study drug was 
administered, which is the nOlmal dose interval during maintenance treatment with 
salmeterol and therefore clinically relevant. Furthermore, a longer interval might 
introduce a rebound increase in airway responsiveness, as has been shown for up to 59 
hours after stopping regular treatment with the short-acting Jl2-agonists terbutaline23 
and salbutamol. 24 Until now, a rebound increase in PD20 after stopping regular 
treatment with salmeterol has not been demonstrated. 1 1,12,25,26 
In our study the protective effect of salmeterol was probably caused by the prolonged 
effect of the drug on airway smooth muscle. This is functional antagonism, a well 
known phenomenon associated with other 13r adrenoceptor agonists. 27 In vitro 
experiments show evidence of an interaction of 13r agonists and methacholine at the level 
of intracellular signal transduction through phosphoinositide metabolism.28 
After the first dose of sabueterol was given we found an improvement in PD20 of 1.7 
DD which is comparable with the results of previous studies.2,3,29 During the treat-
ment period from 1 to 4 months, this protection was constant but reduced to 0.7 DD. 
Two studies in adult patients with asthma investigated the immediate protective effect 
of salmeterol and the effect during regular twice daily treatment. ll ,12 Booth et al 12 
examined 26 patients with mild-to-moderate asthma, in a parallel-group, placebo 
controlled study. The majority of their patients were also receiving inhaled 
corticosteroid treatment. As in our study, the interval between salmeterol administration 
and measurement of airway responsiveness to methacholine was 12 hours. They found 
a small but significant protection during 8 weeks of sabneterol treatment, which did not 
differ from the single dose effect. 12 A reduction in protection during regular twice daily 
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treatment with salmeterol was found by Cheung et al. 11 They reported a reduction in 
protection from 3.3 DD after the single dose of salmeterol was given to 1.0 DD after 
4 and 8 weeks of treatment. Airway responsiveness was measured 1 hour after 
salmeterol administration, and maintenance treatment was stopped for 36 hours. 
Although unlikely from the data at the end of their study, a possible rebound increase 
in airway responsiveness could not be excluded. As in our study, Cheung et alii 
selected subjects with mild asthma who were not treated with inhaled corticosteroids. 
The reduction in protection occurred within 4 weeks after the start of maintenance 
treatment and remained at the same level after 8 weeks of treatment. The explanation 
for this tolerance remains unclear but may be the result of receptor downregulation. 
Tachyphylaxis to nonpulmonary effects (e.g., tremor, increased QTc interval, and 
elevated blood glucose levels) has been found after 2 weeks of treatment with salmeterol 
in healthy subjects. 30 The use of inhaled corticosteroids may protect against the 
development of tachyphylaxis to pulmonary effects of B,-agonists and may explain the 
different results obtained by Booth et al. 12 Reversal of tachyphylaxis by systemic 
corticosteroids has been shown in vitro and in vivo.31 
In our study significant, stable protection remained throughout the 4 months of 
treatment with salmeterol. So, if any downregulation of the B,-receptors occurs, titis 
seems incomplete. Because we selected children with little or no bronchoconstriction, 
the effect could not be explained by an improvement in airway caliber.14 This is 
supported by the fact that no significant changes occurred in FEV 1 and that no 
correlation was found between the changes iu PD20 and in FEV l' Although the 
protection after 4 weeks of treatment was less than after the first dose was given, our 
data do not indicate an ongoing increase in airway responsiveness. A significant degree 
of protection remained during treatment, and this may be of clinical relevance, because 
a decrease in airway responsiveness will improve the tolerance to other exogenous 
stimuli. A direct correlation has been found between the degree of airway 
responsiveness to a non-specific stimulus and the amount of allergen that can be tolera-
ted. 32,33 In our study the changes in airway responsiveness were not reflected by 
changes in symptom scores. However, this may be the result of selecting patients with 
mild asthma who already have very low symptom scores before the start of the study. 
We conclude that the protective effect of salmeterol against methacholine-induced 
airway obstruction during 4 months of treatment is lower than the protection offered by 
a single dose. However, twice daily administration of salmeterol provides significant, 
stable protection compared with baseline and salbutamol treatment. 
According to international consensus reports, asthma therapy should be directed against 
airway inflammation, and inhaled corticosteroids are now the mainstay of asthma 
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treatment. 34 It is unlikely from the data now available that salmeterol in itself 
influences chronic airway wall inflammation.35 Addition of salmeterol to inhaled 
corticosteroid treatment may have beneficial effects on symptom scores and airway 
responsiveness. 13 Studies are now being performed in children with asthma to evaluate 
the effect of addition of sa!meterol to treatment with a conventional dose of an inhaled 
corticosteroid, as compared with increasing the dose of an inhaled corticosteroid. 
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One year treatment with salmeterol compared 
to beclomethasone in children with asthma 
6.1 SUlllJllary 
The aim of this study was to compare the effects of salmeterol and bee/omethasone on 
lung jUllction and symptoms in children with mild to moderate asthma. Sixty-seven 
children not treated with inhaled cOlticosteroids lVere randomized in a double-blind 
parallel study either to salmeterol 50 M b.i.d. or bee/omethasone 200l'g b.i.d. After 
olle year, FEV} significantly increased in the bec/ometilasone group, whereas in the 
salmeterol group there was a small reduction. Differences be/ween groups were 14.2 % 
predicted (p < O. 000]) and 7.0 % predicted (p=0. 007) for pre- and postbroncilOdilator 
FEV] values, respectively. PD,o methacholine decreased by 0.73 DD (p=0.05) in the 
salmeterol group and increased by 2.02 DD (p < O. 0001) in the bee/omethasone group. 
MOllling and evening PEF alld symptom scores improved ill both groups, although more 
in the beclomelhasone group. Asthma exacerbations, for which prednisolone was 
needed, were morejrequelll in the salmeterol group (J7versus 2), as were the number 
of withdrawals due to exacerbations (6 versus 1). However, growth was significantly 
slower in the beelomethasone group (-0.28 SDS) compared with that ill the salmeterol 
group (-0.03 SDS) (p=0.00]). We COli elude that treatmellIwith a moderate dose of 
beclomethasolle is superior 10 sa/meterol ill children with mild to moderate asthma and 
recommend that sa/meterol should not be used as mOllotherapy. 
6.2 Introduction 
Short-acting inhaled beta-agonists offer rapid and effective symptom relief in asthmatic 
children.! Their limited duration of action, however, makes them less suitable for 
controlling symptoms throughout the entire 24-hour period. Furthennore. asthma is now 
recognized as a chronic inflanunatory disease of the airway wall; hence, recent 
guidelines have focused on anti-inflammatory treatment by either cromoglycate or inha-
led corticosteroids.2 3 Despite this daily prophylactic treatment many children still 
suffer from asthma symptoms.4 In particular, exercise-induced and nocturnal symptoms 
result in substantial discomfort to children as well as to their parents.5 Taken as a 
single dose salmeterol, a new long-acting inhaled fi,-agonist, has a bronchodilating 
effect of at least 12 hours in adults as well as children.' 7 Protection against methacho-
line- and histamine-induced airway obstruction lasts for 12 to 24 hours. 7 8 Single-dose 
studies show prolonged protection against other bronchoconstricting stimuli such as 
exercise,' hyperventilation with dry cold air lO and allergen. II Twice daily dosing 
of salmeterol may result in a 24-hour protection against various bronchoconstricting 
stimuli and therefore lessen symptoms in astluuatic patients. Compared with salbutamol, 
twice daily salmeterol for several weeks or months in adults as well as children results 
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in fewer symptoms, less need for additional bronchodilator treatment and better impro-
vement in peak flow rates. 12 13 However, in these studies some of the patients were 
already on treatment with either cromoglycate or inhaled corticosteroid, making it 
difficult to estimate the true therapeutic potential of salmeterol. The aim of our study 
was to compare the effect of one year treatment with salmeterol with the effect of 
treatment with an inhaled corticosteroid. The primary efficacy outcome parameters were 
airway caliber, measured as forced expiratory volume in 1 second (FEV I) and ainvay 
responsiveness to methacholine. Symptom scores, exacerbations, additional use of short-
acting fiz-agonists and peak flow rates were considered as secondary outcomes. 
6.3 Material and methods 
6.3.1 Patiellls 
Sixty-seven children aged 6 to 16 years with mild to moderate asthma were selected 
from the outpatient pediatric clinics of 9 hospitals, 6 university hospitals and 3 general 
hospitals. Patients were recruited between September 1992 and October 1994. All chil-
dren had mild to moderate asthma according to the American Thoracic Society 
criteria." Patients included in the study had to have: (I) a FEVro that was 55-90% of 
predicted value andlor a ratio of FE V, to forced vital capacity (FVC) that was 50-75%, 
(2) an increase of at least 10% in FEV, after inhalation of 0.8 mg salbutamol, (3) 
airway hyperresponsiveness to methacholine, i.e. a 20% fall in FEV, after inhalation 
of 150 I'g or less methacholine (PD,o methacholine); this being more than two standard 
deviations below the mean value in healthy children", (4) an ability to produce 
reproducible lung function tests, i.e. a variation in three consecutive measurements of 
FEV rof less than 5 %, (5) a history of stable asthma for at least 1 month without 
exacerbations or respiratory tract infections, (6) not used inhaled corticosteroids in the 
previous 6 months or cromoglycate in the previous 2 weeks. The study was approved 
by the medical ethics committees of the participating centers. Written informed consent 
was obtained from all patients and their parents. 
6.3.2 Study design 
The study was a double-blind, randomized clinical trial. It consisted of a 6 week run-in 
period, a treatment period of 54 weeks and a follow-up period after treatment of 2 
weeks. In the run-in period the only medication allowed was salbutamol 200 I'g on 
demand, with a maximum of 6 inhalations per day. In the first and the last week of the 
run-in period measurements of FEV, and FVC before and after bronchodilatation and 
measurements of PD20 methacholine were performed. Lung function inclusion criteria 
had to be fulfilled at one of these visits. At the end of the run-in period, patients were 
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allocated to one of the two treatments by an independent randomization center. 
Randomization was stratified for sex, age, center, baseline FEV,-value, baseline PD20 
and prior use of inhaled corticosteroids more than 6 months before starting the study, 
using a computerized minimization method. 16 Using this method a patient is allocated 
to a treatment so as to minimize any imbalance between the treatment groups for each 
stratification factor. Snldy treatment consisted of either salmeterol xinafoate 50 p.g b.Ld. 
or beclomethasone dipropionate 200 I'g b.i.d. All dlUgs were administered as 
RotadisksR in combination with a Diskhaler (Glaxo Wellcome, Greenford, United 
Kingdom). All children were instlUcted in the use of this inhalation device prior to 
entry into the study and their inhalation technique was checked at every visit. For relief 
of symptoms during the treatment period the use of salbutamol 200 I'g Rotadisk was 
allowed, with a maximum dose of 6 inhalations per day. Asthma symptoms, which did 
not sufficiently improve with the maximum dose of rescue salbutamol, were treated 
with a standard course of prednisolone. On the first day this started with a dose of 30 
or 35 mg, depending on the weight of patients, and was tapered off to zero in 7 days. 
During the treatment period the response to a bronchodilator (at 12, 24, 36 and 48 
weeks) and PD20 methacholine (at 6, 18, 30, 42 and 54 weeks) were measured 
alternately at intervals of 6 weeks. After 54 weeks all patients stopped taking 
randomized treatment for a period of 2 weeks. During this follow-up period the only 
medication allowed was salbutamol on demand. At the end of this period PD20 metha-
choline was measured. 
At each clinic visit FEV" FVC, PEP, height, body weight, heart rate, systolic and 
diastolic blood pressure were measured. Height was measured using a stadiometer in 
centimeters, corrected to one decimal place. Furthermore, the patients were asked about 
adverse events and the number of used blisters of study medication and rescue salbu-
tarnal were counted. 
Throughout the study period patients kept diary cards on which symptoms and additi-
onal use of rescue medication were recorded. They also measured PEF using a mini-
Wright peak flow meter (Clemente Clarke International Ltd., Harlow, Essex, U.K.) at 
home. Symptoms and PEF measurements were recorded during the first 2 weeks of 
each 6-week period between clinic visits. Dyspnoea, wheeze and cough in the morning 
and the evening were scored separately, using a scale from 0 to 3. PEF was measured 
in triplicate morning and evening before taking study medication and all three values 
were recorded. 
Patients were withdrawn from the study if they needed 3 or more prednisolone courses 
within 3 months, if according to the investigator it was not ethical to continue blinded 
treatment, or if patients or parents wanted to discontinue. 
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All data were collected and checked by the coordinating center in Rotterdam to ensure 
completeness. Interim analyses of the study data were made by an independent 
statistician every year and reviewed by a data monitoring committee. Investigators were 
kept blind to the results of the interim analyses. The data monitoring committee allowed 
the study to continue until all patients had completed. 
6.3.3 Lung junction measurements 
All lung function measurements were performed between 12 and 18 hours after 
inhalation of the study drug. For each patient the time of measurement was constant 
throughout the study period. Patients were instructed to take their last dose of study 
drug before the clinic visit at a fixed time the previous evening. Rescue salbutamol was 
not allowed in the 8 hours before lung function measurement. The time of inhalation 
of the last dose of study drug, and any use of salbutamol was checked before taking 
measurements, and, if necessary, lung function measurements were postponed. No lung 
function measurements were perfonned less than 4 weeks after a course of predni-
solone. 
FEV I and FVC were measured according to the recommendations of the European 
Community for Steel and Coal, by using a water sealed or dry rolling seal spirometer 
or pneumotachometer. 17 At least 3 manoeuvres were perfonned with FEV 1 and PVC 
within 5%. Maximal 5 manoeuvres were allowed and the largest FEV, and FVC were 
taken for the analysis. Reference values of Zapletal and coworkers were used. IS Post-
bronchodilator FEV, was measured after inhalation of 0.8 mg salbutamol in order to 
obtain maximal bronchodilatation. 19 Salbutamol was administered by a Volumatic 
spacer as 4 puffs of 0.2 mg, one at a time, inspiring slowly from functional residual 
capacity to total lung capacity and holding each breath for about 10 seconds. FEV, was 
measured 20 minutes after inhalation of the last puff. PEF was measured in triplicate, 
using the patient's own Mini Wright peakflow meter. Methacholine provocation tests 
were performed using a modification of the dosimeter method by Chai, as described 
previously.20 Preparation of methacholine solutions was standardized in all centers. 
Nebulized methacholine bromide in unbuffered saline solution was given in doubling 
concentrations (0.125 to 39.2 mg/ml). The aerosol was generated by a DeVilbiss 646 
nebulizer (DeVilbiss Co., Somerset, PA) attached to a Rosenthal dosimeter (Laboratory 
for Applied Immunology, Fairfax, VA), driven by air at 137.8 kPa (20 psi) with a 
timing adjustment of 0.6 seconds. Output of the nebulizers was measured before the 
start of the study. All parts of each nebulizer were marked with waterproof paint to 
prevent interchanging. Nebulizers were cleaned after each measurement to prevent 
precipitations, and orifices were checked weekly according to recommendations. 21 
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Aerosolized solution was delivered to the mouth in 4 consecutive breaths. Mouth doses 
were 2.5 to 784 I'g of methacholine. Saline was inhaled before methacholine to exclude 
a non-specific response. The effect of each dose was determined by measuring FEY 1 
in triplicate 3 minutes after administration. PD20 methacholine was calculated by a 
computer program from a log-dose-response plot by Bnear interpolation. Airway 
responsiveness was only measured if FEY 1 before methacholine provocation was 80% 
or more of the individual's baseline value at entry into the study. 
All centers used written guidelines for lung function measurements. Teclmicians 
attended a training course before the start of the study. Site visits were made once a 
year by the primary investigator and a pulmonary physiologist to inspect the equipment 
and the methods used. 
6.3.4 Statistical analysis 
The study was designed to have 90% statistical power to detect a difference of 8% 
predicted FEY I using a statistical significance level of 5 %. 
Changes in FEY I and the logarithm of PD20 within each group over the study period 
were assessed using paired t-tests for matched data. Changes in PD10 were reported as 
numbers of DD. Comparisons of FEY I and the logaritluu of PD,o between groups at 
each clinic visit were made using analysis of covariance to adjust for mean pre-interven-
tion levels. Comparisons of both morning and evening PEF measurements recorded 
during the 2-week diary periods were made using analysis of covariance to adjust for 
mean pre-intervention levels. Morning and evening PEF variability for each patient was 
expressed as the standard deviation of the PEF measurements. Each measure of day-to-
day variability was compared between treatment groups using the Mann-Whitney test. 
Distributions of symptoms during the 2-week diary periods were compared using the 
Mann-Whitney test, as were the numbers of blisters of rescue salbutamol used over this 
period. Where patients failed to complete their daily record cards for more than 7 days 
in any 14 day period such assessments were not included in the analysis. Otherwise, 
when there were missing days in the record, pro rata adjustment was made to give a 
2-week assessment. Comparison of heights between groups were made using analysis 
of covariance to adjust for pre-intervention levels. Heights were also expressed as SDS 
using Dutch reference growth charts. 12 Changes in SDS over time within each group 
were assessed using paired t-tests for matched data, and comparisons between groups 
at each clinic visit were made using analysis of covariance to adjust for mean pre-
intervention levels. The analysis of covariance model was extended to allow for the 
effect of puberty on SDS and to lest for a possible interaction between puberty and 
treatment. All reported p-values are for two-sided tests and for simplicity of presenta-
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Table 6.1 Baseline characteristics at the S1art of the run-in period and at randomization by treatment group. 
At start of run-in period: 
sex 
age (years): 
mean(sd) 
duration of asthma 
(mean) (years) 
atopy status: 
none 
house dust mite 
cot 
dog 
grasspollcn 
previous treatment: 
cromoglycate 
inh.corticosteroids 
FEV! % predicted: 
mean (sd) 
prebronchodilator 
postbronchodilator 
PDlO (microgram): 
median (quarliles) 
height (cm)(sd) 
At randomization: 
FEV] % predicted 
mean (sd) 
prebronchodilator 
postbronchodilator 
PDN (microgram): 
median (quartiles) 
PEF (llmin) mean(sd) 
morning 
evening 
Days in two weeks 
with symptoms: 
median (quartiles) 
Nights in two weeks 
with symptoms: 
median (quartiles) 
height (cm)(sd) 
100 
Salmeterol 
(n~32) 
9FI23~-I 
10.6 (2.9) 
6.6 
0/32 
30/32 
18132 
19132 
25/32 
15132 
5132 
85.6 (15.0) 
100.8 (10.9) 
13.5 (6·35.5) 
144.9 (16.4) 
82.0 (13.9) 
99.2 (13.8) 
18 (6.546) 
297 (96) 
301 (94) 
6 (3·11) 
7 (4·10) 
145.6 (16.5) 
Beclomethasone 
(n:=:35) 
13FI22M 
10.5 (2.3) 
6.3 
6135 
28/35 
14/35 
20/35 
18/35 
15/35 
6/35 
86.3 (13.6) 
99.7 (14.0) 
18 (840) 
144.8 (12.6) 
84.4 (16.7) 
99.2 (15.3) 
20.5 (8·39) 
284 (69) 
299 (71) 
6 (2·12) 
6 (2·13) 
145.3(12.5) 
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Han are without fOlmal adjustment for multiple comparisons over time. Confidence 
intervals for means were calculated parametrically assuming normality. Confidence 
intervals for medians were calculated to be consistent with the results of the Wilcoxon 
test. 23 
6.4 Results 
Between October 1992 and October 1994, 67 patients (45 boys, 22 girls) were enrolled 
into the study. Patient characteristics at entry (beginning of the run-in period) and at 
randomization were similar in the two treatment groups (Table 6.1). 
Ten patients withdrew during the study period. Seven patients withdrew because of 
exacerbations (6 in the sahneterol group), 2 because of non-compliance (both in the 
beclomethasone group) and I because of dizziness and nausea (salmeterol group). 
Compliance with study treatment did not differ between the groups: the median number 
of blisters used per day were 1.82 and 1.84 in the salmeterol and beclomethasone 
groups respectively; ie. 91 respectively 92 % of the prescribed study medication was 
used. 
6.4.1 Ainmy caliber 
At the end of the 54-week treatment period the mean difference in FEV, between treat-
ment groups was 14.2 % predicted (95% confidence interval(CI) 8.3;20.0)(p < 0.0001) 
in favour of the beclomethasone treated group. On average FEV, levels declined in the 
salmeterol treated group over the course of the study. However, at no time point was 
the reduction from pretreatment values statistically significant. At the end of treatment 
the average change was -4.5 % predicted (95%CI -9.0;0.1). In the beclornethasone trea-
ted group average FEV, levels significantly increased (p<O.OOOI) by about 10% pre-
dicted at all visits (Figure 6.1). Two weeks after discontinuation of beclornethasone 
treatment, a significant reduction in FEV, was noted (p=0.02). Despite this reduction 
FEY, levels at the end of the follow-up period were still significantly higher 
(p<O.OOOI) in the beclomethasone group than in the salmeterol group. 
Postbronchodilator results of FEY, were similar to the prebronchodilator results. After 
one year, the mean treatment difference was 7.0 % predicted (95%CI 2.0;11.9)(p-
=0.007). On average FEV, levels declined in the salmeterol treated group and 
increased in the beclomethasone treated group. At the end of treatment the changes 
were -4.0 % predicted (95%CI -8.2;0.2) and 3.2 % predicted (95%CI 0.2;6.3) 
respectively. 
Figure 6.2 shows the mean levels of FEY, before and after bronchodilatation. 
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Figure 6.1 
Changes in FEV!% predicted (means, 95% CI) from baseline during 
treatment with salmeterol ( • ) or beciomethasonc ( • ). 
6.4.2 Ainvay respo/lsiveness 
At the end of the treatment period the difference between groups was 2.79 DD (95 %CI 
I. 75;3.84)(p <0.0001). On average PD2o methacholine declined in the salmeterol treated 
group over the course of the study. At the end of treatment the average reduction was -
0.73 DD (95%CI -1.46;O.OO)(p=0.05). Ainvay responsiveness gradually improved in 
the beclamethasone treated group. At the end of treatment the average increase in PD20 
methacholine was 2.02 DD (95%CI 1.26;2.78)(p <0.0001) (Figure 6.3). After one year 
median PD10 values were 7 and 58 j!g for the salmeterol and beclomethasone treated 
groups, respectively. Two weeks after discontinuation of beclomethasone PD10 
methacholine dropped on average 0.76 DD (p=0.004) to a median of 47 Jig, whereas 
after stopping salmeterol it dropped 0.4 DD (p=0.09). 
The differences in improvement between treatment groups for FEV, and airway 
responsiveness are also reflected in the difference in the percentage of patients impro-
ving (Table 6.2). 
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Table 6.2 Percentage of patients showing an improvement in FEYj (pre- and postbronchodilator) and 
PD20 by treatment group 
Treatment 
week 6 12 18 24 30 36 42 48 54 follow-
up 
Salmeterol 
FEYj pre 61 53 58 45 34 48 35 30 46 24 
FEYj post 44 35 45 30 
PD" 58 52 37 25 26 26 
Beciomefhasone 
FEYj pre 91 86 88 85 88 88 85 85 88 77 
FEV\ post 74 79 79 67 
PD" 77 76 76 82 81 77 
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Changes is airway responsiveness in doubling doses (means, 95% el) 
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Mean changes in ll10ming and cvening PEF (Umin, 95% CI) during 
treatment with sahneterol (. ) or beclol11cthasonc (. ). 
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6.4.3 Peak e.lpiratol)' flOlV rates 
Morning and evening PEF improved in both groups, with a tendency for more 
improvement in the group treated with beclomethasone (Figure 6.4). However, at the 
end of treatment there were no significant differences between groups. Mean increases 
in morning PEF were 48.8 IImin and 60.9 llmin for salmeterol and beclomethasone 
respectively, mean increases in evening PEF 48.9 IImin and 54.3 l/min. Day-to-day 
variability in both morning and evening PEF was also lower in the beclomethasone 
group (Figure 6.5). 
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Figure 6.5 
Standard deviation between days in moming and evening PEF (llmin, medians, 
95% eI) during treatment with salmeterol ( • ) or bec1omethasonc ( • ). 
6.4.4 Symptoms 
Daytime and nighttime symptoms diminished in both treatment groups, with fewer 
symptoms in the patients treated with beclomethasone. However, the difference between 
salmeterol and beclomethasone was only significant at some time points. The percentage 
of children in the beclomethasone treated group reporting no symptoms during the 2-
week diary card periods increased from 6% in the run-in period to 55% after one year 
of treatment (Figure 6.6). In comparison, 3% and 36% were asymptomatic during the 
corresponding periods in the sahneterol treated group. The need for additional salbu-
tamol during daytime and nighttime, as noted on the diary cards, significantly 
diminished throughout the treatment period in the beclomethasone group (Figure 6.7). 
The median number of additional salbutamol inhalations per day. as counted from the 
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Table 6.3 Most common reported adverse events during the treatment period 
Number of patients 
Number of patients 
with any adverse event 
Number of patients with: 
asthma 
rhinitis 
fever 
nausea and vomiting 
headache 
malaise and fatigue 
viral infections 
breathing disorders 
cough 
upper resp. tract infection 
viral respiratory infection 
throat irritation 
injuries 
Salmcterol Group 
30 
25 
N 20 
." ro 
" 
IS ~ 
0 
!l 10 ~ 
Z 5 
0 
o 6 18 30 42 54 
Salmeterol 
32 
30(94%) 
18 (56%) 
9 (28%) 
8 (25%) 
7 (22%) 
6 (19%) 
4 (13%) 
4 (13%) 
4 (13%) 
3 (9%) 
3 (9%) 
2 (6%) 
2 (6%) 
o 
nlll-in follo\v-up 
Time on treatmcnt (weeks) 
Figure 6.6 
30 
25 
20 
15 
10 
5 
o 
Beclomelhasone 
35 
31 (89%) 
3 (9%) 
5 (14%) 
4 (11 %) 
4 (II %) 
11 (31 %) 
10 (29%) 
3 (9%) 
3 (9%) 
8 (23%) 
5 (14%) 
10 (29%) 
3 (9%) 
4 (11 %) 
Beclo111cthasone Group 
o 6 18 30 42 54 
run-in follow-up 
Time on treatment (weeks) 
Number of days out of 14 with symptoms during salmeterol (left) and beclomcthasone 
(right) treatmcnt. Days with symptoms per two weeks: missing, D ; 8-14, D ; 4-7, 1m; 
1-3,11; 0, •. 
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Salmeterol Group: Daytime Bcclomethasone Group: Daytime 
30 ---<--' 
25 
~ 20 
.'" \l 15 
... 
o 
~ 
1 10 5 
o 
30 
25 
~ 20 
.! 15 
'B 
!O 
5 
o 
o 6 18 30 42 54 
mn-in follow-up 
Time on treatment (weeks) 
Salmcterol Group: Nighttime 
o 6 18 30 42 54 
nUl-in follow-up 
Time on treatment (weeks) 
Figure 6.7 
30 
25 
20 
15 
!O 
5 
o 
35 
30 
25 
20 
15 
!O 
5 
o 
o 6 18 30 42 54 
follow-up 
Time on treatment (weeks) 
Beclomethasone Group: Nighttime 
o 6 18 30 42 54 
ll.lll-in follow-up 
Time on treatment (weeks) 
Number of blisters of salbutamol used in the 14 days period during daytime and 
nighttime for the salmeterol group and beclomethasone group: 
missing, 0; 15+,0; 8-14,1m; 1-7,11;0,11. 
used blisters, during the treatment period was 0.44 in the salmeterol treated group and 
0.07 in the beclomethasone treated group (p=O.OOOI). 
During the treatment period 19 courses of prednisolone were given, 17 of these to 15 
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Figure 6.8 
Change in height as SDS (means, 95% CI) during treatment with 
sahneterol ( • ) or beclomethasone ( • ). 
patients in the salmeterol group (2 patients received 2 courses). 
6.4.5 Adverse events 
At no point during the treatment period were any significant changes in heart rate, 
systolic and diastolic blood pressure found in either treatment group. 
Table 6.3 shows the most common reported adverse events. 
The mean increase in height was 6.1 em (95%CI 5.3;6.9) in the salmeterol treated 
group, compared with 4.7 em (95%CI 4.0;5.3) in the beclomethasone treated group 
(p=0.007). SDS showed a change of -0.03 SDS in the patients treated with salmeterol 
compared to 0.28 SDS in the patients treated with beclomethasone (p=O.OOI) (Figure 
6.8). No interaction was found with gender. A significant interaction (p=0.03) was 
found with puberty; the mean difference in SDS between groups was -0.10 (95%CI-
0.29;0.10) for patients with puberty stages 2 and more and -0.37 (95%CI -0.58;-0.16) 
for prepubertal patients. 
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6.5 Discussion 
This is the first long term study to compare treatment with a long-acting 6,-agonist with 
treatment with an inhaled corticosteroid. We selected children with mild to moderate 
asthma, who were not treated with an inhaled corticosteroid, as this is the category of 
patients for whom monotherapy with a long-acting B2-agonist may be considered. For 
salmeterol twice daily 50 I'g is recommended as the optimum dose in childhood 
asthma.l3 Inhaled corticosteroids are the most effective asthma treatment currently 
available and so they were chosen as the comparator treatment. A daily dose of 400 I'g 
beclomethasone was chosen, as this is considered to be a moderate dose in the treatment 
of childhood asthma. 2 
The data from this study show that treatment with beclomethasone is superior to 
treatment with salmeterol in tenus of airway caliber, airway responsiveness, symptoms 
and exacerbations. Two short-term studies have compared inhaled corticosteroid with 
salmeterol treatment. In an open uncontrolled study 23 children received either twice 
daily 100 I'g budesonide or twice daily 50 I'g salmeterol for 3 weeks.24 FEY! values 
after budesonide were not significantly higher than after salmeterol. Both treatments 
improved symptoms and peak flow rates. A randomized study in 46 adults showed no 
significant difference in the effect on FEV 1 and PC20 after 6 weeks of treatment with 
salmeterol 50 "g twice daily, fluticasone 250 "g twice daily or the combination.25 No 
differences may have been found in these studies because of the small number of 
patients included and/or the short duration of treatment. However, in our study signifi-
cant differences between treatments in FEV! and airway responsiveness were apparent 
already after 6 weeks. The rapid improvement in FEV\> which occuned within 6 weeks 
after the start of beclomethasone treatment compares well with the data found by Van 
Essen et al. in a three year follow-up study, in which budesonide 600 I'g daily was 
given. 26 In that study, ainvay responsiveness also improved, but more gradually than 
in the cunent study. After 12 months inhaled corticosteroid treatment PD20 increased, 
on average, by less than 1.5 DD, whereas in this study it improved by 2 DD. It is 
likely that the patients in Van Essen's study had more severe asthma; their mean 
baseline FEV! was 76% of predicted, compared to 86% in the current study. Although 
baseline PD20 values were similar to the PD20 values in this study, more than half of 
their patients had recently been treated with inhaled corticosteroids and it is therefore 
possible that part of the potential improvement had already taken place. Another 
difference is that in Van Essen's study the inhaled corticosteroid was combined with an 
inhaled short-acting 6,-agonist and one might hypothesize that regular use of 6,-agonist 
reduces the improvement caused by the inhaled corticosteroid. This has been suggested 
in a study by Sears et al. 27, who found a negative effect of regular use of fcnoterol on 
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several outcomes of asthma, compared to it's use on demand. However, a later 
publication indicated that the differences were small. 28 
With salmeterol we observed a tendency to gradual deterioration in FEV! and PD20 • 
This became more pronounced at the end of the one year treatment period. In a 
previous study of 4 months duration with salmeterol 50 "g b.Ld. we did not observe 
such a decline in FEV! or PD20•29 However, in that study lung function measurements 
were performed exactly 12 hours after inhalation of salmeterol and it could be argued 
that a negative effect was masked by the residual bronchodilator effect of salmeterol. 
This seems unlikely, because in the present study comparison of subgroups according 
to the measurement interval after salmeterol inhalation did not reveal any differences 
in the magnitude of the decrease in FEY, or PD,o' Tolerance to the bronchoprotective 
effects of salmeterol has been described and seems to occur within a period of a few 
days after starting daily treatment. 29 30 In the longest follow-up study so far,29 there 
was no evidence for a progressive decline of protection after 4 months, and therefore 
it is unlikely that increasing tolerance explains our results. Salmeterol, on contrast to 
inhaled corticosteroid treatment, does not reduce airway waH inflammation.3! We think 
it likely that ongoing inflammation might be the cause of the decrease in FEY, and PD,o 
in the salmeterol group. Thickening of the ainvay wall due to inflammatory changes 
will result in a lower airway diameter and might also explain the increase in airway 
responsiveness. 32 This is consistent with the fInding that postbronchodilator FEV! 
during salmeterol treatment tends to decrease. Whether ongoing inflammation is the 
result of the underlying disease itself or whether it is negatively influenced by the use 
of a regular fi,-agonist could only have been shown by incorporating a control group 
with placebo treatment into the study design. This was considered not feasible. The 
drop in FEY, and PD
'0 after stopping salmeterol treatment suggests that during 
treatment there was a benefIcial effect of salmeterol on airway caliber and airway 
responsiveness. 
Despite a deterioration in FEV! and PD20 symptoms diminish and peak flow rates 
increase in the patients on salmeterol. This is in agreement with the clinical impro-
vement found in previous studies in which saImeterol was compared to salbutamol. 12 13 
However, in our study, sahneterol was compared to treatment with inhaled corticoste-
roid and improvements were less in the salmeterol group. Asthma exacerbations were 
rare in the children treated with beclomethasone. In contrast, they were the most fre-
quent reason for withdrawal in the children treated with salmeterol. In most other 
studies with salmeterol a significant reduction of astluna exacerbations was not 
observed, despite reductions in symptoms. 12 13 
In this study treatment with 400 "g beclomethasone daily. administered as dry powder. 
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resulted in decreased growth compared to salmeterol treatment. So far, most studies 
with inhaled corticosteroids have not shown an effect on long- and intermediate-term 
growth in children." Recently a study by Doull et a!. 34 revealed growth impainnent 
during 7 months of treatment with beclomethasone 400 J'g/day as dry powder in chil-
dren with mild asthma. Compared to placebo, a growth difference of 1.0 cm was found. 
This is consistent with our observed difference of 1.4 em over a 12 months period. In 
both studies no differences were found between boys and girls. The study of Doull et 
a!. only included prepubertal children. In our study the effect on growth was more 
marked in prepubertal children. Doull's study as well as this study used dry powder 
inhalators, compared to former studies in which usually metered dose inhalers were 
used." Differences in delivery systems and thereby in lung and oropharyngeal 
deposition may account for the differences in effect on growth. From the scarce data 
available, children with asthma usually grow to their predicted height. 35 It is unlikely 
therefore, that a negative effect of inhaled corticosteroids on height will continue for 
years during treatment. One might speculate that it is a transient effect which will be 
followed by a catch-up growth later on. Further prospective long-tenn studies are 
necessary to address this issue. 
From the results of this study we conclude that treatment with inhaled corticosteroid in 
a moderate dose provides better asthma control and lung function improvement 
compared with monotherapy with a long-acting fi,-agonist in children with mild to 
moderate asthma. This study shows that a reduction in symptoms and an increase in 
PEF may well occur during treatment with salmeterol without a corresponding improve-
ment in airway caliber and airway responsiveness. Monotherapy with a long-acting fir 
agonist therefore canies a risk of masking the severity of the disease and probably 
allow ongoing inflanunation. We suggest that salmeterol should not be used as a mono-
therapy in children with astbma. We further advocate the careful monitoring of indivi-
dual growth during treatment with inhaled corticosteroids. 
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Addition of salmeterol versus doubling the dose 
of becIomethasone in children with asthma 
7.1 Summary 
Studies in adults revealed Ihal addilion of salmelerol 10 a moderale dose of inhaled 
CO/ticosleroid resulled in beller symplom con/rol and higher PEF compared wilh 
doubling Ihe dose of inhaled cO/ticosleroid. The aim of Ihis 3-group study was 10 
compare the effects of a moderate dose of beclomethasone, the same dose of beclome-
thasolle with salmeterol alld a doubling dose of bec/omefhasolle Oil lung junction and 
symptoms ill children with moderate asthma. Olle hundred alld seventy-seven children, 
already Irealed with illhaled corticosleroids. were randomized ill a double-blind parallel 
sludy eilher 10 salmelerol 50 1'8 b.i.d., bee/omelhasolle 200 I'g b.i.d. or placebo. 
Bee/omelhasone 200l'g b.i.d. lVas cOlllinued in all groups. No significanl differences 
between groups were found in FEV}, PD20 methacholine, symptom scores Gild 
exacerbalioll rales after olle year. Salmelerol resulled ill slightly beller PEF ill Ihe firsl 
momhs oflrealmelll. FEV] alld PD,o melhacholine significalllly improved ill all groups. 
After olle year meall challges in FEV] %predicled were 4.3% (95%CI 1.3;7.2), 5.8% 
(95%C1 2.9;8.7) and 4.3% (95%CI 2.1;6.5) for salmelerol, bee/omelhasone and 
placebo, respeclively. Changes in ainl'ay responsiveness lVere 0.60 (95 %CI O. 05; 1.14), 
1.30 (95%CI 0.73;1.87) and 0.80 (95%CI 0.33;1.27) doubling doses. Growlh was 
significantly slower in the group with the doubling dose of beclomelhasone. We conclude 
that 110 additiollal benefit was found of adding either sa/melerol or more beclomethasone 
10 a daily dose of 400 I'g bee/omelhasone ill Ihis group of childrell wilh excellenl 
compliance of medicatioll. 
7.2 Introduction 
Salmeterol, taken as a single dose, has a bronchodilating effect of at least 12 hours in 
adults and children.' , Protection against methacholine and histamine-induced airway 
obstlUction lasts for 12 to 24 hours. 2 3 4 Single-dose studies show prolonged protection 
against other bronchoconstricting stimuli such as exercise,5 hyperventilation with dry 
cold air' and allergen.' 8 Compared with salbutamol, twice daily salmeterol for several 
weeks or months has been shown to result in fewer symptoms, less need for additional 
bronchodilator treatment and better improvement in peak flow rates in studies in adults 
and in children.' 10 II International guidelines recommended the use of long-acting 
fi,-agonists, such as salmeterol, either as an addition to conventional doses of inhaled 
corticosteroids or as an additive treatment in patients on higher doses of inhaled 
corticosteroids.1 2 13 14 Two studies in adults have focussed on this subject. The fIrst 
study was carried out in patients treated by general practitioners who were still 
symptomatic on 400 I'g budesonide or beclomethasone. Salmeterol50 I'g b.Ld. together 
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with beclomethasone 200 p,g b.Ld. was compared with beclomethasone 500 p,g b.Ld. I ' 
This study showed better peak flow rates, less diurnal variation of peak flows and fewer 
symptoms after 21 weeks treatment in the group in which salmeterol was added to the 
inhaled corticosteroid. Similar results were obtained in a 24-week study of patients 
treated in hospital, in whom addition of salmeterol50 p,g b.Ld. and sahneterol 100 p,g 
b.Ld. to beclomethasone 500 I'g b.i.d. was compared with beclomethasone 1000 I'g 
b.i.d.16 We set out to investigate whether beneficial effects also occur in children with 
astluna. The aim of our 3-group study was to compare the effects of one year treatment 
with beclomethasone 200 I'g b.Ld., the same dose of beclomethasone together with 
salmeterol50 I'g b.Ld. and beclomethasone 400 I'g b.Ld. The primary efficacy outcome 
parameters were airway calibre, measured as forced expiratory volume in 1 second 
(FEV,) and airway responsiveness to methacholine. Symptom scores, exacerbations, 
additional use of short-acting fi,-agonists and peak expiratory flows (PEF) were secon-
dary outcome parameters. 
7,3 Material and methods 
7.3.1 Pa/iellls 
One hundred and seventy-seven children aged 6 to 16 years with moderate asthma were 
selected from the outpatient paediatric clinics of 9 hospitals, 6 university hospitals and 
3 general hospitals. Patients were recruited between September 1992 and May 1995. 
All children had mild to moderate asthma according to the American Thoracic Society 
criteria. 17 Patients included in the study had to have: (1) an FEVI between 55-90% of 
predicted value and/or a ratio of FEVI to forced vital capacity (FVC) of 50-75%, (2) 
an increase of at least 10% in FEVI after inhalation of 0.8 mg salbutamol, (3) airway 
hyperresponsiveness to methacholine, Le. a 20% fall in FEVI after inhalation of 150 
flg or less methacholine (pDzo methacholine), which is more than two standard 
deviations below the mean value in healthy children l8 , (4) an ability to produce 
reproducible lung function tests, i.e. a variation in three consecutive measurements of 
FEV I of less than 5 %, (5) a history of stable asthma for at least I month without 
exacerbations or respiratory tract infections, (6) used inhaled corticosteroids between 
200 to 800 I'g daily for at least 3 months before the start of the study. The study was 
approved by the medical ethics committees of the participating centers. Written 
informed consent was obtained from all patients and their parents. 
7.3.2 Study design 
The study was a double-blind, randomized clinical trial. It consisted of a 6 week run-in 
period, a treatment period of 54 weeks and a follow-up period of 2 weeks. In the run-in 
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period all patients received beclomethasone 200 I'g b.Ld. Salbutamol200 I'g on demand 
was allowed as rescue medication, with a maximum of 6 inhalations per day. In the first 
and the last week of the run-in period FEV! and FVC before and after bronchodilatation 
and PD20 methacholine were assessed. Lung function inclusion criteria had to be 
fulfIlled at at least one of these visits. At the end of the run-in period patients were 
allocated to one of the three treatments by an independent randomization center. 
Randomization was stratified by sex, age, center, baseline FEV!, baseline PD10 and 
prior dose of inhaled corticosteroids, using a computerized minimization method.!9 
Study treatment consisted of either salmeterol xinafoate 50 I'g b.Ld., beclomethasone 
dipropionate 200 pg b.i.d. or placebo b.Ld., while beclomethasone 200 I'g b.Ld. was 
continued in all treatment arms. All drugs were administered as RotadisksR in 
combination with a Diskhaler (Glaxo Wellcome, Greenford, United Kingdom). All 
children were instructed in the use of this inhalation device prior to entry into the study 
and their inhalation technique was checked at every visit. For relief of symptoms during 
the treatment period the use of salbutamol 200 pg Rotadisk was allowed, with a 
maximum of 6 inhalations per day. Asthma symptoms, which did not sufficiently 
improve with the maximum dose of rescue salbutamol, were treated with a standard 
course of prednisolone. On the first day tlus started with a dose of 30 or 35 mg, 
depending on the weight of patients, and this was tapered off to zero in 7 days. During 
the treatment period the reversibility of FEV! to salbutamol (at 12, 24, 36 and 48 
weeks) and PD20 methacholine (at 6, 18, 30, 42 and 54 weeks) were measured 
alternately at intervals of six weeks. After 54 weeks all patients stopped taking 
randomized treatment for a period of 2 weeks. During this 2-week period patients 
continued with beclomethasone 200 pg b.i.d. and salbutamol on demand. At the end of 
this period PD20 methacholine was measured again. 
At each clinic visit FEV!, FVC, PEF, height, body weight, heart rate, systolic and 
diastolic blood pressure were measured. Height was measured using a stadiometer in 
centimeters, corrected to one decimal place. Furthermore, the patients were asked about 
adverse events and the number of used blisters of study medication and rescue salbu-
tamol were counted. 
Throughout the study period patients kept diary cards on which symptoms and additi-
onal use of rescue medication were recorded. They also measured PEF using a mini-
Wright peak flow meter (Clemente Clarke International Ltd., Harlow, Essex, U.K.) at 
home. Symptoms and PEF measurements were recorded during the first two weeks of 
each six-week period between clinic visits. Dyspnea, wheeze and cough in the morning 
and the evening were scored separately, using a scale from 0 to 3. PEF was measured 
in triplicate in the morning and evening before taking study medication and all three 
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values were recorded. The highest value was used in the analysis. Patients were 
withdrawn from the study if they needed 3 or more prednisolone courses within 3 
months, or if it was not ethical to continue blinded treatment according to the investiga-
tor or if patients or parents wanted to stop. 
All data were collected and checked by the coordinating center in Rotterdam to ensure 
completeness. Interim analyses of the study data were made by an independent 
statistician every 6 months and reviewed by a data monitoring committee. Investigators 
were kept blind to the results of the interim analyses. The data monitoring committee 
allowed the study to continue until all patients had completed follow-up. 
7.3.3 Lung junction measurements 
Lung function measurements were performed between 12 and 18 hours after inhalation 
of the study medication. For each patient the time of measurement was constant 
throughout the study period. Patients were instructed to take their last dose of study 
drug before the clinic visit at a fixed time the previous evening. Rescue salbutamol was 
not allowed in the 8 hours before lung function measurement. The time of inhalation 
of the last dose of study drug and any use of salbutamol were checked before 
perfonning measurements and, if necessary, these measurements were postponed. No 
lung function measurements were done within the 4-week period after a course of 
prednisolone. 
FEV 1 and FVC were measured according to the recommendations of the European 
Community for Steel and Coal, by using a water sealed or dry rolling seal spirometer 
or pneumotachometer. 20 At least 3 manoeuvres were perfonned with FEV 1 and FVC 
within 5 %. A maximum of 5 manoeuvres were allowed and the largest FEV 1 and FVC 
were taken for the analysis. Reference values of Zapletal and coworkers were used.21 
Postbronchodilator FEV, was measured 20 minutes after inhalation of 0.8 mg 
salbutamol," Salbutamol was administered by a Volumatic spacer (Glaxo Wellcome, 
Greenford, UK) as 4 puffs of 0.2 mg, one at a time, inspiring slowly from functional 
residual capacity to total lung capacity and holding each breath for about 10 seconds. 
PEF was measured in triplicate, using the patient's own Mini Wright peakflow meter. 
Methacholine provocation tests were perfonned using a modification of the dosimeter 
method by Chai, as described previously." Preparation of methacholine solutions was 
standardized in all centers. Nebulized methacholine bromide in unbuffered saline 
solution was given in doubling concentrations (0.125 to 39.2 mg/ml). The aerosol was 
generated by a DeVilbiss 646 nebulizer (DeVilbiss Co., Somerset, PAl attached to a 
Rosenthal dosimeter (Laboratory for Applied Immunology, Fairfax, VA), driven by air 
at 137.8 kPa (20 psi) with a timing adjustment of 0.6 seconds. Output of the nebulizers 
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was measured before the start of the study. All parts of each nebulizer were marked 
with waterproof paint to prevent interchanging. Nebulizers were cleaned after each 
measurement to prevent precipitations, and orifices were checked weekly according to 
recommendations. 24 Aerosolized solution was delivered to the mouth in four 
consecutive breaths. Mouth doses were 2.5 to 784 I'g of methacholine. Saline was 
inhaled before methacholine to exclude a non-specific response. The effect of each dose 
was determined by measuring FEV 1 in triplicate 3 minutes after administration. PD20 
methacholine was calculated by a computer program from a log-dose-response plot by 
linear interpolation. Airway responsiveness was only measured if FEV 1 before 
methacholine provocation was 80% or more of the individual's baseline value at entry 
into the study. 
All centers used written guidelines for lung function measurements. Technicians 
attended a training course before the start of the study. Site visits were made once a 
year by the primary investigator and a pulmonary physiologist to inspect the equipment 
and the methods used. 
7. 3. 4 Statistical analysis 
The study was designed to have 90% statistical power to detect a difference of 6% 
predicted FEY, between any two (of three) treatment groups using a statistical 
significance level of 5 %. 
Changes in FEY, and the logaritlun of PD,o within each group over the study period 
were assessed using paired t-tests for matched data. Changes in PD20 were reported as 
numbers of doubling doses (DD). Comparisons of FEY, and the logarithm of PD,o 
between groups at each clinic visit were made using analysis of covariance to adjust for 
mean pre-intervention levels. Comparisons of both morning and evening PEF 
measurements recorded during the 2-week diary periods were made using analysis of 
covariance to adjust for mean pre-intervention levels. Morning and evening PEF varia-
bility for each patient was expressed as the standard deviation of the PEF measure-
ments. Each measure of day-to-day variability was compared between pairs of treatment 
groups using the Mann-Whitney test. Distributions of symptoms during the 2-week 
diary periods were compared using the Mann-Whitney test, as were the numbers of 
blisters of rescue salbutamol used over this period. Where patients failed to complete 
their daily record cards for more than 7 days in any 14 day period such assessments 
were not included in the analysis. Otherwise, when there were missing days in the 
record, pro rata adjustment was made to give a 2-week assessment. Comparison of 
heights between groups were made using analysis of covariance to adjust for pre-
intervention levels. Heights were also expressed as standard deviation scores (SDS) 
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Table 7.1 Baseline characteristics at the slart of tbe run-in period and at randomization by treatment 
group. 
All values are means (sd) unless stated otherwise 
At start of run-in period: 
Salmeterol Bcclomethasone Placebo 
(n~60) (n~60) (n~57) 
sex, F/M 20/40 24/36 21/36 
age, yr 10.8 (2.5) llA (2.9) 11.1 (2.7) 
height, em 143.6 (1504) 147.9 (17.0) 145.6 (1504) 
duration of asthma, yr 7.8 (3.5) 9.0 (3.1) 8.5 (3.1) 
atopy status: 
none 7/60 5/60 7/57 
house dust mite 46/60 45160 44/57 
cat 29/60 35/60 23/57 
dog 34/60 31/60 30/57 
grasspollen 30/60 28/60 26/57 
inh.corticosleroid 
treatment: 
dose, p.g 490 (154) 503 (201) 488 (149) 
<400 ~g 1I60 6/60 2/57 
>400 "g 21160 22160 20157 
duration, yr 3.2 (2.2) 304(2.1) 2.9 (2.0) 
FEY 1• %prcdicled: 
prebronchodilator 87.2 (13.0) 85.3 (13.8) 86.5 (13.2) 
postbronchodilator 103.2 (14.1) 100.9 (12.3) 102.2 (12.0) 
PDlO J.lg~ 24.5 (11-47.5) 22.5 (7.5-42.5) 26 (12-38) 
At randomization: 
height, em 144.1 (15.4) 148.5 (17.0) 146.1 (15.4) 
FEY" %predicted: 
prebronehodilator 89.7 (11.8) 8704 (12.3) 89.2 (13.4) 
postbronehodilator 103.5 (13.1) 102.3 (1I.4) 103.0 (13.6) 
PD lI» p.g~ 29 (9-59) 20 (6-56) 27 (16.5-44) 
PEF. IIrnin: 
morning 299 (79) 315 (90) 317 (79) 
evening 306 (82) 323 (92) 325 (80) 
Days in two weeks 
with symptoms* 6 (3-11) 5 (1.5-10) 4 (1-9) 
Nights in two weeks 
with symptoms~ 6 (3-10) 4.5 (I-II) 5 (1-9) 
* median and quartiles 
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using Dutch reference growth charts. 25 Changes in SDS over time within each group 
were assessed using paired t-tests for matched data, and comparisons between groups 
at each clinic visit were made using analysis of covariance to adjust for mean pre-
intervention levels. This model was extended to simultaneously investigate the effect of 
treatment group and puberty (pre- and postpubertal according to Tanner stages) on SDS. 
All reported p-values are for two-sided tests and for simplicity of presentation are 
without formal adjustment for multiple comparisons over time or for multiple 
comparisons between groups. Confidence intervals for means were calculated 
parametrically assuming normality. 
7.4 Results 
Between October 1992 and May 1995, 177 patients (112 boys, 65 girls) were enrolled 
into the study. Patient characteristics at entry (beginning of the run-in period) and at 
randomization were similar in the three treatment groups (Table 7.1). 
Fifteen patients withdrew during the study period, 5 in the salmeterol treated group, 6 
in the beclomethasone group and 4 in the placebo group. Eleven patients withdrew 
because of non-compliance or failure to return. Three patients withdrew as a result of 
an adverse event: 2 patients, both in the salmeterol group, because of alopecia or 
ingestion of corpus alienum, 1 patient in the beclomethasone group because of vomiting. 
Only 1 patient, treated with placebo, withdrew because of an exacerbation. 
Compliance with study treatment was slightly better in the salmeterol group than in the 
beclomethasone group (p=O.OI) and the placebo group (p=O.OI). The median number 
of blisters of study medication used per day were 1.88, 1.77 and 1.75 in the salmeterol, 
beclomethasone and placebo groups respectively; i.e. 94%, 89% and 88% of the 
prescribed shldy medication. Compliance with maintenance beclomethasone treatment 
was comparable to that with study medication; the median number of blisters per day 
were 1.89, 1.81 and 1.75 respectively. 
7.4.1 Ailway calibre 
At the end of the 54-week treatment period no significant differences in FEV, 
%predicted between treatment groups were found. Significant changes in FEV1 occurred 
in all groups. Mean changes in prebronchodilator FEY, from baseline to the end of the 
treatment period were 4.3 %predicted (95% confidence interval(CI) 1.3;7.2)(p=O.005), 
5.8 %predicted (95%CI 2.9;8.7)(p=O.0002), and 4.3 %predicted (95%CI 
2.1 ;6.5)(p=O.0003) for the salmeterol, beclomethasone and placebo groups respectively 
(Figure 7.1). 
No differences between treatments were found after analyzing subgroups according to 
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Figure 7.1 
Changes in prebronchodiJator FEV\% predicted (means, 95% Cl) from 
baseline during treatment with salmeterol (. ), beclomethasone ( • 
or placebo ( 0 ). 
prestudy dose and duration of inhaled corticosteroid, baseline levels of FEYr and PDzo 
and the numbers of daytime or nocturnal symptoms. 
After stopping treatment with salmeterol, there was a significant fall in FEY r of 5.6 
%predicted (95%CI 2.1 ;9.1)(p=0.003). Stopping of either beclomethasone or placebo 
did not result in significant changes. 
Mean changes in postbronchodilator FEY r were -0.1 %predicted (95%CI -2.3;2.1-
)(p=0.9), 3.5 %predicted (95%CI 1.6;5.4)(p=0.0005) and 2.0 %predicted (95%CI -
0.6;4.5)(p=0.13) for the sahneterol, bedomethasone and placebo groups respectively 
(Figure 7.2). The difference between the levels in the salmeterol and beclomethasone 
groups was of borderline statistical significance at 48 weeks (p=0.04) but not at any 
other time point. 
7.4.2 Ai/way responsiveness 
At the end of the treatment period no significant differences between groups were 
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.<igul"c 7.2 
Changes in postbronchodilator FEV1% predicted (means, 95% el) from 
baseline_during treatment with salmctcrol ( • ), beciomethasone ( • ) 
or placebo ( 0 ). 
found. Median PD20 values were 36, 39.5 and 35 ~g for the salmeterol, beclomethasone 
and placebo groups, respectively. All three groups showed a significant improvement 
in PD,o' Changes in PD,o compared to baseline were 0.60 doubling doses (DD)(95%CI 
0.05;1.I4)(p=0.03), 1.30 DD (95%CI 0.73;I.87)(p=0.00003) and 0.80 DD (95%CI 
0.33; i.27)(p=0.00i) for the sahneteroi, beciomethasone and placebo groups respective-
ly (Figure 7.3). 
After stopping salmeterol there was a small but not significant decrease in PD20 (-0.28 
DD), whereas after stopping placebo treatment an increase in PD,o was found (0.6 
DD)(p=0.003) and after stopping beclomethasone no change occurred. As for FEV!, 
subgroup analysis revealed no trends in favor of any of the treatments. 
7.4.3 Peak expiralOl)' jlow 
Morning and evening PEF improved in all treatment groups. During the first months 
of treatment changes were larger iu the salmeterol group than in the other two groups 
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Figure 7.3 
Changes ill airway responsiveness in doubling doses (means, 95% CI) 
during treatment with salmeterol ( • ), bcclomcthasone ( • ) 
or placebo ( 0 ). 
with the differences between the salmeterol and placebo groups being statistically 
significant at some time points (Figure 7.4). After one year mean increases in morning 
PEF were 41.8 IImin, 41.llImin and 27.3 I/min for the salmeterol, beclomethasone and 
placebo groups respectively. Mean increases in evening PEF were 38.6 I/min, 37.6 
I(min and 24.9 11m in respectively. Differences between mean follow-up levels in the 
placebo group and each of the other two groups were of borderline statistical 
significance for both morning and evening PEF (0.05 < P <0.1 for each comparison). 
There was some evidence that at the first follow-up visit, day to day variability was 
greater in the beclomethasone group than in the sa!meterol group (p=0.004 am, 
p=0.003 pm) and the placebo group (p=O.03 am, p=0.06 pm), however, especially 
for the moming PEF day to day variability at baseline was already higher in the 
beclomethasone group. Day to day variability did not differ significantly between 
groups at any other follow-up visit. 
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Figure 7.4 
Mean changes in Illoming and evening PEF (Umin, 95% el) during treatment with 
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7.4.4 Symptoms 
Daytime and nighttime symptoms diminished in all treatment groups in a similar way. 
The percentage of children reporting no symptoms during the 2-week diary card periods 
increased from 3 %, 13 % and II % for the salmeterol, beclomethasone and placebo 
Table 7.2 Most common reported adverse events during the treatment period 
Salmeterol Beclolllethasone Placebo 
Number of patients 60 60 57 
Number of patients 
with adverse event 59 (98%) 52 (87%) 52 (93%) 
Number of patients with: 
headache 25 (42%) 16 (27%) 23 (41 %) 
rhinitis 21 (35%) 20 (33%) 14 (25%) 
viral resp. infection 17 (28%) 18 (30%) 14 (25%) 
asthma 16 (27%) 19 (32%) 16 (29%) 
upper resp, tract 
infe\:lion 16 (27%) 15 (25%) 9 (16%) 
cough 12 (20%) 16 (27%) 13 (23%) 
fever 12 (20%) 7 (12%) 8 (14%) 
nausea and vomiting II (18%) 5 (8%) 7 (13%) 
diarrhea 8 (13%) 2 (3%) 4 (7%) 
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groups respectively in the run-in period to 34%, 39% and 35% after one year of 
treatment. At no time point were there statistically significant differences in symptom 
scores between the groups. 
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Figure 7.5 
Change in height as SDS (means, 95% CI) during treatmcnt with 
salmctcrol ( • ), bcclomcthasonc ( • ) or placcbo ( 0 ). 
There was some evidence that the use of additional salbutamol, as noted on the diary 
cards, differed between groups, particularly during the first two weeks of treatment this 
was higher in the beclomethasone group than in the other groups. The median number 
of additional salbutamol inhalations per day during the treatment period, as counted 
from the used blisters, was 0.19, 0.33 and 0.15 for the salmeterol, beclomethasone and 
placebo group respectively. The difference between the rates in beclomethasone and 
placebo was of borderline statistical significance (p=0.06). 
During the treatment period 34 courses of prednisolone for exacerbations were given; 
13 courses to 10 patients in the salmeterol treated group, 8 courses to 7 patients in the 
beclomethasone treated group and 13 courses to 10 patients in the placebo treated 
group. 
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7.4.5 Adverse events 
During the treatment period no consistently, clinically significant differences in heart 
rate, systolic and diastolic blood pressure were found between treatment groups. 
Table 7.2 shows the most commonly reported adverse events. 
The mean increase in height was 5.! cm (95%CI 4.5;5.7) in the salmetero! group, 
compared with 3.6 cm (95%CI 3.0;4.2) in the beclomethasone group and 4.5 cm 
(95%CI 3.8;5.2) in the placebo group. A slightly greater proportion of patients were 
pre-pubertal in the placebo group (47%), than in the salmeterol (43%) or 
beclomethasone (35 %) groups. The reductions in SDS were greatest in the pre-pubertal 
patients. After adjustment for puberty, the reduction in SDS was significantly greater 
in the beclomethasone group than in the other two groups (p=0.006 compared with 
sahneterol, p=0.02 compared with placebo). Mean changes in SDS were -0.10 (95%CI 
-0.19;-0.02), -0.27 (95%CI -0.34;-0.19) and -0.16 SDS (95%CI -0.24;-0.07) for 
salmeterol, beclomethasone and placebo respectively (Figure 7.5). 
7.5 Discussion 
This is the first long tenD study comparing the addition of a long-acting fi,-agonist with 
a doubling dose of an inhaled corticosteroid in asthmatic children on maintenance 
treatment with inhaled corticosteroid. We selected children with moderate asthma, who 
had used 200 to 800 I'g of inhaled corticosteroid for at least 3 months before the start 
of the study. During the six week run-in period they were treated with 200 I'g 
beclomethasone b.Ld., which is considered a moderate dose in the treatment of 
childhood astluna. 14 Despite this treatment all children were symptomatic and had 
reversible ainvay obstruction and airway hyperresponsiveness. The dose chosen for 
salmeterol (50 I'g b.i.d.) is recommended as the optimum dose in childhood asthma. II 
The data from this study show no statistically significant differences in airway calibre, 
airway responsiveness, symptom scores and exacerbation rates between 200 p.g 
beclomethasooe b.Ld., 200 I'g beclomethasooe plus salmeterol 50 I'g b.Ld. or 400 I'g 
beclomethasone b.Ld. Although FEY I and airway responsiveness tended to be slightly 
better in the group on the high dose of inhaled corticosteroid, only for postbroncho-
dilator FEYI was the difference between this group and the salmeterol group of 
borderline statistical significance (p=0.04) at the end of the treatment period. During 
the first months patients in the salmeterol group tended to have higher peak flow values. 
Our results differ somewhat from those from the two adult studies which have 
compared the addition of salmeterol with increasing the inhaled corticosteroid dose. IS 
16 Both studies lasted about 6 months and showed a significantly better improvement 
in PEF with the addition of salmeterol. Symptoms were less in patients on sahneterol 
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treatment, especially in the study by Woolcock et al. 16 and at some time points in the 
study by Greening et al. IS These studies as well as our study selected patients with 
reversible airway obstruction. In contrast with our study. in which inclusion criteria 
were based on ainvay caliber and ainvay responsiveness, inclusion criteria of both adult 
studies were based on symptom scores in the run-in period prior to randomization and 
PEF variability. This may have led to the selection of highly symptomatic patients. In 
the study by Woolcock et al. 16 beclomethasone was increased from 1000 to 2000 p.g. 
This dose increase may already be on the Uflat part" of the dose response curve for anti-
asthma effects of inhaled corticosteroids", which could explain the better symptomatic 
improvement with salmeterol. In the study by Greening et al. IS the beclomethasone dose 
increased from 400 to 1000 p.g daily. This lower dose range was probably on the "steep 
part" of the dose-response curve, which may explain why differences in symptom 
scores between salmeterol and the high dose of inhaled corticosteroid were less obvious. 
Based on PEF and FEVI data, the degree of obstruction in the adult studies is more 
severe than in our study: the mean baseline PEF in the study by Greening" was 74 % 
predicted, the mean baseline FEVI in the study by Woolcockl6 was about 72% predicted 
compared to 86% in our study. This suggests that there might have been more room for 
improvement by a bronchodilator in these studies and may explain why in our study, 
no differences were found between salmeterol and beclomethasone in terms of FEVI 
improvement. However, subgroup analysis by FEV l at baseline did not reveal a larger 
effect of salmeterol in those asthmatic children who had more severe airway 
obstruction. For PEF, also in our study salmeterol was slightly superior to 
beclomethasone during the first 24 weeks of treatment, although the differences between 
salmeterol and beclomethasone in our study were less than in the adult studies and not 
consistently statistically significant. 
All treatment groups in our study showed a significant improvement in airway 
responsiveness compared with baseline. For the beclomethasone group this was 1.3 DD, 
comparable with 1.5 DD found after one year of treatment with 600 p.g budesonide 
daily in an earlier study on asthmatic children.27 However, the latter study selected 
children not on inhaled corticosteroids before inclusion into the study. Further data of 
that study showed a plateau of PD,o improvement after 22 months of treatment. 28 It 
is remarkable that a comparable improvement in PD,o was found in our study despite 
the fact that the mean duration of inhaled corticosteroid use before study entry was 
about 3 years. No differences between subgroups who had used inhaled corticosteroids 
for less than 2 years and those who had been on corticosteroid treatment for 2 years or 
more were found. In the study by Woolcock et a1. 16 , the improvement in airway 
responsiveness was far less: 0.6 DD after salmeterol 50 p.g b.i.d. and 0.4 DD after 
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beclomethasone 1000 I'g b.Ld. However, their study population consisted of patients 
with longstanding asthma, who had been taking inhaled corticosteroids for several years 
and so their response might have reached a plateau. Furthermore, for the patients who 
doubled their inhaled corticosteroid dose, the plateau phase of the dose-response curve 
for PD20 may have been reached. An explanation for the relatively favorable response 
in our study as well as that in the study by Van Essen et al. 28 may be that in children 
the inflammatory changes in the airways are more reversible by inhaled corticosteroid 
treatment than they are in adults, who typically have longstanding asthma. There is 
some evidence that a delay in the introduction of inhaled corticosteroid leads to a 
smaller improvement in lung function in children as well as adults. 29 30 In our study 
even the placebo group, who continued with 400 I'g beclomethasone, showed a 
significant improvement in FEV 1 as well as in PD20 : an effect, which is most likely 
attributable to the excellent compliance ofneady 90% of prescribed medication, which 
was probably belter than before due to the strict study protocol and patient control. 
All treatment groups showed a decrease in height growth over the one year treatment 
period. Several explanations are possible: growth of asthmatic children may be impaired 
as a result of their chronic disease or due to delayed puberty'l or may be due to the 
adverse effects of the inhaled corticosteroid. The unusually high compliance with 
medication in this study may have resulted in effects on growth with relatively low 
doses of inhaled corticosteroid. Furthenllore, the use of a dry powder inhaler with a 
high lung deposition may playa role. The effect on growth in this study appeared to 
be dose-dependent. The changes in SDS in the two groups treated with 400 I'g beclome-
thasone daily (resp. -0.10 and -0.16 SDS) were less than those found in another study 
in which the same dose of beclomethasone was given for the first year (mean change 
in SDS was -0.28)." Since children had used inhaled corticosteroids for a number of 
years before entry into the current study, this may suggest that the effect of inhaled 
corticosteroids on growth diminishes during prolonged treatment. Further long-term 
studies are necessary to address this issue. 
We conclude that adding salmeterol or doubling the dose of beclomethasone gave no 
additional benefit over that from 200 I'g beclomethasone b.Ld. in tlus selected group 
of cluldren with moderate asthma, in which the compliance with medication was 
excellent. This study also showed that with strict monitoring of the children and 
frequent control visits the compliance with medication was high, which resulted in 
considerable improvements in lung function and symptoms. Further studies are needed 
in order to evaluate which of the approaches is best in children with severe asthma. The 
possible advantage of a lugher dose of inhaled corticosteroid in suppressing airway 
inflammation should than be balanced against the adverse effects, especially on growth. 
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We advocate careful monitoring of children for medication compliance and growth 
during treatment with inhaled corticosteroids. 
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8.1 Summary 
The long-acting ill-agonist, salmeterol, was first introduced for the treatment of asthma 
in adults at the end of the eighties. I The subject of this thesis was to evaluate the effect 
of salmeterol after a single dose and during long-ternl treatment on several outcome 
parameters of asthma in children, and to establish the place for salmeterol in the 
treatment of childhood asthma. Primary outcome parameters were airway calibre, as 
measured by FEV 11 and airway responsiveness, as measured by PD20 methacholine. In 
the long-teon studies secondary outcome parameters were symptom scores, PEF, use 
of additional short-acting B,-agonists and exacerbations of asthma. 
Chapter 1 gives a general introduction and describes the pathophysiology of asthma as 
an inflammatory disease of the ainvays. Current guidelines for the treatment of asthma 
are discussed. The place of long-acting 6r agonists in the stepwise treatment of asthma 
is not unequivocally defined in international consensus reports. 2 3 4 5 They are 
positioned either as additional treatment to higher doses of an inhaled corticosteroid, or 
one step earlier, when a moderate dose of an inhaled corticosteroid is not sufficient to 
reduce symptoms. The phannacology and clinical aspects of inhaled corticosteroids, 
short-acting 3r agonists and long-acting Bragonists are described in more detail. These 
drugs now fonn the cornerstones of asthma treatment for children and adults. 
Chapter 2 gives a review of the literature on the effects of short-acting and long-acting 
32-agonists on airway responsiveness to histamine and methacholine. Short-acting 32-
agonists have a short-lasting acute protective effect, shifting the dose-response curve to 
a bronchoconstrictor to the right. Long-term treatment with short-acting .B2-agonists has 
no beneficial effect on airway responsiveness; some studies have even suggested 
worsening of airway responsiveness from the continuous use of short-acting Bragonists. 
Single doses of the long-acting B,-agonists salmeterol and formoterol give prolonged 
protection for up to at least 12 hours against methacholine- and histamine-induced 
bronchoconstriction. After prolonged use for weeks or months, long-acting B2-agonists 
still protect against bronchocollstricting stimuli. Some tolerance seems to develop for 
this protective effect, while the bronchodilating effect is maintained. 
Chapter 3 reviews the literature on clinical studies with salmeterol and fonnoterol, 
focusing on paediatric data. After single doses both drugs produce bronchodilation for 
up to at least 12 hours. Also, there is prolonged protection against various 
bronchoconstricting stimuli, such as exercise, methacholine, histamine and allergens. 
Twice daily use for weeks or months results in better symptom control and increased 
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peak flow values compared with treatment with a short-acting B,-agonist. Although 
tolerance seems to develop for the protective effects, residual protection remains over 
several months of treatment. The clinical relevance of this is not yet clear. Adverse 
events did not differ from those found in studies with short-acting B,-agonists. 
Chapter 4 presents a single dose study with salmeterol. In a double-blind, placebo-
controlled, cross-over design the effect of 50 Jig salmeterol on airway caliber and 
airway responsiveness to methacholine was investigated. Twenty children with mild to 
moderate astluna participated; the majority of children was on treatment with inhaled 
corticosteroids or disodium cromoglycate. Salmeterol in a dose of 50 pg resulted in 
significantly better FEV1 values for up to 12 hours after inhalation. The maximum 
response was reached 4 hours after administration with a mean FEV} of 18.6% ± 2.5% 
(mean±sem) above baseline. Significant protection against airway responsiveness to 
methacholine was found for up to 24 hours after salmeterol inhalation. At this time 
point the mean PD20 was still 1.22 ± 0.29 DD above baseline. The maximum 
protection was nearly 4 DD at 1 hour. We concluded that a single dose of salmeterol 
resulted in prolonged bronchodilation and protection against methacholine-induced 
ainvay obstruction. 
In chapter 5 the effect of a single dose of salmeterol on ainvay responsiveness was 
compared with the effect of treatment for 4 months. In a double-blind, parallel study, 
30 children were either randomized to salmeterol 50 I'g b.i.d daily or salbutamol 200 
pg b.i.d. Children with mild astllll1a, not on treatment with inhaled corticosteroids or 
disodium cromoglycate. who had little or no bronchial obstruction and were 
hyperresponsive to methacholine were selected. Airway responsiveness was measured 
before study entry, 12 hours after a single dose, and monthiy during 4 months of daily 
treatment. Measurements were always performed at the same time of the day, 12 hours 
after the last dose of medication was administered. No significant differences in FEV} 
were found between treatments at any time point. PD20 methacholine increased by 1.7 
± 0.3 DD after the first dose of salmeterol. This protection was reduced to 0.6 ± 0.3 
DD after 1 month, which was still significantly different from baseline and from 
salbutamol treatment, and remained at the same level during the rest of the treatment 
period. We concluded from these data that tolerance to the protective effect of 
salmetero1 to methacholine-induced bronchoconstriction develops within I month after 
starting treatment, and that no further tolerance occurred during several months of 
treatment. 
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Chapter 6 describes the results of a multicenter study which compares salmeterol 50 
I'g b.i.d with beclomethasone 200 I'g b.i.d during one year. Sixty-seven children with 
mild to moderate asthma, not on treatment with inhaled corticosteroids during the 
previous 6 months and not on treatment with disodium cromoglycate during 2 weeks 
before entering the study, were randomized in a double-blind parallel study. After one 
year of treatment there was a highly significant difference in favor of the beclometha-
sone treatment of 14.2% predicted (95%CI 8.3;20.0) for prebronchodilator FEV" 7% 
predicted (95%CI 2.0;11.9) for postbronchodilator FEV, and 2.79 DD (95%CI 
1.75;3.84) for PD20 methacholine. In the salmeterol group FEV, as well as PD,o tended 
to decrease during the 1 year treatment period, despite improvement in symptoms and 
PEF. Mean decreases were 4.5% predicted (95%Cl -9.0;0.1) for FEV, and 0.73 DD 
(95%CI -1.46;0.00) for PD,o' Between groups there were no significant differences in 
symptoms (daytime and nighttime), use of additional short-acting bronchodilators and 
peak flow values (morning and evening), although results in the beclomethasone group 
tended to be better. Asthma exacerbations for which prednisolone was needed, were far 
more frequent in the salmeterol group, as were the numbers of withdrawals due to 
exacerbations in this group. However, growth in the beclomethasone group was 
significantly retarded compared with that in the ,almeterol group (-0.28 SDS versus -
0.03 SDS). We concluded that treatment with a moderate dose of beclomethasone is 
superior to treatment with salmeterol in terms of lung function parameters, symptom 
scores and exacerbations of asthma in children with mild to moderate asthma. We 
strongly recommend that salmeterol should not be used as monotherapy and advocate 
careful monitoring of individual growth during treatment with inhaled corticosteroids. 
Chapter 7 describes the results of a multicenter study in which the addition of 
salmeterol (50 I'g b.i.d.) to a moderate dose of an inhaled corticosteroid 
(beclomethasone 200 I'g b.i.d.)(SI200 group) was compared to doubling the dose of 
inhaled corticosteroid (beclomethasone 400 I'g b.i.d.)(I400 group) and to the initial 
inhaled corticosteroid dose (beclomethasone 200 I'g b.i.d.)(I200 group). In a double-
blind, placebo-controlled, parallel study, 177 children participated. After one year of 
treatment no significant differences between the three treatment groups were found for 
pre- and post-bronchodilator FEVr values and PD20 methacholine. However, significant 
improvements from baseline values in FEVr and PD10 were found in all groups. For 
FEV, mean changes were 4.3% (95%CI 1.3;7.2), 5.8% (95%CI 2.9;8.7) and 4.3% 
predicted (95%CI 2.1;6.5), for the S[200, 1400 and 1200 groups, respectively. For PD,o 
mean changes were 0.6 DD (95%C[ 0.05;1.14),1.3 DD (95%CI 0.73;1.87) and 0.8 
DD (95%CI 0.33; 1.27) for the SI200, 1400 and [200 groups, respectively. For morning 
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and evening peak flow values Ihere was a slighl advanlage of Ihe SI200 group compared 
10 Ihe 1200 group, especially during Ihe firsl monlhs of Ihe trealmenl period. No 
significant differences were found between groups for symptom scores, use of additional 
salbutamol and exacerbation rates. Growth was significantly more retarded in the 1400 
group. Compliance was high in all Irealmenl groups, where nearly 90% of prescribed 
medication was used. We concluded Ihal adding salmelerol or doubling Ihe dose of 
beclomelhasone had no addilional benefil 10 200 I'g beclomelhasone b.Ld. in Ihis 
selected group of children with moderate asthma, in which the compliance with 
medication was excellent. 
8.2 Conclusions and general discussion 
Comparable with the results in studies in adult asthmatics, we confirmed in asthmatic 
children Ihal salmelerol had a prolonged bronchodilaling and prolecting effecl againsl 
methacholine induced bronchoconstriction.6 In agreement with the results of the study 
by Cheung el aI,' we found a reduction of Ihe prolective effecl during 4 monlhs 
treatment with sahileterol. However, our study revealed that significant residual 
protection remains, and no tendency to further reduction during treatment is apparent. 
As Ihe palients in Ihe study by Cheung and in our study were nol on Irealmenl with 
inhaled corticosteroids, one could hypothesize that inhaled corticosteroids prevent the 
development of tolerance. However, receni data reject this hypothesis. 8 9 10 The 
clinical relevance of the development of tolerance is not yet clear, and so far there is 
no convincing evidence of tolerance for the bronchodilating effect of the drug.7 II 
However, the reason that tolerance for the bronchodilating effect has not been found 
may also be that improvements in ainvay caliber are limited due to a ceiling effect 
when maximum dilatation has been reached, while for dose response curves there is a 
more open-end sealeY 
The two long-teon multicenter studies described in chapter 6 and 7 were perfonned to 
posilion salmelerol in Ihe trealmenl of childhood aslhma. The firsl study clearly showed 
the superiority of a moderate dose of beclomethasone to salmeterol mono therapy in 
teons of lung function improvements (airway caliber as well as airway responsiveness), 
symptom scores and exacerbation rates. Remarkably, even in the salmeterol group 
symptoms, as scored on the diary cards, and PEF improved, although airway caliber 
and airway responsiveness tended to decrease and frequent exacerbations occurred. 
During treatment with 400 Jig beclomethasone daily we found a decrease in the standard 
deviation score of heighl which may be clinically relevant. A recenl Dulch paedialric 
endocrinology consensus considered a change of 0.25 SDS per year clinically relevant. 
The use of a powder inhaler, with relatively high lung deposition and possible 
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oropharyngeal deposition, and a high compliance rate in the study may have influenced 
our results regarding growth. So far data from the literature do not support a clinically 
relevant growth effect of inhaled corticosteroid treatment. 12 
The second long-term study in which the addition of salmeterol to 200 I'g beclome-
thasone b.Ld. was compared to doubling the dose of beclomethasone and to the initial 
beclomethasone dose, did not reveal significant differences between treatment groups 
on lung function, airway responsiveness, symptoms, use of additional fi2-agonists or 
exacerbations. Only for salmeterol there was a slight advantage on peak flow values, 
especially during the fIrst months of treatment. All treatment groups, inclusive the 
placebo group in which the beclomethasone 200 I'g b.Ld. was continued, showed 
considerable improvements of all parameters. Therefore, our results were not due to a 
ceiling effect. We could not identify special subgroups, which could benefit more from 
one of the treatments. The compliance with study medication as well as with 
maintenance beclomethasone was high, nearly 90% in all groups. The substantial 
improvement in the placebo group, which continued beclomethasone 200 I'g b.Ld., can 
only be explained by tltis high compliance, which is likely to be better than before entry 
into the study. This study also suggested a dose-related effect of beclomethasone on 
growth. 
Translating our findings to current asthma treatment guidelines, we conclude that, in 
agreement with these guidelines, salmeterol should not be used as a monotherapy, but 
only in addition to inhaled corticosteroid treatment. On the basis of our data, we could 
not define a dose of inhaled corticosteroid above which introduction of a long-acting fi1-
agortist, such as salmeterol, should be the next step. Regarding the aims of the guideli-
nes to reduce symptoms and exacerbations all three treatment reginlens studied in our 
second multicenter study seem to fulfIll these criteria, with no clear advantage of one 
therapeutic regimen above others. However, our studies clearly showed a dose-
dependent effect ofbeclomethasone on growth. Therefore, careful mOltitoring of growth 
is necessary in all children during treatment with inhaled corticosteroids. It seemed that 
addition of salmeterol may have advantages on peak flow values and use of rescue 
medication during the first few weeks of treatment, without resulting in better symptom 
control, better airway caliber and less airway responsiveness after a year of treatment. 
On the basis of these data in combination with the knowledge of developing tolerance 
during maintenance treatment with saimeterol, at least to non-bronchodilating effects, 
one could argue whether salmeterol could better be used for short periods of time (a 
number of weeks) during symptomatic episodes, instead of as maintenance therapy for 
months or years. Our study also showed that with frequent control of patients and check 
of their medication use, it was possible to achieve excellent compliance rates with 
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subsequent improvements in asthma control. As we studied children with moderate 
asthma, we can not extrapolate our results to more severe asthma. It might well be 
possible that both increasing the inhaled corticosteroid dose and/or adding salmeterol 
has benefits in this group. 
8.3 Directions for future research 
Our data raise some questions about the reliance on symptom scores and peak flow 
values. especially during treatment with long-acting bronchodilators. All current asthma 
guidelines use these parameters as an indicator of asthma severity. The underlying 
hypothesis is that asthma is a chronic inflammatory process of the airways, which 
should be treated. Recent data on treatment with inhaled corticosteroids in adult 
asthmatics showed that airway responsiveness to methacholine correlates best with the 
inflammatory changes found in bronchial biopsies, whereas symptom scores, use of fi2-
agonists, PEP and FEV I were not. 13 One could therefore argue whether measurements 
of airway responsiveness are useful in determining the severity of asthma and 
subsequent treatment. Further studies are necessary to address the question whether 
measurements of airway responsiveness will prove superior as a guide to improve 
treatment adjustments. Therefore, it will be necessary to develop methods to assess 
ainvay inflammation in a non-invasive way. So far, parameters as serum eosinophilic 
cationic protein and eosinophil derived neurotoxin (eosinophil protein X) in serum and 
urine, have been related to disease activity.14 15 Some evidence exists that urinary 
eosinophil derived neurotoxin may be a useful marker of airway inflarmnation during 
treatment with inhaled corticosteroids.16 Recently, the amount of hydrogen peroxide 
in exhaled air of asthmatic children was found to be increased compared to controls. 17 
All these parameters however, show considerable overlap between patients and controls 
and it remains to be proven that this variability is actually due to differences in ainvay 
inflaImnation. 
Our studies showed a dose-dependent effect of beclomethasone on growth in children. 
Although data from the literature so far." do not support an effect of inhaled 
corticosteroids on long-telID growth or adult height, new long-tenn studies are 
necessary to test the hypothesis. that the negative effect on growth will diminish during 
further treatment. Besides bec1omethasone, other inhaled corticosteroids, such as 
budesonide and fluticasone, need to be studied for their effects on growth during long-
tean treatment. 
Studies in children with more severe asthma are necessary to address whether in this 
group of patients higher doses of inhaled corticosteroids andlor addition of salmeterol 
are beneficial. 
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Samenvatting 
Salmeterol, een lang-werkende 6,-agonist werd voor het eerst gelntroduceerd voor de 
behandeling van astma bij volwassenen aan het eind van de jaren tachtig. 1 Doel van 
dit proefschrift was het effect van salmeterol na een eenmalige dosering en tijdeos 
onderhoudsbehandeling te onderzoeken en de plaats van salmeterol in de behandeling 
van astma bij kinderen te bepalen. Primaire uitkomstvariabelen van het onderzoek 
waren de luchtwegdiameter, gemeten als FEV, en de luchtweggevoeligheid, gemeten 
als PDlO voor metacholine. In de lange-tennijn onderzoeken waren secundaire 
uitkomstvariabelen: symptoom scores, piekstroom. gebruik van extra kort-werkende 62-
agonisten en aantal astma-exacerbaties. 
Hoofdsluk 1 omvat een algemene introductie en beschrijft de pathofysiologie van astma 
als een inllammatoire ziekte van de luchtwegen. De huidige richtlijnen voor de 
behandeling van astma worden besproken. De plaats van de lang-werkende 6,-agonisten 
in het stapsgewijze behandelschema voor astma Jigt niet onomstotelijk vast in de diverse 
intemationale consensusrapporten.2 3 4 5 Of weI worden zij als additionele middelen 
geplaatst wanneer reeds hoge doseringen inhalatiecorticosteroi'den worden gebruikt, 
ofwel een stap eerder, wanneer ondanks een lagere dosering inhalatiesterolden nog 
steeds astma symptomen persisteren. De fannacologische en klinische aspecten van 
inhalatiesteroi'den, kort-werkende en lang-werkende B2-agonisten worden uitvoeriger 
besproken. Deze medicamenten zijn nu de hoekstenen van de behandeling van astma 
bij kinderen en volwassenen. 
Hoofdsluk 2 geeft een literatuuroverzicht van de effecten van kort-werkende en lang-
werkende Bragonisten op de luchtweggevoeligheid voor histamine en metacholine. 
Kort-werkende B2-agonisten bebben een kortdurend beschennend effect, waarbij de 
dosis-effect curve voor de luchtwegvemauwende prikkel naar rechts verschuift. Tijdens 
lange-tennijn behandeHng met kortwerkende fi2-agonisten treedt geen vennindering van 
de luchtweggevoeligheid op; sommige onderzoeken hebben zelfs een vers!echtering van 
de luchtweggevoeligheid gesuggereerd tijdens chronisch gebruik van kort-werkende 6,-
agonisten. Eenmalige dosering van de lang-werkende fi2-agonisten salmeterol en 
formotero! geeft langdurige bescherming tot ten minste 12 uur, tegen 
luchtwegvemauwing ge1nduceerd door metacholine of histamine. Bij gebruik van weken 
tot maanden treedt wei lolerantie op voor dit beschermend effect tegen 
luchtwegvemauwende stimuli, echter er blijft beschenning bestaan. Tolerantie treedt 
niet op voor bet bronchusverwijdende effect. 
Hoofdsluk 3 beschrijft de literatuur betreffende k1inische onderzoeken met salmeterol 
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en fonnoteroi, met name de resultaten van onderzoeken bij kinderen. Na een eenrnalige 
dosering hebben beide middelen een luchtwegverwijdend effect van teuminste 12 uur. 
Ook is er eeo langdurig beschermend effect tegen luchtwegvernauwende stimuli, zoals 
inspanning, metacholine, histamine en allergeen. Bij tweemaal daags gebruik gedurende 
weken tot maanden zijn er minder astma symptomen en zijn de piekstroom waarden 
hoger ten opzichte van behandeling met kort-werkende fi,-agonisten. Hoewel er 
tolerantie optreedt voor het beschermende effect, blijft er bescherming bestaan 
gedurende behandeling van enkele maanden. De klinische relevantie hiervan is nog niet 
geheel duidelijk. Bijwerkingen van de lang-werkende fi,-agonisten zijn niet verschillend 
van die van kort-werkende fi2-agonisten. 
In hoofdstuk 4 worden de resultaten gepresenteerd van het onderzoek van een 
eeomalige dosis salmeterol. In een dubbel-blind, placebo-gecontroleerd, cross-over 
onderzoek wordt het effect van 50 p.g salmeterol op luchtwegdiameter en 
luchtweggevoeligheid bestudeerd. Twintig kinderen met matig tot ernstig astma 
participeerden in het onderzoek; de meerderheid van de kinderen werd behandeld met 
inhalatiesterolden of cromoglicaat. Vijftig p.g salmeterol resulteerde in betere FEV,-
waarden gedurende de eerste 12 uur na inhalatie. De maximale respons werd 4 uur na 
inname bereikt: de gemiddelde FEV, waarde lag 18.6 % boven de uitgangswaarde. 
Significante bescherming tegen metacholine gelnduceerde luchtwegvemauwing trad op 
tot 24 uur na inhalatie van sahneterol (geroiddelde PDlO 1.22 verdubbelingsdosis boven 
de uitgangswaarde). De maximale bescherming bedroeg bijna 4 verdubbelingsdoses 1 
uur na inhalatie. Wij concludeerden dat een eenmalige dosis van 50 p.g salmeterol 
resulteerde in langdurige luchtwegverwijding en bescherming tegen metacholine. 
In hoofdstuk 5 wordt het effect van een eeomalige dosering salmeterol op 
luchtweggevoeligheid vergeleken met het effect tijdens chronische behandeling van 4 
Illaanden. In een dubbel-blind, parallel onderzoek werden 30 kinderen gerandomiseerd 
tussen of wei salmeterol 50 p.g twee maal daags ofwel salbutamol 200 p.g twee maal 
daags. Voar dit onderzoek werden kinderen gerecruteerd met mild astma, die geen 
onderhoudsbehandeling hadden met inhalatiesterolden of cromoglicaat en nauwelijks of 
geen luchtwegvernauwing hadden, maar weI een toegenomen luchtweggevoeligheid voor 
metacholine. De luchtweggevoeligheid werd gemeten voor de start van het onderzoek, 
12 uur na de eerste dosis en daama maandelijks gedurende de 4 maanden durende 
behandelinsperiode. De metingen werden altijd op hetzelfde tijdstip van de dag verricht, 
12 uur na de laatste dosis van de medicatie. Voor FEV, werden geen significante 
verschillen tussen de beide behandelingen gevonden. PDlO voor metacholine steeg met 
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1.7 ± 0.3 verdubbelingsdosis na de eerste gift salmeterol. Deze bescherming 
venninderde tot 0.6 ± 0.3 verdubbelingsdosis na 1 maand, hetgeen over de rest van 
de behandelingsperiode niet veranderde en significant beter was dan de uitgangswaarde 
en de behandeling met salbutamol. Wij conc1udeerden dat tolerantie ten aanzien van het 
beschermende effect tegen metacholine ge[nduceerde luchtwegvernauwing optreedt 
binnen 1 maand na start van salmeterol onderhoudsbehandeling, echter dat geen toene-
mende tolerantie optreedt in het verloop van enkele maanden. 
Hoofdstuk 6 beschrijft de resultaten van een multi-center onderzoek waarin behandeling 
met sahneterol 50 I'g twee maal daags vergeleken wordt met bec1ometason 200 I'g twee 
maal daags. Zevenenzestig kinderen met mild tot matig-emstig astma, die tenminste 6 
maanden voor de aanvang geen inhaiatiesteroYden hadden gebruikt en tenminste 2 weken 
geen cromoglicaat, werden gerandomiseerd in een dubbel-blind parallel onderzoek. Na 
een jaar behandeling was er een significant voordeel voor de beclometason groep: in 
deze groep was de FEY, waarde gemeten voor bronchusverwijding gemiddeld 14.2 % 
van voorspeld hoger, de FEV, waarde na bronchusvenvijding gemiddeld 7 % van 
voorspeld hoger en de PD20 voor metacholine 2.79 verdubbelingsdoses hoger. In de 
salmeterol was er een tendens tot verslechtering voor zowel de FEV I als PD20, ondanks 
het feit dat symptomen en piekstroom waarden verbeterden. De gemiddelde daling was 
4.3 % voorspeld voor FEY, en 0.73 verdubbelingsdosis voor PD,o' Yoor wat betref! 
symptomen (dag- en nacht-), gebruik van extra kort-werkende B,-agonisten en piek-
stroom waarden (ochtend- en avond-) waren er geen significante verschillen tussen de 
behandelingsgroepen, hoewel bec1ometason behandeling iets betere resultaten gaf. 
Astma exacerbaties waarvoor prednisolon nodig was, kwamen aanzienlijk vaker voor 
in de salmeterol groep, evenzo was het aantal kinderen dat om deze reden uit de studie 
viel aanzienlijk hoger in de salmeterol groep. In de bec1ometason groep was echter de 
groei vertraagd ten opzichte van de salmeterol groep (-0.28 SDS versus -0.03 SDS). 
Wij conc1udeerden dat behandeling met bec1ometason in deze gemiddelde dose ring 
superieur is ten opzichte van behandeling met salmeterol ten aanzien van longfunctie. 
symptoom scores en astma exacerbaties. We adviseerden salmeterol niet als 
monotherapie te gebruiken en bepleitten controle van de groei tijdens behandeling met 
inhalatiesteroYden. 
Hoofdstuk 7 beschrijft de resultaten van een multi-center onderzoek waarin toevoeging 
van salmeterol (50 I'g twee maal daags) aan bec1ometason (200 I'g twee maal 
daags)(SI200 groep) vergeleken wordt met bec1ometason 400 I'g twee maal daags (1400 
groep) en met bec1ometason 200 I'g twee maal daags (1200 groep). In een dubbel-blind, 
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placebo-gecontroleerd, parallel onderzoek participeerden 177 kinderen. Na I jaar 
behandeling waren er geen significante verschillen tussen de 3 behandelingsgroepen 
voor FEV, en PD20 metacholine. Echter in aile 3 de groepen waren er significante 
verbeteringen ten opzichte van de uitgangswaarden. Voor FEV, waren de gemiddelde 
veranderingen respectievelijk 4.3 % (95%CI 1.3;7.2), 5.8 % (95%CI 2.9;8.7) en 4.3 
% voorspelde waarde (95%CI 2.1;6.5) voor de S12OO, 1400 en 1200 groep. Voor PD,o 
metacholine warende gemiddelde veranderingen respectievelijkO.6 (95%CI 0.05; 1.14), 
1.3 (95%CI 0.73;1.87) and 0.8 verdubbelingsdoses (95%CI 0.33; 1.27) voor de S1200, 
1400 en 1200 groep. Voor de ochtend- en avond piekstroom waarden was er een gering 
voordeel voor de SI200 groep ten opzichte van de 1200 groep, met name in de eerste 
maanden van de behandelingsperiode, Br waren geen significante verschillen russen de 
groepen wat betreft symptoom scores, gebruik van extra salbutamol en astma 
exacerbaties. De lengtegroei was significant verminderd in de 1400 groep. Het gebruik 
van de vaorgeschreven medicatie was zeer goed in alle groepen, waarbij bijna 90% van 
de vaorgeschreven medicatie werd gebruikt. Wij cancludeerden dat toevoeging van 
salmeterol ofverdubbeling van de inhalatiesteroYd dosis geen extra voordeel heef! boven 
200 J.tg beclametason twee maal daags in deze selecte groep kinderen met astma, waarin 
het gebruik van de voorgeschreven medicatie uitmuntend was, 
Conclusies en algemene discussie 
In avereenstemming met de resultaten van onderzaeken bij volwassenen met astma, 
vanden wij dat salmeterol oak bij kinderen een langdurig bronchusverwijdend en be-
schermend effect tegen metacholine geinduceerde luchtwegvemauwing heeft.' Evenals 
de resultaten uit onderzaek van Cheung et al,7 vanden \Vij een vennindering van het 
beschennende effect tijdens 4 maanden behandeling met salmeterol, Echter, OTIS 
anderzoek liet zien dat significante beschenning blijft bestaan zonder dat er cen tendens 
is tot verdere vermindering in de tijd, Aangezien de patienten in zowel het onderzaek 
van Cheung als in OilS onderzoek geen inhalatiesteroi'den gebruikten, zou men kunnen 
veronderstellen dat gebruik van deze het ontstaan van tolerantie zouden kunnen voorko-
men, Recente onderzoekingen venverpen echter deze hypothese,S 9 10 De klinische 
relevantie van het ontstaan van deze tolerantie is Iliet geheeJ duidelijk, en tot dusverre 
is er geen overtuigend bewijs dat tolerantie oak antstaat voor het bronchusvenvijdend 
effect. 7 11 Anderzijds, de reden dat tolerantie niet is aangetoond voor het 
bronchusverwijdend effect zou oak gelegen kunnen zijn in het feit dat verbeteringen van 
de luchtwegdiameter gelimiteerd zijn bij het bereiken van maximale verwijding, terwijl 
voor de dosis-effect curve bij rnetacholine er een open-eind is, lJ 
De twee lange termijn onderzoeken zoals beschreven in hoofdstuk 6 en 7 waren bedoeld 
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om de plaats van salmeterol in de behandeling van astma bij kinderen aan te geven. Het 
eerste onderzoek toonde de superioriteit van beclometason in een gebruikelijke doseting 
ten opzichte van salmeterol monotherapie zowel wat betreft longfunctie verbetering 
(luchlwegdiameter en luchtweggevoeligheid), symploom scores als aanlal exacerbalies. 
Opvallend was dat in de salmeterol groep symptomen en piekstroom waarden 
verbeterden, hoewel de luchlweg diameter en luchtweggevoeligheid enigszins verslech-
terden en er frequent exacerbaties optraden. Behandeling met 400 p.g beclometason per 
dag resulteerde weI in een mogeJijk klinisch relevante afname van de standaard deviatie 
score voor lengtegroei. Een recente Nederlandse kinderendocrinologie consensus 
bijeenkomst beoordeelde een afname van 0.25 standaard deviatie score per jaar als 
klinisch relevant. Het is mogelijk dat in ~ns onderzoek het gebruik van een 
poederinilalalor met relatief hoge longdepositie en mogelijk ook in de mond-kcelholte, 
en de hoge compliance hebben bijgedragen aan deze groeiremming. Tot dusverre 
worden in de literatuur geen aanwijzingen gevonden voor een klinisch relevant effect 
van inhalatiesteroi'den op de groei. 12 
Het tweede lange-termijn onderzoek vergeleek het effect van toevoeging van salmeterol 
aan twee maal daags 200 jlg beclometason met verdubbeling van de beclometason 
dosering en met de initiele beclometason dosering. Dit onderzoek leverde geen 
significante verschillen op tussen de drie behandelingsgroepen voor wat betreft 
longfunclie, luchlweggevoeligheid, symptomcn, gebrnik van extra korl-werkende fi,-
agonisten en aantal exacerbaties. Toevoeging van salmeterol gaf wei iets hogere 
piekstroom waarden. met name in de eerste maanden van de behandeling. ABe 
behandelingsgroepen Heten evenwel significante verbeteringen zien in de gemeten 
parameters, zodat de resultaten niet verklaard kunnen worden uit een gebrek aan ruimte 
voor verbetering. Wij konden geen specifieke subgroepen identificeren. die betere 
resultalen hadden met een van de behandelingsmethoden. Het gebrnik van studic 
medicatie en onderhoud beclometason was uitmuntend; bijna 90% van de 
voorgeschreven medicatie werd gebruikt. De verbetering in de placebogroep die 
beclometason. twee maal daags 200 J.!g. continueerde, is toe te schrijven aan dit hoge 
medicatiegebmik, hetgeen waarschijnlijk beter was dan voor het onderzoek. Dit 
onderzoek toonde een dosis-afhankelijk effect van beclometason op de lengte-groei. 
Wanneer we de gegevens uit bovenstaande onderzoeken vertalen naar de huidige 
richtlijnen voor de behandeling van astma, kunnen we concluderen dat, in 
overeenstemming lUet deze richtlijnen, salmeterol Iliet als monotherapie geblUikt dient 
te worden, maar alleen in combinatie met inhalatiesteroYden. Op basis van onze 
resultaten, konden we geen dosering inhalatiesteroYd aangeven, waarboven toevoeging 
van een lang-werkende B,-agonist, zoals salmeterol, de volgende stap in het 
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behandelplan dient te zijn. De behandeldoelen zoals gesteld in de richtlijnen om 
symptomen en exacerbaties te venninderen worden in aile 3 de behandelingsgroepen 
gehaald, zonder dat een van de behandelingen bier een evident voordeel bied!. Ons 
onderzoek liet weI een duidelijk dosis-alhankelijk effect van bedometason op de 
Jengtegroei zien. Dit maakt een nauwkeurig vervolgen van de lengtegroei bij kinderen 
behandeld met iuhalatiesterolden noodzakelijk. Toevoeging van sahneterol lijkt in de 
eerste weken een positief effect te hebben op piekstroom waarden en gebruik van extra 
kort-werkende fil-agonisten, zonder een effect op symptoom scores, luchtweg diameter 
en luchtweggevoeligheid. Dit gegeven gecombineerd met het feit dat tolerantie, 
temninste voor de niet-luchtwegverwijdende effecten, ontstaat tijdens langdurige 
continue behandeling, zou een argument kunnen zijn om 8almeterol in te zetten in 
kortere periodes (enkele weken), wanneer er meer syrnptomen zijn, in plaats van als 
continue behandeling voor maanden tot jaren. In ons onderzoek bleek dat frequente 
contrale van de patienten, waarbij oak het medicatiegebruik werd gecontroleerd, leidde 
tot een goede compliance en daannee verbetering van het a8tma. We kunnen onze 
resultaten niet extrapoleren naar emstig astma, daar we in deze onderzoeken aIleen 
kinderen met matig-emstig astma onderzocht hebben. Het is zcer wei mogelijk dat bij 
ernstig astma zowel verhoging van de dosering inhalatiesteroi'd als toevoeging van 
salmeterol wei voordeel bieden. 
Aanbevelingen voor toekoIllstig onderzoek 
Onze resultaten werpen de vraag op of symptoom scores en piekstroom waarden 
geschikte parameters zijn met name tijdens gebruik van lang-werkende 
luchtwegverwijders. De huidige richtlijnen gebruiken symptomen en piekstroom 
waarden om de ernst van a8tma te classificeren. De hypothese is dat astma cen 
chronische ontstekingsziekte van de luchtwegen is, die als dusdanig behandeld moet 
worden. Recente data bij volwassen astmapatienten die behandeld werden met 
inhalatiesteroi'den Heten zien dat de mate van luchtweggevoeIigheid voor metacholine 
het best correleerde met de mate van ontsteking in de luchtwegbiopten, terwiji 
symptomen, gebluik van fil-agonisten, piekstroom en FEV 1 hier niet ruee 
coneleerden. 13 MogeJijk is het bepalen van de luchtweggevoeligheid van nut tel' 
bepaling van de ernst van het astma. VerdeI' onderzoek is nodig om de vraag te 
beantwoorden of bepaling van de luchtweggevoeligheid een geschiktere parameter is als 
leidraad voor de behandeling. Het is tevens nodig om niet-invasieve methoden te 
ontwikkelen, die de mate van luchtwegwandontsteking weergeven. Verschillende 
eiwitten, zoals "eosinophilic cationic protein" en "eosinophil derived neurotoxin (eosin-
ophil protein X)" in bloed en urine correleren met de ziekte-activiteit,14 15 Er zijn 
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enkele aanwijzingen dat !1eosinophil derived neurotoxin ll uitgescbeiden in de urine een 
waardevolle graadmeter is van het ontstekingsproces tijdens behandeling met 
inhalatiesteroiden. 16 Vit recent onderzoek blijkt dat de hoeveelheid waterstofperoxide 
in de uitademingslucht bij kinderen met aslma verhoogd is ten opzichte van 
controles. 17 AIle bovengenoemde bepalingen vertonen een grote overlap tussen 
patienten en controles en verder onderzoek zal nodig zijn am aan te tonen in hoeverre 
dit relateert aan de ontsteking in de luchtwegwand. 
Ons onderzoek toonde een dosis-afuankelijk effect van beclometason op de lengtegroei 
bij kinderen. Hoewel de huidige literatuurgegevens een effect van inhalatiesteroiden op 
de lange-termijn groei en op de uiteindeIijke volwassen Iengte niet ondersteunen,12 
dienen nieuwe lange-tennijn studies te worden opgezet om dit verder te onderzoeken. 
Onze hypothese dat de negatieve effecten op de lengtegroei mogelijk verminderen 
tijdens tangere behandeling moet verder onderzocht worden. Naast beclometason dienen 
ook de effecten van de andere inhalatiesteroiden, zoals budesonide en fluticason, op de 
lengtegroei onderzocht te worden. 
Onderzoek bij kinderen met emstig astma is nodig om aan te geven of in deze groep 
hogere doseringen inhalatiesteroid en/of salmeterol een gunstiger effect hebben. 
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zorgden oak voor een perfecte organisatie en veel gezelligheid. De kinderen en oak hun 
ouders waren steeds weer bereid te kamen, mede dankzij de prettige sfeer die jullie 
wisten te scheppen. 
De uitkomsten van het onderzoek waren nooit in dit boekje verschenen, wanneer ruet 
aIle gegevens nauwkeurig waren verwerkt en bewerkt. Pedde Spoel, beste Pedde, het 
is jouw werk geweest am aile data in te voeren. Het was een enonne kIus, waarbij ik 
je eigenlijk nooit op fouten kon betrappen. Veel dank ben ik je oak verschuldigd Vaal' 
de uiteindelijke vonngeving van dit bockje. Irma Beckers wil ik bedanken Vaal' de 
verdere secretariele steun en vocral het gebruik van de printer. 
Mijn aanvankelijke onbegrip van de statistiek is geleidelijk wat verbeterd, doch zander 
de hulp van statistici waren deze resuHaten niet verschenen. Wim Hop, beste Wim, ik 
wil je bedanken Vaal' je analyses en zal je rokerige hal haag in het faculteitsgebouw 
nooit vergeten. Chris Prost, dear Chris, I would like to thank you for all your statistical 
work and last but not least for the excellent collaboration. It will be a pleasure to have 
you in Rotterdam on september 10th. 
In een tijd van steeds krappere budgetten hecft Glaxo-Wellcome het mogelijk gemaakt 
am dit onderzaek te realiseren. Velen binnen Glaxo-Wellcome hebben bijgedragen aan 
het onderzoek. In het bijzonder zou ik willen bedanken Jan Raaijmakers, Mirjam 
Steinbuch, Lucas Paanakker en Niels Ypenburg. De ontwikkeling van de protocollen 
en de data-monitoring vergden een enonne inspanning van jullie allen. 
Mijn oud-collega's van de afdeling kinderlongziekten in het Sophia Kinderziekenhuis: 
Johan de Jongste, Liesbeth van Essen-Zandvliet, Hein Brackel, Hann Tiddens, Govert 
Brinkhorst en Rijn Jobsis wil ik bedanken Vaal' de plezierige samenwerking. Samen met 
mijn huidige collega's Ron van Beek, Stella de Man en Joost Werre wil ik graag 
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bouwen aan de toekomst van de kindergeneeskunde van het Ignatius Ziekenhuis Breda. 
Ik dank hen voor de ruimte die ze mij de afgelopen maanden hebben gegeven am de 
laatste fase van dit proefschrift af te ronden. 
Eric Duivennan en Liesbeth van Essen ben ik zeer erkentelijk dat zij mij als paranimfen 
willen bijstaan. Beste Eric, het is onder jouw hoede in het Juliana Kinderziekenhuis 
geweest, dat ik het enthousiasme voor de kinderlongziekten ontwikkelde. Beste 
Liesbeth, jouw steun en praktische aanwijzingen tijdens de eerste periode van mijn 
onderzoek hebben me veel geholpen. Ik hoop dat onze vriendschap nog lang blijft 
bestaan. 
De meeste dank ben ik echter verschuldigd aan mijn echtgenoot en kinderen. Lieve 
Bart, dit is het resultaat van vele uren die ik niet aan het gezin heb kunnen besteden. 
Door de jaren heen heb je me steeds gesteund en was het mogelijk dat je een deel van 
de zorg voor de kinderen op je nam. Lieve Maud en Floor; mama heeft het boekje nu 
eindelijk af en het feest kan beginnen. Mama hoopt nu weer meer tijd te krijgen voor 
jullie en voor Kai. 
159 
List of abbreviations 
AC 
AMP 
AP-l 
BDP 
b.Ld. 
cAMP 
C! 
CREB 
DD 
DNA 
DP! 
ECP 
EDN 
EPO 
FEV, 
FVC 
GM-CSF 
IFN 
IL 
MBP 
MDI 
NF-KB 
PC,o 
PD,o 
PEF 
PKA 
SDS 
SEM 
sGaw 
Th 
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adenylyl cyclase 
adenosine monophosphate 
activating protein-l 
beclomethasone dipropionate 
twice daily 
cyclic 3' -5 '-adenosine monophosphate 
confidence interval 
cAMP responsive element binding protein 
doubling dose(s) 
deoxyribonucleic acid 
dry powder inbaler 
eosinophilic cationic protein 
eosinophil-derived neurotoxin 
eosinophilic peroxidase 
forced expiratory volume in one second 
forced vital capacity 
granulocyte macrophage-colony stimulating factor 
interferon 
interleukin 
major basic protein 
metered dose inbaler 
nuclear factor-KB 
provocative concentration which causes a decrease in FEV 1 by 20% 
provocative dose which causes a decrease in FEV, by 20% 
peak expiratory flow 
protein kinase A 
standard deviation scores 
standard error of the mean 
specific airway conductance 
T helper lymphocyte 
